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Abstract 
In this thesis, we established methods that use high temperature-HPLC for the 
efficient separation of different groups of pharmaceutical compounds. These groups 
are cephalosporins, non-steroidal anti-inflammatory (NSAID), and diuretic drugs. 
The effect of changes of the temperature of the colunm was studied with respect to 
various chromatographic parameters: retention factors, thermodynamic properties, 
selectivity, efficiency and peak shape. 
Three coluruns (pathfinder, Xterra RP18, and Selerity's Blaze 200) were examined 
for the analysis of cephalosporin drugs under high temperature reversed phase 
HPLC. Several proportion of mobile phases were used with these coluruns. This 
study focused on the effect of colunm temperature on selectivity (a), and efficiency 
(N/m), van't Hoff plots. The best conditions for the separation of these drugs were 60 
°C with 100% water as eluent and this conditions were the best for quantitative 
applications. This condition was validated according to International Conference on 
Harmonisation (ICR) with respects of linearity, limit of detection (L.O.D), limit of 
quantification (L.O.Q), and precision (tIt, relative peak area%, N/m). 
The separation of nine non-steroidal anti-inflammatory drugs (NSAlDs) was carried 
out using high temperature HPLC using three coluruns (Xterra RP18, XBridge™ 
RPl8 shielded (15 cm) and XBridge™ RPIS shielded coluruns (5 cm» The analytes 
were separated using different proportions of both phosphate or acetate buffers with 
acetonitrile (MeCN) as the mobile phase at different pH (3-6) at temperatures 
ranging from (40-140 QC). The studies indicated the effect of temperature, pH, and 
flow rate on retention factors, selectivity (a), and efficiency (N/m), thermodynamic 
properties (van't Hoff plots) of these drugs. Also temperature programming was 
carried out these drugs with both XBridge™ RPl8 shielded (15 cm) and XBridge™ 
RP18 shielded colunms (5 cm) using pure buffer in water as eluent under different 
conditions. It was found that XBridge™ RP18 colurun was better than Xterra RP18 
and the best conditions for the separation ofNSAlDs were observed by using buffer 
75% and MeCN 25% at pH 5 at 80°C and temperature programming on Xbridge 
RP18 colurun (15 cm) regarding both selectivity and efficiency. 
The separation of eleven thiazide and non- thiazide diuretics was made at a high 
temperature (isothermal and gradients temperature) ranging from (40-140 0c) using 
XBridge™ RP18 shielded colunm and XBridge™ C18 colurun. Different 
proportions of acetonitrile (MeCN) with 1 % aqueous acetic acid (AcOH) were used 
Pure water was used as eluent at 140°C with XBridge™ RP18 colurun and the 
separation of the drugs was accomplished. The relationship between increased 
temperature of colurun with retention factors, selectivity (a), and efficiency (N/m), 
thermodynamics properties (van't Hoffplots) ofthese drugs, were investigated. 
Also, temperature-programming technique was used with water as the eluent for the 
separation these drugs and indicated that, a non polar-embedded XBridge™ C18 
colurun provide better separation, time analysis, and peak shape than a XBridge™ 
RP18 shielded colurun. 
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Chapter! High temperature HPLC 
Chapter 1 High Temperature HPLC 
1.1 Introduction 
With the increase in the industrialisation of different fields including the 
pharmaceutical industry, there is a need to develop analytical methods for quality 
control applications in laboratories, especially in fields that are directly related to the 
health of human beings. Analytical method development is considered an important 
role in the manufacturing, discovery, development and production of pharmaceutical . 
products. The official test methods, which result from these processes, are used by 
quality control laboratories in order to· guarantee the identity, purity, potency and 
performance of drug products. Therefore, the need to provide data, which is suitable, 
exact, and reliable, is central to analytical chemistry. The data are used to identify 
potential drug candidates, to help in the development of the synthesis of the drug, 
studies of the formulation, to supervise bulk formulated product and pharmaceutical 
product· stability, and to detemiinate the validity of the product for the launch. The 
quality of the analytical data is a dominant factor in the success of a program of 
development of the drug. The process of the development and the validation of the 
method has a direct impact on the quality of these data. 
Nowadays, the demand to develop rapid analytical chromatographic methods for 
pharmaceutical compounds is becoming more important. However; most HPLC 
methods are carried out at ambient temperature, but temperature is now becoming an 
important parameter to optimise the separation in HPLC and is starting to be used in 
. pharmaceutical analysis. 
Although the effect of temperature on HPLC has been received considerable 
attention for many years, so far, this variable has not been employed extensively in 
pharmaceutical analysis either isqthermally or with a thermal gi'adient. The use of 
elevated temperatures in liquid chromatography has attracted chromatographers as it 
is benefiCial in speeding analysis times, reducing the need· for organic eluent and 
improving separations [1-3]. In addition above its normal boiling point the viscosity· 
of water will be reduced and it has similar properties to strong organic eluents, such 
as acetonitrile (MeCN) and methanol (MeOH) in terms of elution strength. The 
ability of water to dissolve non-polar compounds will also increase at high 
temperature. Also another remarkable advantage of using a purely aqueous mobile 
phase is the elimination of the organic solvent in LC-NMR and LC-MS applications 
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and this can prevent solvent interference in the operation [4-7]. Because the current 
study examined the possibility of using pure water as the eluent in high column 
temperatures for the development of analytical methods for pharmaceutical drugs, it 
is beneficial to investigate the effect of increasing column temperature on the 
separation process in RP-HPLC, Nowadays, it is well known that high temperature 
liquid chromatography can give very attractive improvements compared to classical 
HPLC [8]. Another advantage of this technique'is a reduction inthe organic content 
in the mobile phase that is beneficial both economically and enviromnentaly, and it 
also provides faster separations without loss of efficiency, Furthermore, the use of 
temperature as a separation parameter in order to improve selectivity can be used 
very successfully [9-11]. The major problem of high temperatures is degradation of 
the stationary phase, many of which are largely thermally unstable [12-14]. Silica-
based C18 phases are easlly degraded when using as eluents with a high water 
content at temperatures above 60 ·C and at low pH « 2) as water molecules can 
cause hydrolysis of siloxane bonds (Si-O-Si) and this leads eventually to column 
breakdown, The development of a new generation of hybrid silica based columns as 
well as non-silica based columns, which are much more thermally stable, provides 
the possibility to carry out high temperature experiments without major damage to 
the column packing [15,16]. There are some important requirements in using high 
temperature in HPLC in pharmaceutical analysis which are, firstly, the stability of, 
drugs at the temperatures used during the chromatographic run [17]. The second 
requirement with elevated temperature HPLC application is to ensure there is no 
mismatch temperature of the mobile phase [18]. • 
1.2 Stationary phase of high temperature HPLC 
This section, will review the available stationary phases for high temperature and 
temperature-progranuned LC [19-24]. 
1.2.1 Silica-Based Columns 
The hydrolysis of silica-based columns limits the application of this stationary phase 
. at higher temperatures, especially with aqueous mobile phases. It was reported in a 
previous study [25] that the presence of iitorganic buffers containing carbonate or 
phosphate significantly decreased the thermal stability of silica-based stationary 
2 
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phases. The separation of peptides, proteins, and nucleic acids was achieved at 80°C 
[26J by using superficially porous silica. Also, the separation of peptide and protein 
samples at high temperature could be carried out on another type of stationary 
"sterically protected" silica columns known as "Zorbax column Stablebond" which 
can be operated up to 90 QC [27-29]. The silica-based pellicular stationary phase can 
be used at temperatures at 120°C [30, 31J. The Hytech CI8 column was stable at 
temperatures ranging from 25°C to 100°C [32]. Monomeric C18- bonded silica has 
been used to up to 80°C [33]. NovaPak18 [34], Inertsil ODS-3V [35], Partisil ODS2 
[36], and Zorbax ODS [37J Selerity Blaze C8 and C18 polydentate are special high 
temperature phases [19] columns. The silica-based poly (methyloctylsiloxane) and 
poly(methyloctadecylsiloxane) stationary phases were reported to degrade after the 
passage of approximately 450 column volumes of pH 8.4 mobile phase at 60°C [25]. 
There is now a new generation of hybrid silica based stationary phases with methyl 
bridge in Xterra and ethylene bridge in Xbridge that offer some resistance to 
hydrolysis at elevated pH and high temperature as they have Si-C covalent bonds 
that are much less prone to hydrolysis than Si-O-Si bonds [25). 
1.2.2 Metal Oxide-Based Columns 
The limitation of the thermal stability of silica-based columns led scientists to 
develop new stationary phases by using metal oxides of alumina, titania, and zirconia 
[38,39J. It was reported that the applications of alumna and titania were limited 
because of the solubility of alumina at low pH and· the unavailability of 
chromatographic grade titania-based packing. However, zirconia-based stationary 
phases had a wider applicability and this can be attributed to their stability at higher 
"temperatures [40, 41]. There are many type of zirconia-based packing, such as 
ZirChromcPBD (polybutadiene-coated zirconia) that is stable at 200°C for at least 
1300· column volumes [42,43] and polystyrene-coated, carbon-clad, phosphate-
coated, and polyethyleneimine-coated zirconia [25] Also there is column based on· 
zirconia which can be used up to 200 QC [44]. 
1.2.3 Open- Tubular Columns 
The thermal equilibration time at elevated temperatures for columns is important [18] 
and it can be affected by the internal dimension of columns. To avoid this problem 
3 
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chromatographers introduced new packed-capillary and open-tubular columns which 
have much shorter thermal equilibration times [25]. It was reported that the narrow-
bore columns minimised the effect of axial and radial temperature gradients on 
separation performance [14]. These columns included Hypersil ODS and Kromasil 
C18 with very narrow dimensions (0.32 mm), whkh were stable as high as 200°C 
[45]. An open-tubular column made from a 2-m fused-silica capillary (50 J.!m i.D.) 
with an extensive cross-linking of the octylpolymethylsiloxane stationary phases was 
also reported to be used in high temperature LC [46]. The thermal stability of 
capillaries packed with 5-J.!m PLRP-S at 100°C after passing 7500 void volumes at 
l30 °C were investigated [47] . 
1.3 Control of column temperature in HPLC 
When applying temperature as a variable, it is important to ensure there is no 
mismatch in the temperature between the eluent and column [48-51]. The need to 
know the correct temperature of the column is obvious, especially in high 
temperature applications in HPLC for transfering a method from one instrument to 
another. There are many common ways to control column temperature, such as ovens 
using block heaters, circulating heated air, Peltier heaters, and water or oil baths. 
There are two requirements to obtain efficient separation, Firstly, to adjust the 
temperature controller that generates the required temperature. A second factor, that 
is very important in high temperature HPLC, is to ensure that the eluent at the inlet of 
the column is the same at the temperature of the column and usually this can be 
achieved by using a length of pre-heating tubing [52]. Also, there is a need to cool 
the column eluent outlet. back to around ambient temperatures before entering the 
UV detector [53]. 
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Figure 1.1: Band broadening due to thermal effects [54). 
From previous work [54) (Figure 1.1), the completely equilibrated system as figure 
(a) in which the inlet eluent and oven temperature (column temperature) were the 
same, and the temperature is also similar at the column centre and wall, gave good 
peak ,shapes. However, in figure (b) with a cold eluent, two problems will be 
generated, the column temperature will be lower than required and there will be a 
radial temperature gradient because the temperature at the column wall is higher than 
the column centre, consequently retention times are increased and band broadening 
occurs because of different temperatures across the column. If not enough pre-
heating tubing was used, the peak shape deteriorated. In a real system frictional 
heating causes of the temperature to be different from inlet to outlet, and band 
broadening will be observed as illustrated in figure ( c) because the temperature is 
. less at the column wall than the column centre so that band migration is slower at 
edge of the column. The type of oven plays an important role in effect of frictional 
heating. Band broadening and distortion was less affected by air-bath ovens than by 
contact heaters or water baths when stainless steel columns were used. The band 
broac;lening effect can be removed if the incoming eluent is just below the column 
temperature, and if frictional heating of the solvent is significant as illustrated in Fig. 
(d), where frictional heating effect gradually changes the temperature in the opposite 
direction to the cooling of the inlet to minimise increases in bandwidth [54]. 
The most efficient thermostats with superior heating capacity are liquid jackets and 
baths. But with these types, when temperature is above boiling the point of water, 
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another liquid is needed to replace the water. The performance of heating blocks 
depends mainly on the degree of contact with the column hardware and suffers from 
limited temperature gradient rates. Circulating air oven quickly provide varied 
temperatures and they have a heating capacity that essentially determines the speed 
at which the heated air can be blown around the column. Commercially GC ovens 
are usually used in temperature-programmed liquid chromatography [24]. 
, 
'1.4 Previous studies on HT ·Le 
Many articles sununarising developments and applications of high temperature 
. HPLC have been published recently [20,21,55]. The applications of this technique 
range from polymers and surfactants [56,57], natural products [58,59], 
pharmaceuticals [60,61], to environmental analyses [62,63]. However, using 
temperature as a variable in LC was first reported in middle of last century in 1948, 
when an attempt was carried out to study the effect of temperature in LC [64]. The 
retention of nitroaniline and Iycopene in an open column system packed with silica 
gel was studied over the range 10 to 70°C. It was found that temperature had little 
effect on the retention time. Five years later, another study examined azobenzene 
dyes over the range 55 to 200°C. It was found the retention could increase or 
decrease with temperature according to the solvent system used [65]. After the mid 
sixties, there were many studies on the effect of temperature on solute retention in 
chromatographic systems including liquid-liquid [66], liquid-solid [67,68], ion 
exchange [69,70] and size exclusion chromatography [71,72]. The development of a 
new generation of stationary phases led chromatographers to investigate the effect of 
temperature on RP-HPLC when a variety of compounds, including polycyclic 
aromatic hydrocarbons, drugs and vitamins, were quickly separated at' high 
temperature [73]. Another study examined the effect of high temperature on 
efficiency [74] and concluded that efficiency improved for simple organic 
compounds, such as acetone and benzene. Chromatographers directed their research 
to investigate the effect of temperature on LC applications, such as temperature's 
role on mechanism of retention [33,75-79], effect on number of theoretical plates 
[34,80-82], temperature programming, and high temperature open tubular LC 
[12,83,84]. Nowadays, there are many type of stationary phase that are stable over 
, much wider temperature range than normal silica based bonded phases. Thes~ 
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include polystyrene-divinylbenzene columns, which have been used at high 
temperature for size exclusion chromatography and porous graphitised carbon which 
has been used over lOO °C [85]. 
An examination of the effect of temperature on a polybutadiene (PBD) zirconia 
column with respect to retention, efficiency, and stability was made for the 
separation of alkylbenzenes and a set of tricyclic antidepressant drugs at different 
temperatures up to 100°C [86]. The thennodynamic properties of these compounds 
were also examined and it was concluded that enthalpy changes were between -2 and 
-4 kcallmol and that changes in selectivity varied with the type of solute. The column 
efficiency was improved by 30%, mainly by accelerating the solute diffusion rate in 
the stationary phase. The use of elevated temperatures allows good chromatographic 
efficiency to be provided at flow rates higher than those that are optimal at ambient 
temperature, thus increasing the speed of separation [21]. For example, the thermal 
stability of polybutadiene-coated zirconia reversed phases was measured at elevated 
temperatures up to 200°C and high flow rates up to 5 mllmin for the analysis of 
polyaromatic hydrocarbons [42]. It was found that the run time decreased 18-fold at 
high temperatures and enabled high flow rates with good resolution, relative to 
conventional temperatures and normal flow rates. Reversed phase polystyrene-coated 
zirconia porous particles were studied at high temperature [87]. The column 
efficiency was dramatically improved at 150°C, at a flow rate of 15 mllmin. Long 
chain alkylphenone compounds were totally eluted and the analysis time decreased 
50 fold compared to 25°C and a flow rate 4 mU min. In addition, in this study, five 
phenols were separated within 30s using pure water as eluent. Also in the analysis of 
polar, lipophilic amines on unbonded silica, the role of temperature was shown to 
favourably impact both efficiency and selectivity [88], The temperature behaviour 
appears to support the hypothesis that retention is dependant upon electrostatic and 
adsorptive forces [81]. Both small molecules and biomolecules were separated at 
elevated high temperatures ranging from ambient to 250°C. An analytical 
chromatographic method for the analyses of phenylthiohydantoin (PTH)-amino acids 
using aqueous solutions as the mobile phase at elevated temperatures was developed 
[89]. In this method, the surfaces of microparticulate silica gel were modified by 
using the thermoresponsive copolymer, poly(N-isopropylacrylamide- co-n-butyl 
methacrylate), to regulate the hydrophilic/hydrophobic property changes in water at 
elevated temperatures. It was concluded that there are three major drawbacks with 
high temperature liquid chromatography. Firstly, the ability of the stationary phase to 
7 
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withstand temperatures exceeding 200°C. Secondly, peak broadening can occur 
when there is a temperature mismatch between the incoming eluent and the column ( 
>5 0c) but it can be avoided by using narrow-bore columns (2.I-mm Ld.), lastly, 
ana1ytes must be thermally stable at high temperatures over the analysis run time 
[17]. 
On the other hand, the benefits of high temperature chromatography are decreased 
analysis time, by 5-10-fold, and an increase in analyte diffusitivity. Lower viscosities 
at elevated temperatures decrease the pressure drop across the column and allow the 
use of higher linear· velocities.. Therefore, it is possible by· using elevated 
temperatures to elute compounds that were retained on the column at ambient 
temperatures in less time pompared to classical HPLC because of the elution strength 
of water increases with increasing temperature in reversed-phase chromatography 
[7]. Many studies have reviewed the effect of change of temperature on retention 
[42, 90,91] The studies· on effect of temperature on retention factor have 
. demonstrated that retention factors decrease with increased temperature [35,92]. This 
can be explained according to thermodynamic equation in paragraph (1.6) It was 
reported in that the retention of anilines and phenols was shown to be more sensitive 
to temperature than the retention of alkylbenzenes [93] when using subcritical water 
as eluent over the temperature range lOO-200°C on a Nucleosil CI8 AB column, 
The same effect was observed in the separation of alkylbenzenes, when an increase 
in temperature of 5°C is equal to a I % change in acetonitrile in eluent composition 
[90]. In another study on the separation of a mixture of E vitamins, the retention 
factor values were changed by an equal amouunt, when the temperature increased by 
4 °C as an increase in acetonitrile concentration by I %. It was found that the same 
retention times were obtained at 90°C with 50% acetonitrile, at 110 °C with 45% 
acetonitrile, and at 130°C with 40% acetonitrile [94]. 
Another study indicated that a temperature increase of 3.75 °C has the similar effect 
on retention as a I % increase in methanol [24], and a 5 °C increase can be compared 
to a 1% change in MeCN content [90]. However, retention factors don't always 
decreases with increase temperature. It was reported that some bases and quaternary 
anunonium compounds increased their retention with increased temperature and this 
could be attributed to a decrease in pKa and hence, decreased ionization [95]. A 
similar observation was found in the separation of epirubicin and its analogues as 
their retention increased with increasing with temperature, which is inconsistent with . 
"normal behavior" (decreased retention at elevated temperature) [96]. 
8 
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Utilising increasing column temperature up to 150°C with mobile phases of different 
compositions for the separation of five free sterols was reported [97] with using 
different stationary phases including graphitic carbon, a polymeric Cl8 silica, and a 
.' zirconia-based adsorbent. Some selectivity improvements and some elution order 
reversals were observed in this study. Also, it was found the graphitic carbon column 
produced the best separation of the sterols [97J. The fast (10-20 min) separation of 
vitamin E isomers (a.-;y-,o-tocopherol, and a.-;y-,o-tocotrienol) and a-tocopherol 
acetate was evaluated under high temperature-HPLC using a polybutadiene-coated 
zirconia column at temperatures of 80 and 140 QC [98]. In this study it was noted that 
the van't Hoffplot tended to deviate from linearity at higher operating temperatures 
(98]. Also the separation of mixture of a-helical peptides at pH 2.0 and 7.0 on the 
SB-C8 column was investigated with respect of retention time, selectivity and 
efficiency [99]. It was found that increasing temperature decreased retention time, 
and increased efficiency and optimum resolution was obtained at 65 ·C [99]. 
The development of a rapid and simple analytical method for complex lipid 
(ceramide type 1II and type IV) analysis was carried out using a high temperature 
micro-liquid chromatographic system (HTLC) coupled to an evaporative light 
scattering detector with Hypercarb column [100]. In this study, the temperature effect 
on the kinetic performances in HTLC was investigated and alcohol solvents were 
used as the mobile phase to elute lipids without the use of chlorinated solvents [100]. 
The effect of high temperature and flow-rate on the separation of testosterone and 
several related compounds with respect of selectivity and retention patterns were 
investigated on aporous, polybutadiene-coated zirconia column at temperatures up to 
200°C and compared with that of a porous silica, octadecylsilane-coated column and 
the zirconia column under traditional reversed-phase conditions of an acetonitrile-
water mobile phase at 40°C [101]. The use of high temperature HPLC in chiral 
separations was investigated over the temperature range of 5-70 ·C to separate 
enantiomers of a-substituted glycine analogs, on a quinine-based anion-exchanger 
chiral stationary phase at different mobile phase compositions, using isocratic elution 
in the reversed-phase mode. This study also calculated the thermodynamic constants 
(Alt', Llff') and Lla" by using van't Hoffplots that were linear over the temperature 
range, 5-70 QC [102]. The influence of temperature on the separation of epirubicin 
. drug and its analogues was examined (96]. In organic-rich mobile phases, it was 
found that temperature effects on elution times showed irregular increases. However, 
with aqueous rich mobile phases, regardless of the nature of the organic solvent and 
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pH, both efficiency and resolution were appreciably improved [96]. The performance 
of a novel polydentate C18 silica column was investigated at high temperature 40-
200°C under acidic, basic, and neutral mobile phase conditions using MeCN and 
methanol as the mobile phase organic modifiers and changes in the mobile phase pH 
from 2 and 12. Under neutral conditions, at temperatures ranging betWeen 120 and 
200°C in methanol-water and MeCN-water solvent systems, good column thermal 
stability was obtained. Between pH 2 and 3 up to about 160°C, the column 
performed well at two fixed MeCN-buffer compositions whereas, with basic 
conditions at high temperatures, the column material deteriorated more rapidly, but 
was still stable up to 100°C at pH 9 and 60°C at pH 10 [103]. A wide range of 
further applications of high temperature in pharmacentical analysis have been 
reported (Table: 1.1) 
Table 1.1: Pharmaceutical compounds separated using high temperature by 
HPLC 
Drugs -cc\ ... Mobile phases Stationary . Temperature 
Ref 
phase . \. 
Tricyclic - PBD-zirconia 40 -100°C 
antidepressants 
[86] 
Benzodiazepines Acetonitrile- PBD Zirconia 100°C 
[19] 
water (non-porous) 
Barbiturates Acetonitrile- ODS+ silica + 30-80°C 
water PDB zirconia 
[104] 
Vitamin A and Acetonitrile- SuplexpKb- 25 -60°C 
[105] 
Retinoids water 100 
. 
Barbiturates Deuterium PS-DVB 200°C 
oxide 
[106] 
Sulfonamide Buffered water PS-VB 70-190°C 
pH 3-12 
[107] 
Steroids Water Zirconia PDB 170 - 200°C [108] 
Analgesics Deuterium NovapakC18 80 -130°C 
paracetamol, oxide 
caffeine and 
[4] 
phenacetin 
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Drugs Mobile phases Stationary Temperature 
Ref 
phase 
Anticancer Water PS-DVB Up to 160 °C 
drugs pH 11.5 and [109] . 
3.6 
Caffeine, Deuterium OasisHLB 185°C 
paracetamol, oxide 
amitriptyline Xterra 85°C [107] 
and phenacetin 
Paracetamol Water Hypercarb, Up to 225 °C 
Antipyrine and PS-DVBand [101] 
caffeine Zirconia PDB 
Paracetamol. Water PS-DVB 75 -185 °C 
salicylamide, 
methyl paraben, [110] 
phenacetin ethyl 
paraben . 
. 
1.5 Temperature programming: 
Temperature programming has not received as much interest as isothermal high 
temperature HPLC as rapid changes in temperature may result in radial temperature 
gradients in the column with concomitant loss of efficiency [90], therefore packed 
capillary columns have been recommended for this technique. Due to their smaller 
. diameter and lower mass, they are more suitable for temperature programming than 
conventional HPLC columns. The use of appropriate heating systems and choice of 
column dimensions and mobile phase flow rate can help to improve the performance 
of temperature programming [14]. For example in the separation of structural 
isomers of anthraquinone disulfonic acid [Ill], on micro-bore and capillary HPLC 
columns [84]. The use of linear and step temperature gradients in separations in 
reversed-phase and normal phase with open tubular capillary LC was reported for the 
separation of chlorobenzenes when the temperature was increased within 12 minutes 
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from 90 to 160°C [112] and the separation of oligonuc1eotides from 12 to 60 base 
pairs was obtained by temperature programming [113]. 
The role of heating and flow-rates in temperature programming on the separation of 
a1kylbenzenes was investigated [90] and it was found that by using a fast heating rate 
and high collimn inlet pressure the separation time can be shortened significantly 
compared to isothermal high temperature HPLC [90]. Also in this study, temperature 
programming was used for the separation of a mixture of four standard proteins from 
30°C at a heating rate of 30 °C/min [90]. In comparison to isothermal high 
temperature HPLC at 50 and 80°C, it was concluded that the resolution of the two 
closely related proteins (13-1actoglobulins A and B) was higher with temperature 
programming than by isocratic elution [90]. Temperature progranuning to separate a 
mixture of chlorobenzenes was achieved using an open tubular capillary column 
packed with Hypersil ODS 3 JLm particle size [114]. It was found in this study that 
the desired resolution of early eluting solutes was accomplished at a low temperature 
and the strongly retained solutes were removed by increasing the temperature [114]. 
A specially designed heating system for temperature-programmed HPLC was used to 
separate cytostatic and antibiotic drugs with a temperature gradient using only water 
as the mobile phase [115]. In comparison to an isocratic elution of this mixture at 
room temperature, the overall analysIs time could be reduced from 20 to 10 min. by 
applying a temperature gradient starting from 40 to 130°C over 4 min [115]. From 
this study, it was concluded that a change in column temperature affects the whole 
column immediately, therefore, system re-equilibration is only possible after the last 
compound has been completely eluted from the column [115]. It is recommended 
that when temperature progranuning is applied, heaters with a large thermal mass 
should be avoided as a slow change in temperature will limit the application rsnge of 
the temperature programming mode to very slow temperature variations with time 
[14]. A temperature gradient was used to resolve and separate the five structurally 
related triazines (atrazine, simazine, propazine, ametryn, and terbutryn) from 170 to 
250°C at 10°C /min with superheated water as the mobile phase [116], enabled all 
five compounds to be resolved on polymer, silica and porous graphitic carbon 
(pGC)-based columns [116]. In another study [19], the evaluation of six 
commercially available analytical (Blaze C8, PRP-1, HyperCarb, the ZirChrom 
DiamondBond, CARB, and PBD ) columns were studied with respect to their 
stability and performance at extreme temperatures under temperature-progranuned 
high-temperature liquid chromatography (HTLC) and solvent gradient conditions 
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using three different mobile phase compositions (acidic, basic and neutral). This. 
study examined seven acidic, basic and neutral compounds. The findings of this 
study were that the three zirconia based stationary phases bleed under temperature 
programmed conditions (up to 200°C), whereas, there was no degradation of a 
polydentate silica (up to 100°C) column, a polystyrene divinylbenzene (PS-DVB) 
polymeric column (up to 150°C), and a graphitic carbon column (up to 200°C) [19]. 
1.6 Association of Thermodynamic properties with high temperature 
chromatography 
The concept of chromatography is based on the distribution between two phases 
(stationary and mobile phase) and the equilibration between these phases can be 
expressed as the distribution coefficient K [117] (equation 1.1) 
(1.1) 
Where Cs is the concentration. of solute in the stationary phase and CM is the. 
concentration of solute in the mobile phase. The operating temperature in liquid 
chromatography affects this distribution. This coefficient can be expressed relative to 
the retention factor (k) as follows: 
Where (Vs) is the volume of the stationary phase and (V M) is the volume of the 
mobile phase [117]. When there is a transfer of solutes between two phases, the 
relation between the free energy (Globs energy) and distribution coefficient follow 
equation (1.3): 
AGO = - RT In K (1.3) 
Where (R) is universal gas constant, (T) is the absolute temperature, and AGO is the 
standard free energy change. which can be expressed as : 
M1' = Ml' -T~ (1.4) 
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Where MI' and AS' are the standard enthalpy and entropy for the solute transfer 
between mobile to stationary phase. By replacing equation (1.4) in equation (1.3) the 
distribution coefficient can be written as: 
In k=·( Ml'IRT)-( AS'IR) (1.5) 
By replacing the equation of retention factor K with k in previous equation: 
" 
Ink = -&r/RT + &'/R + In tjJ (1.6) 
The term (~) is the phase ratio of the column and is simply is (ysfVM). 
A plot ofln k against lIT will resulting a straight line. This plot is known as a van't 
Hoffplot. The slope qfthis line will be -&r'1R and the intercept is ~SolR + In~. 
This plot in chromatography can be used to determine the thermodynamic variables 
and lead to an understanding the mechanism of separation [118]. 
A 
B 
~ -.lli"/R 
-Mr'/R 
Lnk V Lnk 
1 · 
6.SO/R + Incj> 
t-- 6.SO/R + Incj> 
11 T (k-I) liT (k-I) 
Figure 1.2: Two type ofvan'tHoffplots in liquid chromatography [117] 
Two types of van't Hoff plots can be seen [118]. In type (A), where the slope is 
large, the effect of enthalpy on the retention mechanism is higher and that means that 
the molecular forces of the interaction between the solute and the stationary phase 
principally govern elution. In this case, the separation is thermodynamically 
expressed (enthalpy driven). With large molecules, separation processes are much 
affected with increasing temperature [118]. In type (B), when the intercept is larger 
than the slope, the molecular forces don't govern the solute distribution between the 
two phases and mechanism of separation is controlled by the molecular order 
(entropica1ly driven). This means that the random distribution of solute in the 
stationary phase is limited. In this type, the separation is entropically driven, such as 
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in chiral separations [118]. In separation of polymer chains it was found that the 
slope of the van't Hoff plot was positive that means the sorption process of the 
polymer chains to the stationary phase is exothermic as (MI" < 0), and the intercept 
was negative indicates that the sorption process is entropically unfavorable (I!.S" < 0) 
[119]. However, in other study it was found that negative slopes of the van't Hoff 
plot were observed in the separation of the epirubicin and its analogues that indicate 
a . thermally positive or endothermic process (MIQ >0). This was interepreted as 
meaning that water molecules were dislodged by the solute from the surface of the 
silica but were more likely to partition within a hydration shell close to the surface of 
the silica [96]. 
The linearity of the van't Hoff plots was observed between 40 QC to 180 QC in the 
separation of mixture of drugs (antipyrine, aminohippuric acid, paracetamol, 
hydroxyantipyrine, aminoantipyrine, atenolol, aminobenzoic acid~ theophylline, 
phenacetin, and caffeine) indicating that there was no change in retention mechanism 
[7]. The linearity of van't Hoff plots were observed for basic analytes over the 
temperature range (range 10 to 80°C) [120]. Linearity of the van't Hoffplot is not 
always observed and therefore cannot be used to provide an energetic or entropic 
description of mechanism of separation [33,75,77,121]. At high temperatures the 
hydrogen-bond network in water will be weakened and water molecules will start to 
exist as monomeric species with a decrease in the specific permittivity of water 
[122]. Therefore, at high temperatures, as the hydrogen-bond is disrupted, this results 
in a marked change. The retention shifts from being entropically driven to 
enthalpically driven [93,123]. It was reported that the value of enthalpy MI" is 
considered as an indicator of the degree of interaction between an analyte and the 
stationary phase, and when it is a more negative it means a higher degree of 
interaction. With increased organic modifier ( acetonitrile) content, the value of MI" 
became less negative. An weak retention interaction between analyte and stationary 
phase occurred when the percentage of organic modifier in the eluent was increased 
[43]. In the separation of vitamin E isomers (a-, Y-, o-tocopherol, and a-, Y-, 0-
tocotrienol) and a -tocopherol acetate using a polybutadiene-coated zirconia colunm 
at temperatures ranged from 80 to 140°C, it was found that the separation was an 
. exothermic process as the MIQ values were negative, therefore, it is energetically 
more favorable for the vitamin E isomers to stay in the stationary phase than in the 
mobile phase [98]. The thermodynamics properties for non-polar solutes (diethyl 
phthalate, toluene, ethylbenzene, dichlorobenzene, 4-chlorotoluene) were 
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investigated using pure water at superheated temperatures, between 100 and 200 QC, 
as eluent and compared to the thermodynamics of the retention process at low 
temperature (15-55 QC). Considerable differences in the enthalpy of the retention 
process were observed between the two temperature ranges. This was attributed to 
changes in the hydrogen-bond network of the pure-water mobile phase, which would 
change the solvation [124]. 
1.7 Effect of temperature on selectivity 
Temperature is considered as one of the parameters that plays an important role in 
, selectivity [125], particularly for polar and ionisable compounds, since'ionisation 
equilibration are temperature dependent. Considerable changes in selectivity were 
observed in previous studies with temperature (25-50 QC) for the retention of 
ionisable compounds in methanol-water mobile phases [126] and MeCN-water 
mobile phases [127]. However, the effect of temperature on selectivity is often hard 
to predict because of the influence of other chromatographic parameters that govern 
retention [118]. The shape of solute and stationary phase are important where the 
retention mechanism governs the selectivity changes with temperature [128-\31]. As 
the retention time of analytes and usually changing in a very similar way with 
changing temperature, significant differences in selectivity may occur only if the 
degree of ionisation of anaIytes changes, especially if the analytes have different 
functional groups [131]. In general, higher temperature should reduce differences in 
K, and thus decrease selectivity between analytes. It was reported [102] that the 
effect of temperature was more pronounced for ionised samples and samples with 
more polar substituents [102]. However, in the separation of mixtures ofE vitamin, 
there was a systematic decrease in resolution with increasing temperature from 80 QC 
140 QC [140]. For each compound studied the resolution responsed inversely to the 
percentages of organic modifier used in the mobile phase at all temperatures studied. 
The resolution between y-tocopherol la-tocopherol at 100 QC using acetonitrile-water 
45:55 (v/v) was 3.59, while it was reduced by two and half fold at a temperature of 
120 QC [98].' In the separation of mixture of tricyclic antidepressants (quinidine, 
norephidrine, and tryptamine) using a PBD-coated zirconia column [86] in a mobile 
phase of a 40:60 (v/v) acetonitrile and water at pH 10, there was a significant 
improvement in selectivity for a mixture of tricyclic antidepressants on increasing the 
temperature from 40 to 100 QC. The same study reported [86] that in the separation of 
a1kylbenzenes, the selectivity decreased for all species with increased temperature. 
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1.8 Effect of temperature on efficiency 
One of the main reasons for the interest in temperature as a tool for the optimisation 
of chromatographic separations is the reported improvement in efficiency at elevated 
temperatures, because of the increased diffusion rate of the analyte [132]. The 
efficiency is significantly affected because the viscosity of the mobile phase is 
dependent on temperature according (0 equation (1.7) : 
11= Q exp (Pff) (1.7) 
Where Tt is the viscosity and T is (he absolute temperature. The values (0:) and (p) are 
constants which are dependent on the solvent used. If the temperature is increased 
that will lead to a decrease in viscosity thus the rate of mass transfer will decrease, 
with a increase in diffusivity of analytes at high temperatures [7], the efficiency will 
improve. Also another advantage of an increase in temperature is the reduction in 
back pressure which permits the use of high flow rates or smaller particle sizes and 
with the use of longer columns providing higher plate numbers. A flattening of the 
van Deemter curve enables the use of higher flow rates without hampering efficiency 
[82,97) (Figure 1.3) 
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Figure1.3: Plate height vs. linear velocity at various temperatures[87) 
H=LIN = A + Blu + Cu equation (1.8) 
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H is the theoretical plate height and L length of the column and N is efficiency of the 
column (number of theoretical plates), and A, B, and, C are in order the coefficients 
for "eddy "diffusion (which allows for the different paths a solute may follow when 
passing over particles of different sizes), longitudinal diffusion (which describe the 
contribution caused by molecular diffusion of the solute while passing through the 
column), and finally resistance to mass transfer (which allow for the limitation of the 
rate of transfer of the solute between the stationary phase and mobile phase) [133] 
The effect of elevated temperature on the coefficients (A, B, and, C) can be 
summarised in next table 1.2 [134]. 
Table 1.2: The effect of elevated temperature on the coefficients of van 
Deemeter curve (A, B, and, C) [134) 
Coefficients Effect of elevated temperature 
A (eddy "diffusion) Uncertain, improves the laminar flow 
and lateral mixing of analyte molecules 
from different flow channels due to the 
increased diffusivity, although the 
improvements may not be significant 
B (longitudinal diffusion) Increases with increasing temperature 
C (adsorption/desorption kinetics, mass Decreases with increasing temperature 
transport between phases and diffusion 
inside the stationary phase) 
However, a study carried out to model the effect of temperature on column efficiency 
in high temperature [135] concluded that at constant linear velocity, the mass transfer 
term C in the van Deemter equation governs the plate height, more than at lower 
temperatures. [24] Therefore, the plate height decreases with increasing temperature 
whereas at low flow rate, it increases with increasing temperature because of the 
longitudinal diffusion term CB term). This observation also was confirmed in other 
studies [135]. It was reported the efficiencies of mixture of three dyes (yellow, red, 
blue) increased with decreasing eluent temperature to sub-cooling temperatures 
[136]. In another study, the efficiency of separation of l-phenylnonane was improved 
by as much as 30% on increasing temperature from 25 QC to 65 QC [86]. An 
investigation to study the effect of temperature on peak shape of basic compounds 
was carried out, using Inertsil ODS-3V column and under different pH of mobile 
phase (3 .0 and 7.0) [35]. It was found that the efficiency of compounds used in the 
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experiment (pyridine, quinine, and nortriptyline) showed an increased in both the 
acidic and neutral buffers with increasing temperature also it was found that the peak 
asymmetries of quinine and nortripyline were reduced at pH 7, there was no effect on 
the neutral compound benzene. These observations were attributed to kinetic effects 
associated with the desorption from silanol binding sites [35]. The effect of the 
elution strength of subcritical water has been investigated [91] on peak asymmetry 
and efficiency for catechol, aniline and pyridine on Chromatorex C-18, Zorbax RX-
C-18, and poly (styrene-divinylbenzene) columns using temperature ranged from 60 
to 200 °C. It was found that the efficiency and peak symmetry were improved with 
subcritical water separation compared to traditional separations using organic 
solvent- ambient water mixtures on the PRP-I [91]. On increasing the temperature 
from 25 to 65 °C on a zirconia based packing the efficiency improved by 30% [1 37], 
while an increase between 25 to 70 °C on a silica-based packing improved efficiency 
by 48% [105]. 
1.9 The effect of temperature on ionisable compound: 
The pH of the mobile phase plays important role in the retention of ionisable 
compounds in HPLC as it governs their form during separation. However, 
pharmaceutical compounds often contain ionisable functional groups such as 
carboxylic acid groups, amino groups, sulphonamide groups, and their separation 
depends on the degree of ionization. The degree of ionisation is affected by different 
parameters including pH, mobile phase composition and temperature. It is well 
known that the changes in retention and selectivity with pH may be extremely large 
for some acidic and basic compounds [138]. The separation of ionisable analytes 
depends on the protonic equilibrium between two phases. 
HA .~-----
HB++4----- ~ 
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Figure 1.4: The elTect pH of mobile phase 011 the retention time of basic, acid, 
neutral compounds only for RP-HPLC. 
14 
The effect of pH of mobile phase 011 the retention time of basic, acid, neutral 
compounds can be illustrated (Figure 1.4). For acidic compounds, it is clear that at 
low pH the compound will be retained as it existsing neutral form. Whereas at high 
pH the acids will exist as an ionised form therefore the interaction between the 
analyte and the stationary phase will decrease which will lead to rapid elution. 
However, with basic compounds this observation will be the mirror image as at low 
pH they will separate quickly as they will be in the ionised form, whereas they will 
be neutral at high pH and well retained. It is recommended to use pH one unit higher 
or lower than the pKa depending on whether the compounds is acid or base in order 
to stablise the compound' s ionisation. Neutral compounds are not effected by pH. 
Many buffers are used to adjust mobile phase pH, such as phosphate, formic acid, 
acetate buffer. However, it was reported for the carboxylic groups, acid dissociation 
is an energetically unfavourable process. An increase in temperature will therefore 
increase the degree of dissociation and the amount of A· therefore the retention time 
will decrease (11]. In another study [96], the temperature effect upon 
chromatographic separation on epirubicin and its analogues at different pHs was 
investigated. It was found that an increase of retention was observed at low pH 2.9 
while the retention values of the solutes decreased little at pH 4.2. Finally a 
considerable drop in retention was observed at pH 5.2 as the ionisation of the silanols 
20 
Chapter 1 High temperature HPLC 
on the silica surface steadily increased and the solutes were kept in a protonated state 
[139). This will change the mechanism of retention from hydrophobicity to cation-
exchange. In this situation when ion-exchange becomes the governing mechanism, 
the pKa of the analyte plays an key role in influencing retention and selectivity. 
However, it is well known that the protonated state of the solutes will be reduced 
with an increase in temperature and a weakened ion-exchange contribution, thus the 
retention of the solutes would decrease [95,140). Another study on the separation of 
ionisable compounds concluded that the selectivity will improve at high temperature 
and at high mobile phase pH for solutes that undergo two independent retention 
processes [11). In the analysis of some diuretics drugs, the effects of pH and the 
modifiers acetonitrile on the peak retention time (138) found compatible results 
(Figure 1.4.) The retention factors of the acidic diuretics (xiparnide, canrenoic acid, 
piretanide, furosemide, bumetanide, ethacrynic acid and probenecid) decreased with 
increasing pH. However, there was no change in the retention factors with increasing 
pH of neutral diuretics (spironolactone) and weakly acidic (cWorthalidone, 
acetazolamide and thiazides). Whereas for the basic diuretics amiloride and 
triamterene, the retention increased with pH [138) . The effect of temperature on the 
selectivity of ionisable compounds, such as carboxylic acids, amines, amino acids, 
and peptide compounds has been studied [11). It was found the selectivity of 
ionisable compounds improved at elevated temperature, and this improvement for 
carboxylic compounds is roughly related to the pH of the mobile phase. The mobile 
phases (PH > 7) were more effective for the analysis of these compounds. Moreover, 
the buffers can play a key role in affecting the retention, selectivity and changing the 
selectivity with temperature, particularly for coeluted compounds. The separation of 
basic compounds at high temperature was studied with respect of retention and the 
peak shape [35). Between pH 3.0 and 7.0, the retention time decreased,for neutral 
compounds with increasing temperature and increased for basic compounds. The 
peak asymmetry was significantly reduced and efficiency was increased with 
temperature at the same range of pH. In another study [95), it was found that the 
peak shapes for bases improved significantly at elevated temperature (up to 70 °C), 
with the weakest bases studied (pKa - 8) giving greater improvement than the 
strongest bases (pKa- 10). ) and in the same study, quaternary ammonium 
compounds showed a modest change in retention that might be influenced 
significantly by a decrease in the pKa of bases with temperature, leading to reduction 
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in protonation. The selectivity is influenced by solvent strength to a greater extent 
than the temperature [141]. 
However, the efficiency of weak bases was improved at higher temperatures as pKa 
will decrease with increased temperature and there was slightly improvement in the 
efficiency of quaternary compol!Ilds as no change in ionization with pH [24]. The 
effect of temperature on the efficiencies of epirubicin and its analogues at different 
pHs showed that at constant temperature the higher the pH, the lower the efficiency 
as result of the effect of ion-exchange interaction as this interaction is responsible for 
retention of solutes at higher pHs. Whereas with increasing temperature at constant 
pH, improved efficiencies were observed however [96]. In this study, also, [96] it 
was found that at pH 5.2, the elution order between epirubicin and daunorubicin 
drugs was reversed with increasing temperature. This indicated that the impact of 
temperature on retention for various solutes was different. 
The ion-pair chromatography of carboxylic acids, showed a decrease in selectivity 
with increased temperature [11] if the ion-pair complex formation and its retention 
enthalpy is dominant, otherwise an improvement in selectivity may be seen [11]. The 
understanding of the effect of temperature on selectivity is still controversial as 
different results were observed for different systems, especially for analytes that exist 
in secondary equilibrium. It can be difficult to experimentally understand the effect 
of temperature on selectivity [11] . As it was reported in previous studies [142,143], 
with increasing temperature the pKa of solutes decreases, and this behaviour is 
greater when the base has a smaller pKa. This observation was found in the 
separation of epirubicin (pKa 8.08) which is smaller than that of daunorubicin (pKa 
8.46) [96]. A greater reduction of the protonated species will be obtained for 
epirubicin as the retention decreased more quickly for epirubicin than for 
daunorubicin, and the two solutes move closer and closer with increasing 
temperature. Another conclusion from previous studies, concluded that if the van't 
Hoff relationship of two solutes indicated one retention mechanism, increasing 
temperatures will be expected to decrease selectivity, since the temperature is 
inversely proportional to In k especially for small solutes with simple interaction 
mechanisms [144,145]. However, at elevated temperatures, it is more important to 
improve the peak shapes of broad or asymmetric peaks than small changes in the 
selectivity. In the separation of ionisable compound such as carboxylic acids and 
amine compounds, it was reported that the increasing temperature at high pH 
improve selectivity [35,146]. 
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1.10 Aim of this study 
As has been seen, temperature is a key parameter in separations by reversed-phase 
high performance liquid chromatography. This work, the high-temperature high 
performance liquid chromatography (HT-HPLC) of a range of different group of 
pharmaceutical compoUnds (carboxylic acidic, moderate acidic sulphonamide)wiU be 
examined on different stationary phases, including Pathfinder® RP, Selerity 
Blaze200, Xterra RP18, XBridge™ RP18 shielded, XBridge™ C18 columns using 
different proportions of mobile phase and pure water as eluent in a new approach for 
the separation ofthese selected group of drugs: 
1) Cephalosporin drugs (cephadroxil, cephaclor, cephalexin, and cephradine). 
2) Non-steroidal anti-inflammatory drugs (NSAID) (ketoprofen, sulindac, 
indoprofen, flurbiprofen, suprofen, naproxen, indomethacin, diclofenamic, 
and niflunamic acid) . 
3) Diuretic drugs (chlorothiazide, hydrochlorothiazide, hydroflumethiazide, 
chlorothalidne, clopamide, methyc1othiazide, c1orexolone, mefruside, 
benzothiazide, polythiazide and lastly cyclopenthiazide). 
The selectivity and retention patterns of these drugs will be investigated at different 
temperatures ranged from 25 to 140 QC. The resolution and efficiency of the 
separation ofthese drugs will be examined. Van't Hoffplots will be used to compare 
the effect of increasing temperature with the effect of changes in the organic 
proportion of mobile phase on the retention mechanism. FinaUy, an attempt to 
establish the best conditions for the separation of these drugs using these columns 
will be determined for qualitative and quantitative purposes. 
Finally, a full validation study will be done only on cephalosporins study, 
according to International Conference on Harmonisation (ICH) standards to 
determines LOD, LOQ, reproducibility, linearity and precision 
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2.1 Reagents 
All mobile phase solvents were bought from Fisher Scientific Company 
(Loughborough), methanol (MeOH), acetonitrile (MeCN), acetic acid (AcOH) were 
HPLC grade. Ammonium acetate, orthophosphoric acid and potassium dihydrogen 
orthophosphate from Fisons Company, Loughborough (U.K). Sodium acetate 
anhydrous was from BDH limited, Poole, England. Double-distilled deionised water 
of at least 18 MO was purified by a Elga Maxima unit (Elga Ltd. Wycombe, Bucks. 
UK). Cephalosporins, non-steroidal anti-inflammatory (NSAIDs), and diuretics 
drugs were purchased from Sigma-Aldrich. (U.K). 
2.2 Chromatographic equipment 
The chromatographic separations were carried out on the different columns listed in 
(Table 2.3). The HPLC system (figure 2.1) consisted of a SP8810 isocratic pump 
(Spectra-Physics, San Ions, CA, USA), an Applied Biosystems 757 absorbance 
detector set at: cephalosporins 254 run, NSAIDs at 230 run, and diuretics at 271 run, 
(California, USA), and either a Shimadzu CTO-610 module column oven, (Japan) or 
a 5890 GC oven, Hewlett Packard, (USA). The eluent flow rate was 1 m1lmin unless 
other were stated. Samples were injected using a 10 ilL syringe (SGE, Australia) 
using a Rheodyne 7125 injection valve (Cotati, USA) fitted with a 20 ilL loop. [pH 
meter 220, Ciba Coming Diagnosis Limited, (Suffolk, England)]. The column 
temperatures ranged from 25 to 140°C. The length of connecting tubes between 
injector and column was 90 cm. A computer was used for the integration and 
calculation data with Windows 98 and Star chromatography programme (Varian). 
[The sonication bath was VWR international model USC300T, (Malaysia)]. 
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Injector Cooling 
~--------, Coil ,----, 
Pump Column 
Pre-Heating Column Oven 
Detector 
Data · 
Collection 
Figure 2.1: Diagram of high temperature HPLC system 
2.3 Column systems 
Table 2.1: Columns examined in this project_ 
Tradename Phase Particle Size Column Manufacture 
Chemistry /p,m. Dimension/ 
mm 
Pathfinder Encapsulated 3.5 (4.6 x150). Simadzu 
®PSlOO silica C18, Company 
and low 
amount 
ammo on 
surface 
XterraRP18 hybrid 3.5 (4.5x150) Waters 
(Figure 2.2) particle and Company 
shield 
technology 
XBridge™ Internal 3.5 (4.5x150) Waters 
RP18 ethylene Company 
shielded bridge group 
(long) with amide 
(Figure 2.3 & silica C18 
2.5) 
XBridge™ Internal (4.5x50) Waters 
RP18 ethylene Company 
shielded bridge group 
(short) with amide 3.5 
(Figure 2.3 & silica e18 
2.5) 
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Tradename 
XBridge™ 
CI8 (short) 
(Figure 2.4) 
Selerity 
Blaze200 
(Figure 2.6) 
v 
Phase 
Chemistry 
Internal 
ethylene 
bridge with 
out amide 
group 
polydentate 
silica phase 
Particle Size 
Illm. 
3.5 
3.5 
MQlhylPo lyolhoxy~llong 
IMPEOSI 
Experimental 
Column Manufacture 
Dimensionl 
mm 
(4.5x50) Waters 
Company 
(2.1x150) Selerity 
Company 
WCcerr 
I I 
Waters Patented Technology 
us Potonl: 6 ,686,035 82 
Dole of Polont: Fob 3, 2004 
[ 
,.0 
2 EO /' i' .... OEI 
'''' 
·F ] , 
• • 
ElO ,-' I .... 00 
.0 
TotrOQlnoxy,Uono Molhyltr lothoxysllano 
{TEOSI IMTEOSI 
Figure 2.2: Stationary phase of Xterra RP18 [Waters catalogue] 
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OH 
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Figure 2.3: Stationary phase of Xbridge colulllus [Waters catalogue] 
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R 
I 
.JVVI,S i 
I 
0 
I 
Experimcntal 
Figurc 2.4: Stationary phase of XBridge™ C18 
[Waters catalogue) 
Figu"e 2.5: Polar embedded stationary phase of 
XBridge™ RP18 [Waters catalogue) 
R R 
I I 
Si S i'\lV\. 
I I 
0 
n 0 
Gen. 1 Polydentate 
Figure 2.6: Stationary phase of Selerity Blaze200 [Selcrity catalogue} 
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2.4 Procedure 
2.4.1 Preparation of stock solution of drugs 
2.4.1.1 Stock solutions of cephalosporin drugs (500 ppm) were prepared by 
dissolving 12.5 mg of each compound in 25 ml deionised water. Mixtures of the 
cephalosporins (80 ppm) were prepared by diluting in an appropriate mobile phase. 
2.4.1.2 Stock solutions of NSAIDs drugs (500 ppm) were prepared by 
dissolving 12.5 mg of each compound in 25 ml MeOH. Mixtures of the NSAIDs (SO 
ppm) were prepared by diluting in an appropriate mobile phase. 
2.4.1.3 Stock solutions of diuretic drugs (500 ppm) were prepared by 
dissolving 12.5 mg of each compound in 25 ml MeCN. Mixtures of the diuretics (SO 
ppm) were prepared by diluting in an appropriate mobile phase. 
2.4.2 Preparation of buffer: 
SO mM phosphate or acetate buffer was prepared by weighing the required weight of 
salts in appropriate volume of deionised water and adjusted the pH using pH meter 
before mixing with. the organic solvent. 
2.4.3 Preparation of mobile phase: 
It was prepared by mixing an appropriate volume MeCN or MeOH with the buffer 
solution or water. 
2.4.4 Void volume (to) determination 
Void volume (to) was determined [147J by using a diluted solution of uracil in water. 
The values varied with eluent and temperatures (Tables 2.2-2:4) 
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Table 2.2: Void volume (to) determination for cephalosporins: 
, Mobile ' ' 
"Phase*' " Dead volume (to) Column .' '" Column temperature ("C) (v/v) 25 40 60 80 
MeOH-H2O 2.58 N.d N.d N.d [30:70] 
MeOH-H2O 
2.62 [15:85] 2.43 2.40 N.d 
Xterral 
MeOH-H20 
[10:90] 2.64 2.54 2.42 N.d 
column 
MeOH-H2O 
[5:95] 2.82 2.71 2.58 N.d 
H20 [100%] 3.11 ' 2.99 2.78 N.d 
, MECN-H20 
2.80 [3:97] 2.78 2.60 N.d 
',' MeOH:H20 
\ [10:90] N.d 1.46 1.45 1.32 
MeOH-H20 
[5:95] N.d 1.53 1.48 1.40 
Selerity 
Blaze2002 H20 [100] 
colunms N.d 1.76 1.56 1.44 
'MeCN-H20 
[3:97] N.d 1.47 1.36 1.31 
MeCN-H20 
N.d 1.39 1.38 1.36 [6-94] 
.. 
* All mobile phases contained 0.1 % AcOH 
1) Xterra column, flow rate Imllmin, injection volume (10 JlL). 
2) Selerity Blaze200 column, flow rate 0.5mllmin, injection volume (2 JlL). 
N.d= not determined. 
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100 
N.d 
N.d 
N.d 
N.d 
N.d 
N.d 
1.29 
1.33 
1.36 
1.30 
1.30 
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Table 2.3: Void volume (to) determination for NSAIDs study: 
Mobile 
. Peadvolume (to) 
Column Phase* 
MeCN-Buffer . Column temperature ("Cl 
. (v/v)· 40 60 80 
[25:75], pH 3 1.64 1.63 1.60 
[25:75], pH 4 2.11 1.96 1.71 
[25:75], pH 5 2.01 1.93 1.65 
XBridge™ 1.78 1.70 1.62 RP18 [25:75], pH 6 
shielded 
N.d 1.81 1.77 [10:90], pH 4 
[10:90], pH 5 N.d 1.81 1.57 
[10:90], pH 6 N.d 2.12 1.82 
...,. Mobile __ . ...,....,. . Colu~ temperature ("C) 
• . 0. Phase* .... 
40. 60 80 I 100· 120 140 MeCN-Buffer 
[45 :55], pH 4 1.70 1.70 1.68 1.68 N.d N.d XterraRP18 
[25:75], pH 4 1.95 1.84 1.81 1.79 1.77 1.80 
[25:75], pH 5 1.90 1.87 1.62 1.53 1.50 1.51 
---
Mlibjle Phase* 
. F10wrate .. . .. .... M~CN-Buffer 
.. 
. (riilImin) . •. [10:90], pH .... [5:95], plI 6,. [0:100], pH 6, 
Short 6,80rb . 80-(00 120-(O"C) 
XBridge™ 1 0.72 0.73 0.74 RP18 
shielded 
2 0.37 0.36 0.32 
3 0.22 0.25 N.d 
* At pH 3 & 4 phosphate buffer (50 mM) with phosphoric acid. 
* At pH 5 & 6 sodium acetate buffer (50 mM)with acetic acid. 
N.d = not detennined. 
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Table 2.4: Void volume (to) determination for diuretic drugs study: 
Mobile .. 
Column Phase* Dead volume (to) 
MeCN-H2O Column temperature ("C) 
(v/v) 40 60 .' SO 
[30:70] 1.62 1.57 1.50 
60 SO 100 
Long 
[15:S5] 1.71 1.66 1.63 
XBridge™ . 100 120 140 RPlSshielded [5:95) 1.69 1.69 1.75 
[lOO] .. 100 . 120 140 . 
1.S6 1.7S 1.74 
* All aqueous portions contained 1 % AcOH and flow rate was at 1 mllmin. 
2.5 Data acquisition and manipulation: 
The calculations of the separation parameters were performed using Star 
chromatography programme. Excel was also used for some calculations. 
The following equations were used. . 
1. Retention factor (k): is known as the ratio of the reduced retention volume to 
the void volume. 
k= 
. Equation 3.1 
tR = retention time, to = dead time (volume) 
2. Selectivity: is the ratio of the retention factors of two analytes according to 
bellow equation. 
a 
Equation 3.2 
k = retention factor, n = peak number 
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3. Efficiency (N): 
The efficiency detennines the band broadening and the number of theoretical plate 
(N) of analytes in the column and is usually expressed as using the following 
equation: 
Equation 3.3 
HETP=~ 
N 
Equation 3.4 
Wb = the peak width at base, Wh = the peak width at half, n = peak number., L= length 
of column in meter. 
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Chapter 3 Cephalosporin study 
3.1 General background 
3.1.1 Introduction 
Cephalosporins 
Cephalosporin was discovered in 1945, when it was isolated by Italian scientist 
Bortzu from Cephalosporium acremonium fungus from the sea that was close to a 
sewer outlet off the Sardinian coast [148] Crude filtrates from this fungus contained 
sub~tances that were effective in curing Salmonella typhi, the cause of typhoid and 
inhibited the in vitro growth of Staph. aureus [149]. The cultures from this fungus 
were found to contain three distinct antibiotics, which ,are known as cephalosporin P, 
N, and C [149]. 
3.1.2 Chemical structure 
Cephalosporins are a group of broad-spectrum antibiotics that are based around the 
p-lactam ring structure (Figure 3.1& Table 3.1) and are widely used in veterinary 
and human medicine for preventing and treating bacterial infections [150]. They cure 
infectious diseases caused by both gram-negative and gram-positive bacteria. 
Cephalosporins are among the oldest and most regularly prescribed of naturally 
occurring antimicrobial agents [151]. All of cephalosporins derive from the 7-
aminocephalosporanic acid composed of a p-lactam ring integrated with a 
dihydrothiazine ring (Figure 3.1), but differ in the nature of the substituent at the 3-
and/or 7 -positions of the cephem ring. The pharmacokinetic properties of 
cephalosporins are dependent on substituents at 3-position and the antibacterial 
spectrum activity depends on 7-position substituents [152]. 
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H RyN S 
7 
0 N ~ 
0 X 
eOOH 
Figure 3.1: General chemical structure of cephalosporin 
Table 3.1: Typical cephalosporin drugs 
Drug Strnctnre 
XLogP 
[153] 
H , 
o 0 
Cefadroxi l 
-0.355 
H ·N 
• 
" I o 0 
Cephaclor 
0.517 
It _ N~ 
" 
" I o 0 
Cephalexin 
0.019 
H _N, 
" 
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Structure 
XLogP 
Drug 
[153] 
H , 
~oy~ 0 
Cephoxazole 
1.768 11 ~ 
H ~ 
0 
"" 
~ / 
I N 
# 
C l 
" 
, 
Cefamandole ·f]l Y~w • / -0.025 
0 
" I 
o 0 
Cephradine 
-0.772 
,{ ~ 
H ~ N, 
H 
XLog [153] is partition coefficient in octanol!water (logP) and is used to measure the 
hydrophobicity character of an organic compound. 
3.1.3 Classification of cephalosporin 
The development of a range of cephalosporin drugs led to a method to classify them 
into four generations, based on their activity against bacteria [149] (Table 3.2). 
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Table 3.2: Classification of cephalosporin 
Type of 
Medicinal activity Drugs 
generation 
1 sI generation Activity against Escherichia Cefacetrile, cefadroxil, cefaiexin, 
coli, Klebsiella pneumoniae cephaloglycin, cefalonium, 
and Proteus mirabilis, cephaJonium, cephaloradine, 
spectrum penicillinase- cephalothin, cephapirin, cefatrizine, 
producing, methicillin- cefazaflur, cefazedone, cephazolin, . 
susceptible staphylococci cephradine, cefroxadine, ceftezole. 
and streptococci 
200 generation Strong activity to Gram- Cefachlor, cefonicid, cefprozil, 
I negative spectrum while cefuzonam, cefamandole, 
retaining some activity ceforanide, cefotiam, carbacephem, 
against Gram-positive cocci, cephamycin. 
resistant to beta-Iactarnase. 
3YO generation Broad spectrum of activity, Cefcapene, cefdaloxinie, cefdinir, 
activity against Gram- cefditoren, cefetamet, cefixime, 
. 
negative organisms, Gram- cefinenoxime, cefinenoxime, 
positive organisms, used to cefodizime, cefoperazone, cefteram 
treat hospital-acquired cefotaxime, cefpimizole, ceftiolene 
infections, cefpodoxime, ceftiofur, ceftibuten, 
ceftizoxime, ceftriaxone, cefsulodin 
ceftazidime, cefpiramide. 
4 tn generation Activity against Gram- Cefquinome, cefpirome, cefozopran, 
... positive organisms as I sI cefoselis, cefluprenam, cefepime, 
generation, greater resistance cefc1idine 
to beta-Iactamases than 3 rd 
generation. Can cross blood 
brain barrier and are 
effective against meningitis. 
3.1.4 Medicinal importance of cephalosporin [149J 
The cephalosporin drugs are used in the treatmen.t of infectious diseases that result 
from bacteria organisms by the inhibition of bacterial cell-wall synthesis to block the 
construction of the cell walls. This causes the walls to break down and eventually the 
bacteria die[149]. However, cephalosporinscan treat many bacterial infectious 
diseases, such as urinary tract infections, and upper respiratory infections, such as 
pharyngitis (throat inflarmnation) and tonsillitis, and also treat otitis media 
(infiarmnation of the middle ear), skin infections, bronchitis, pneumonia, and 
occasionally bone infections. [154]. Another role of cephalosporins is to be used as 
prophylaxis for surgery where infections in the operating area could pose a serious 
risk [155]. 
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3.1.5 Cephalosporin analysis by HPLC 
. Many methods have been reported for cephalosporin analysis, including iodometric 
titrations [156,157], microbial assays [158], spectrophotometric UV-vis analysis 
[159], fluorometry [160, 161], chemiluminescence (CL) [162,163], and capillary 
electrophoresis (CE) [164]. HPLC with ultraviolet absorption detection is the most 
popular method and is frequently used for cephalosporin analysis in pharmaceutical, 
biological and clinical samples because of its speed and specificity (selectivity), and 
because it allows the simultaneous analysis of several different drugs. Different 
separation conditions of HPLC with different detectors have been used in order to 
increase the selectivity and sensitivity [165,166] (Table 3.3). It was reported [167] 
that the separation of the individual cephalosporins usually requires a low proportion 
of organic solvent (9-20%) for weakly retained analyts (i.e., cephalexin) than for a 
strongly retained compounds (Le., cefamandole). As a result the mobile phase in 
most cases has a high portion of water (Table 3.3) [167]. One previous article has 
reported the use of high temperature for the analysis of cephalosporins (cefaclor, 
cephazolin, cefodizime, cephaloridine, cephamandole, and cephalotin) using 
different concentrations of acetate buffer/isopropanol under temperature ranging 
from 20-60 °C [168]. It was found in this study that the retention time decreased with 
increasing temperature and linear of van't Hoff plots were observed. The present 
study set out to develop confirmatory methods of analysis using high temperature 
. high performance liquid chromatography coupled with UV detector (HT -HPLC-UV) 
for cephalexin, cefamandole, cefaclor, cefadroxil cephradine and cephoxazole. The 
methods will be validated according to ICH. 
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Cephalexin, cefamandole" cefaclor, 
Ceftxime, cefacior, cefadroxil, 
cephalexin, and cephradine 
Cefaclor, cefadroxil, cefamandole nafate, 
cefamandole, cephalexin, cephradine 
Cefalcor, cefalexin, cefradine, cefadroxil, 
Cefaclor,cefotiam,cefazolin, 
cephalexin, cephradine 
Cefadroxil, cephalexin. 
Cephalexin and cefaclor 
. 
Cefaclor 
0.01 M CH3COONa 
/MeCN-MeOH, pH 5.2. 
Waters. C IS ,/L-Bondapak 
(300 x 4 nun, 10/Lm) 
MeOH 1 KH2i'04 buffer pH CS (4.6 x 150 nun, 5/Lm) 
2.6 (20/S0) 
MeOH -water-AcOH 
(30 + 70 + 0.1) 
50 mM KH2P04 buffer (PH 
3.4) /MeCN (S7.5:12.5) 
20 mM CH3COO~ 
/MeOH (80:20 ) 
om M KH P04- MeCNin 
gradient .mode 
Tetrabutylannnoniutn 
hydrogen sulphate (0.025 
M)-MeOH-MeCN (96:2:2) 
pH 3.0 
0.05 M CH3COO~­
MeCN (9S.5/1.5) , 
CIS 
Hypersil ODS ClS 
(200 x 4.6 mm, 5 /Lm) 
Mightysil-Cl8 
(150 x 4.6 mm,) 
Supelcosil LC-18 column 
(150 x 4.6 mm, 5 /Lm) 
Metaphase-CrestPak-
ODS 
(250 x 4.0 nun, 5 /Lm), 
RP-ClS 
UV254 167 
UV240. 169 
UV254 170 
UV254 171 
UV220 172 
173 
UV260 
UV248 174 
UV254 175 
Cephalexiri, cephapirin 
Cephalothin, cefoxitin, cefamandole, 
cefuroxime, cefotaxime, ceftazidime and 
cefoperazone. 
Cephalexin, cefuroxime, cefoidtin and 
cephaloridine 
Cephalexin, cefaclor. 
cefadroxil, cephradine, 
Cefaclor, ceftizoxime, cefaJoridine, 
cefazolin 
Cephradine and cephaloridine (internal 
standard) 
Water and MeCN acidified 
with 0.1 % fonnic acid. 
Gradient mode 
40g ofN-cetyl-N,N,N-
trimethylammonium 
bromide. 50ml ofO.02M 
Titrisol-phosphate buffer 
(PH 7) and 0.1 ml AcOH to 
350 m1 of MeCN. 
MeCN in 0.02 M acetate 
buffer (PH 4.3) (15:85 v/v) 
87% 0.01 M acetate buffer 
(PH 4.7) with the balance 
being organic modifier as 
either MeCN, MeOH, or a 
mixture of the two. 
Water- MeOH -AcOH 
(60:40:0.5) 
MeCN-20mM 
(NH4)H2P04 (10.5:89.5), 
pH 2.75 
RP18 
(250 x 4 mm, 5 /lm) 
LiChrosorb RP 18 
(250 x 4 mm, 5/lm.) 
Partisil ODS-3 
(250 x 4 mm i.d.) 
Nova-PakCl8 Radial-
Pak cartridge 
(lOO x 8, mm, 4 /lm) 
C18 
(150 x 0.3 mm) 
PLRP-S 
(ISO x 4.6 mm I.D.,S 
/lm). 
MSIMS 
UV240um 
UV254nm 
Pulsed amperometric 
detection (P AD) 
UV262 
UV260 
176 
177 
178 
155 
179 
180 
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3.2 Results and discussion 
3.2.1. Introduction: 
A high temperature high-performance liquid chromatographic method using different 
columns, Pathfinder® RP column, Xterra RP18 artd Selerity Blaze200 has been 
examined for the simultaneous analysis of six cephalosprins. The analytes were 
chromatographed using different proportions of acetonitrile (MeCN) and methanol 
(MeOH) with aqueous acetic acid (AcOH) as the mobile phase at different 
isothermal temperatures ranging from 25 to 80°C . The effluent from the column 
was monitored at 254 urn. 
3.2.2 Pathfinder column 
The Pathfinder® RP columns are designed to have both the strength of polymer and 
'. silica based HPLC packing materials [181] and to have high efficiency and pressure 
stability. They are recommended for use with 100% water and at elevated 
temperature LC (IIT-LC, green HPLC) [181]. The column used in our study was the 
PS phase, which is a polymer-encapsulated silica with polymer and low amount of 
amino activity on the surface besides C18 chains. Analysis of six cephalosporins was 
carried out this column under different conditions with a variety of column 
temperatures. These drugs are cephaclor, cephoxazole, cephalexine, cephadroxil, 
cephradine, and cephamandole. A standard solutions (80 ppm) were prepared from 
. these drugs by dissolving the appropriate amount into deionised water. The initial 
study was based on a method developed by Signs and co-workers [167].They used a 
Waters C-18 10 p.m particle, p.-Bondapak C18 column which was changed in our 
method to be Pathfinder@PSI003.5 column. 
3.2.2.1 Preliminary investigation 
a) Group one (cephalexin, cephaclor and cephoxazole) 
The present study used a Pathfinder @PSI00 3.5 column with an eluent of 
MeOHlMeCN (96:4) with aqueous buffer at pH 5.2 is different proportions at 
temperatures from 25-70 °C (Table 3.4) for the separation of Cephalexin, Cephaclor 
and Cephoxazole. A mobile phase consisted of 0.01 M sodium acetate (90) 
40 
Cbapter3· 
lacetonitri1e-methano1 (10), pH 5.2. The organic 
acetonitrile 4% methanol. Flow rate was (lmllmin). 
CepbaJosporins 
phase used consisted of 96% 
Initially the connection tube between the injector and column was PEEK (red line) so 
there is some difference' in temperature between column and incoming solvent 
temperature. The separation between three drugs occurred quickly in the order 
cephalexin, cephac10r and lastly cephoxazole. With increasing temperature it was 
found that coe1ution occurred at 50, 60 (Figure 3.2) and 70 DC between cephac10r 
and cephalexin (Table 3.4). A strange behaviour was found as with increasing the 
temperature the run time increased. Therefore it was decided to change the 
connection tube to stainless steel connection to preheat the mobile phase before it 
enters the column to avoid unacceptable peak broadening [87]. However with 
preheating, no improvement in the shape of the peaks or resolution was found but the 
retention time increased (Table 3.4) suggest that the column. was hotter .. There was 
no peak overlap between cephalexin and cephac10r; It was suspected that the degree 
of ionisation had changed with temperature hence an abnonnal temperature effect, 
Therefore the mobile phase was changed to 70% ofbuffer at pH= 5.2 prepared from 
. anunonium acetate 0.01 M adjusted by phosphoric acid and 30% of methano1. 
However, at 40 DC, cephac10r and cephoxazo1e were coe1uted as one peak but the 
retentions decreased with increased temperature (Table 3.4). To increase retention; 
the percentage of water was changed to 90% and pH changed to 4. A full separation 
was only present between the drugs at 25 and 40 DC as at higher temperature, 
cephalexin and cephac10r coe1uted (Figure 3.3). 
It was concluded that the previous conditions were not effective for the separation of 
all three drugs, also the peak shapes were poor. 
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Table 3.4: Retention time of cephalosporins on Pathfinder@PSI00 column at 
. I 'f~ different co umn temperature and dl erent eluent 
-Mobile Phase Retention time (till 
Organic-water Drug 
, 
Column temperature lC 
2S 40 
VN 
CephaIexin 
7.28 7.04 1) (MeOH 96%: 
MeCN 4%) with Cephaclor buffer [9:1], 9.06 7.55 
pH=S.2 
Cephoxazole 9.28 8.55 
2) (MeOH 96%: Cephalexin 7.57 7.99-
MeCN 4%) with 
buffer [9:1], Cephaclor 
pH=4 8.01 7.99-
Cep_hoxazole 9.20 9.58 
- Cephalexin 4.45 3.66 
MeOH-buffer 
[7:3], pH= 5.2 Cephacior 
4.99 4.01* 
Cephoxazole 5.66 4.01* 
CephaIexin 
20.13 15.07 
MeOH-buffer Cephaclor [9:1], pH= 4 20.63 15.51 
Cephoxazole 31.62 23.37 
1) Before using preheating [PEEK inlet] 
2) After using preheating [with stainless steel inlet] 
* Cephaclor and Cephoxazole co eluted. 
-Cephaclor and CephaIexin coeluted. 
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50 60 
7.41 7.74 
8.98* 9.34* 
8.98* 9.34* 
8.25- 8.86-
8.25- 8.86-
9.79 10.32 
= = 
= = 
= = 
12.83- = 
12.83- = 
-19.08 = 
70 
7.97 
9.80* 
9.80* 
= 
= 
= 
= 
= 
-
9.41-
9.41-
12.67 
Chapter 3 Cephalosporins 
1+2 
4~-------c~------r-------'--------r------~ 2.5 5.0 7.0 10 
Time (Mins) 
Figure 3.2: Separation of three cephalosporin drugs on Pathfinder PSI00 
column (150 x4.5 mm I.D.). Chromatographic conditions: mobile phase 
consisted (90:10) of 0.01 M ammonium acetate lacetonitrile, pH 4. Flow rate was 
ImIlmin,temperature: 60 °C, detection: UV absorbance at 254 nm, injection 
volume: 10 IlL, l-Cephalexin, 2-Cephaclor 3- Cephoxazole. 
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Figure 3.3: Separation of three cephalosporin drugs on Pathfinder PSI00 
column (150 x4.5 mm I.D.). Chromatographic condition: mobile phase consisted 
of 0.01 M ammonium acetate I methanol (90:10), pH 4. Flow rate was (Im11min), 
temperature: 70 °C, detection: UV absorbance at 254 nm, injection volume: 10 
fLL, l-Cephalexin, 2-Cephaclor 3- Cephoxazole. 
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b) Group two (cephadroxil, cephradine, cephalexin and cephamandol) 
A second mixture of four cephalosporins (10 ppm) (cephadroxil, cephradine, 
cephalexin and cephamandol) was examined at different temperature from 25 until 
80°C using the Pathfinder @PSI00 column. The initial mobile phase consisted of 
70% of buffer ammonium acetate 0.01 M adjusted with phosphoric acid to pH 5.2 
and 30% of methanol. The elution of the drugs was in the order cephadroxil, 
cephalexin, cephradine and cephamandol (Table 3.5). A good separation was found 
at lower temperatures {25 (Figure 3.4), 40, and 50°C). In addition, the. best peak 
shape was at room temperature, except for cephamandol peak. With increasing' 
column temperature, the peaks of cephradine and cephalexin coeluted and at 60°C 
appeared as one peak. The base line also drifted at 80 QC. Because all the drugs have 
carboxylic acid groups, which could be ionized at pH 5.2, the pH was reduced to 4 
but this had little effect (Figure 3.5). From (Table 3.5), the separation of the first 
three drugs was within 6 minutes but cephamandol was retained for long time (34.90 
minutes at 25°C). This could be attributed the difference in structure of cephamandol . 
which includes an addition five nitrogen ring. The peak shape was acceptable for the 
first three drugs and poor for last one. With increasing temperature, it was noted that 
the retention time decreased and the base line started to drift. Cephalexin and 
cephradine were coeluted at 80°C (Figure 3.5). Because the cephamandol was 
retained for a long time it was excluded from the mixture and mobile phase changed 
to 20% of methanol. The best separation was found on this column under these 
conditions. There was no peak overlap between any drugs at any temperature. But 
the base line was not stable with increasing temperature and the drift increase with 
temperature. There was no change in selectivity at all. The run time was reduced to 
5.28 mins at 80°C (Figure 3.6) (Table 3.5). The amount of methanol was then 
reduced to 10%, also here, there was no peak overlap between the drugs. The run time 
was 32.6 mins at 25°C arid reduced with increased temperature until reached to 11.6 
mins at 80°C (Table 3.5). The noise in the base line is still appeared with increased 
temperature with a drifting base line. The shape of peaks was not sharp enough for 
quantification study. By using 100% of buffer ammonium acetate 0,01 M at pH 4 as 
mobile phase, but only cefadroxil was eluted for 2 and half hours at all studied 
temperatures. Cephradine and cephalexin were examined but were not eluted. 
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Figure 3.4: Separation of four cephalosporin drugs on pathfinder column (150 
x4.5 mm I.D.). Chromatographic conditions: mobile phase consisted of 0.01 M 
ammonium acetate / methanol (70:30), pH 5.2. flow rate was (Iml/min), 
temperature: 25°C, detection: UV absorbance at 254 nm, injection volume: 10 
ilL, l-cepbadroxil, 2-cephradine, 3-cepbalexin, 4-cephamandol. 
Table 3.5: Retention time of cepbalosporins on Pathfinder @PSI00 column at 
fti d d'f~ t di erent column temperature an I eren eluent 
I" Mobile ..... ...... 
.' . 
.. 
.. 
< r . '.,'." 
Pbase*' . .........•. Retention time (till 
. 
Drug ... Buffer- . Column temerature lC) . .... 
M.eOH 25 40 50 ". 1 60 . 70 . 80 
v/v ...... . . . ' . 
. . ' Cephadroxil 2.62 2.47 2.43 2.41 2.46 2.49 
[7:3] .... Cephalexin 4.90 4.99 4.99 5.11* 5.13* 5.04* 
pH 5.2.'.' .. '. Cephradine 6.02 5.51 5.26 5.11* 5.13* . 5.04* 
Cefamandol 38.58 23.61 18.27 14.75 11.98 10.08 
Cephadroxil 2.46 2.44 2.40 2.23 2.20 2.22 
[7:3] Cephalexin 4.41 3.91 3.86 3.41 3.32 3.56* pH4 Cephradine 5.57 4.73 4.48 3.82 3.60 3.56* 
Cefamandol 34.90 24.65 19.83 14.90 12.17 10.61 
Cephadroxil 3.45 2.75 2.64 2.48 2.46 2.38 
[8:2] . Cephalexin 8.74 6.35 5.66 5.18 4.93 4.72 pH 4 Cephradine 12.60 8.65 7.35 6.42 5.82 5.28 
Cefamandol = = = = = . = 
Cephadroxil 5.30 4.35 3.88 3.43 3.13 2.94 
[9:1]. Cephalexin 20.43 16.34 13.62 11.60 10.10 9.06 pH4 Cephradine 32.60 25.41 20.24 16.54 13.52 11.60 
Cefamandol = = = = = = 
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.. 
Cephadroxil 25.14 16.79 
[10] Cephalexin N.B· N.B pH4 Cephradine N.B N.B 
. Cefamandol = = 
* (0.01) M buffer ammonium acetate 
* cephalexin and cephradine coeluted. 
N.E= not eluted. 
1 
4 
CeDhaloSDorins 
12.39 9.75 7.67 6.30 
N.B N.B N.B N.B 
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Figure 3.5: Separation offour cephalosporin drugs on Pathfmder PSI00 colunm 
(150 x4.5 mm I.D.). Chromatographic conditions: mobile phase consisted of 0.01 
M amnionium acetate-methanol (70:30), pH 4. Flow rate (Im11min), 
temperature 80°C, detection UV absorbance at 254 nm, injection volume: 10 
ilL, l-cephadroxil, 2-cephradine, 3-cephalexin, 4-cephamandol. 
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Figure 3.6: Separation of three cephalosporin drugs on Pathfinder PSI00 
column (150 x4.5 mm I.D.). Chromatographic conditions: mobile phase 
consisted of 0.01 M ammonium acetate I methanol (80:20), pH 4. Flow rate was 
(Iml1min), temperature: 80°C, detection: UV absorbance at 254 nm, injection 
volume: 10 JIL, l-cephadroxil, 2-cephradine, 3-cephalexin, 4-cephamandol. 
3.2.2.2 Summary 
Although the Pathfinder column has been marketed as a high temperature phase, it 
caused much trouble in the separation of drugs. Under all the conditions examined, 
the column did not give a good separation for cephalosporins. Therefore, it was 
moved to another column. 
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3.2.3 Xterra RP18 Column 
3.2.3.1IntroductioiJ 
Cepbalosporins 
As Pathfinder PS 1 00 column did not give a good separation of the cephalosporins, it 
was decided to, move to Xterra RP18 column. This column combines both hybrid 
particle and shield technology, including a embedded polar group ( amide) is claimed 
to provide the best possible peak shape [182]. This column can be used for 
developing fast methods by presenting an exclusive selectivity. Another benefit of 
this column should be to exhibit excellent water wetabiIity even with using an eluent 
of 100% water [182]. The initial experiment with this column was based on a 
method by Ting [170]. It used methanol-water-acetic acid (30 + 70 + 0.1) as mobile 
phase using Xterra RP18 column at various temperatures ranging from 25°C to 60 
°C with different mobile phase compositions were examined (Table 3.6), at flow rate 
of 1 mVmin. The elution order of the drugs was cephfadroxil, cephaclor, cephalexin, 
and cephradine (Table 3.6). This order is based on the polarity of drugs. 
3.2.3.2 Retention of Drugs with Respect to Temperature 
Different compositions of mobile phases from 70%-100% water-MeOH were studied 
with 0.1 % AcOH in each case as an additive to prevent the ionisation of carboxylic 
group of drugs. From (Table 3.6), it is immediately noticeable that with increasing 
temperature the retention factor decreased for all drugs (Table 3.6). The elution of 
cephadroxil was fast at most compositions of mobile phase. It also was observed that 
the retention factors of all the drugs were almost similar at 60°C when using 5% of 
MeOH as using mobile phase 3% ofMeCN. 
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Table 3.6: Retention factors of four cephalosporin drugs on Xterra RPI8 
column as a fuuction of temperature using different proportions of organic 
modifier 
MobIle Phase*.,. 
.' ' •..... '. '.' ." ". . 
Retention factor, k 
.; ............•..... --'.............. . ......•..... 
'l\1eOH-wllter . 
Drugs 
Column. temperature rC) 
.... 
25 40 60 
'. 
(v/v). 
.... ........•. . 
I,. "., CephadroxiJ O.ol 
0.'. '.~--~~----~----+------~ 
.: '. '.' Cephac10r 0.19 
0. 30:70 ........ f--C-ep-h-a-le-x-in-+--O-.1-9-+--=--t---=---l ~~i:· 
:C.,"- ..•............. ~,..... Cephradine 0.33 
:.;., .'............ Cephadroxil 0.13 0.10 0.03 
E.;.15:~5J ••.• · •.. , .. i-'::C::-e-:p_ha::-c-:lo:-r -t-_O_.8:-:4_+---::"0.~79:---+ __ 0::-.4:-4_-l 
: ".""' ,Cephalexin 0.84 0.88 0.53 
::;:",!_,ii' ./;:':l--c:--ep-hr-a-:-:di-ne-l--l-.3-4-+--,1-.3-0-1--0-.7-4--I 
}i::'/':~;;i "<. t,·)f-C-,ep::--:ha_dr--:-O_xi_l -1-_0_.4::-:-1_+---::0--::.2_8 _1---:°--::.1_6_-1 
~1:;,.·' .• ·.·····.lO:9?,:i_. ~::~::: ~::~ ~::: ~::~ 
" : .. " •.... /-----+----+----+-----1 iE ........• .;.' Cephradine 2.73 2.16 1.46 
Cephadroxil. 0.85 0.59 0.34 
Cephaclor 2.89 2.3 7 1.73 
Cephalexin 3.11 2.49 1.73 
;i;!' . ....... Cephradine 5.26 4.24 2.88 
~>i.: · ...•........ . ... f-c=ep_h-:-adr---:-o_xi_I-j---:.1-:.44-:--t_-:-1.--:-23:---!-__ 0.--:-7-:-5 --\ 
(;' O'lod Cephac10r 4.81 4.41 3.18 
' .•..... ,..,: ,'. I---:-Cc-e-ph-al-e-'xin:--+---5-.7-8-+--5.-20--+--3-.5-8--l 
t' -.; ". 
:".:;i}.: ..... ' Cephradine 10.14 9.02 6.02 
il;'< . ."> .....•. f--C_ep_h_a_dro_x_i_l +-_o._7_3 _+-_0_._58_-+ __ 0._33_--1 
:,'M;eCN-water Cephaclor 2.69 2.33 1.66 
1;. 1---:-::--:---:---:--+--:--:-:---!--::----+------1 lP 3:97;" Cephalexin 2.69 2.33 1.66 
~~: "." ·.·.·:·:'·i-'::C-ep-hr-adi--:-:-·n-e-+-4-.4-8-+--3.-86-+--2-.7-0--l 
:,.:.:.... . ."-'--'-
. * All mobile phases contained 0.1 % AcOH 
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3.2.3.3 Van't Hoft plots 
The relationship between the temperature and retention factor can be defined by 
van't Hoff equation: 
In k=-Mlo/RT + ~So/R + In ~ (3.1) 
Where m is the enthalpy change related to the analyte transfer between phases, 
& is the change of the entropy, R is real gas content, T is the absolute temperature 
and rjJ is the phase ratio of the column. To study the effect of temperature on the 
mechanism of separation on Xterra RP18 column, In (k) vs. lIT were plotted for the 
cephalosporin drugs for each mobile phases over the temperature range frorn 25 to 60 
°C (Figures 3.7 to 3.10). The relationship was not linear in case of the mobile phase 
containing 15% of methanol. The values of thermodynamic properties of all drugs at 
each case of mobile phase were calculated based on van't Hoffequation. In all cases, 
Mf' values were negative indicating that retention of cephalosporins studied is an 
exothermic process (Table 3.7). It is energetically more favourable for these drugs to 
remain in the stationary phase than in the mobile phase. It can be seen from the 
results that with increasing polarity of mobile phase the enthalpy (become less 
negative) and entropy values (indicated by increasing value of intercept) of solutes 
increased. This demonstrated that a strong retention interaction between mobile and . 
stationary phase occurred when the percentage of organic modifier in eluent 
increased. This observation was opposite to what was reported in literature [93,123]. 
The only exception of this observation was with cephalexin using 5% of MeOH as 
eluent. Another observation from these results was that the thermodynamic values of 
cephadroxil were different from other drugs which have results close together and 
. this could be explained as cephadroxil contain phenolic group. The best linearity was 
cephadroxil with 5% of Me OH. 
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Table 3.7: Analysis of linear Van't Hoffplots on Xterrascolumn with different 
mobile phase: 
Mobile phase* 
. 
r2 Drug 
MeOH-water 
(v/v) 
. 
15:85 Not linear 
10:90 1.00 
5:95 1.00 Cefadroxil 
0:100 0.94 
MeCN-water 
3:97 0.97 
15:85 Not linear 
10:90 0.99 
5:95 0.99 Cephac10r 
0:100 0.93 
MeCN-water 
3:97 0.97 
15:85 Not linear 
10:90 0.99 
5:95 0.99 Cephalexin 
0:100 0.93 
MeCN-water 
3:97 0.97 
15:85 Not linear 
10:90 0.99 
5:95 0.99 Cephradine 
0:100 0.94 
MeCN-water 
3:97 0.97 
* N.D( the value could not be detenmned), 
* All mobile phases contained 0.1 % AcOH. 
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KJmorl Kcalmorl 
N.D* N.D* 
-22.10 -5.26 
-21.67 -5.18 
-15.57 -3.72 
-18.90 -4.52 
N.D* N.D* 
-12.14 -2.90 
-12.15 -2.90 
-9.90 -2.39 
-11.48 -2.74 
N.D* N.D* 
-12.14 -2.90 
-13.89 -3.32 
-11.45 -2.74 
-11.48 -2.74 
N.D'" N.D* 
-14.82 -3.54 
-14.28 -3.41 
-12.46 -2.98 
-12.05 -2.88 
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Figure 3.7: Van't Hoff plots for cephadroxil on Xterra RP18 column with 
different mobile phases 
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Figure 3.8: Van't Hoff plots for cephaclor on Xterra RP18 column with 
. different mobile phases 
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Figure 3.10: Van't HoCC plots Cor cephradiue on Xterra RP18 colunm with 
different mobile phases 
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3.2.3.4 Selectivity on Xterra RP18 column 
The effect of temperature on the selectivity of cephalosporins was investigated as a 
function of column temperature and mobile phase composition on the Xterra RP18 
column (Table 3.8). When using a mobile phase of 15% MeOH at 25°C, there was 
no separation between cephaclor and cephalexin. On increasing the temperature to 40 
cC, it was observed that the separation between cephadroxil and cephaclor decreased 
and separation starts to exist between cephaclor and cephalexin. This separation also 
improved at 60 QC. The cephradine was last drug was separated. This observation 
lead us to decrease the amount of organic modifier to 10%. However, cephaclor and 
cephalexin appeared together as one peak at all temperatures and the selectivity 
between their peak and cephadroxil was increased on increasing temperature. 
Therefore, the percentage of MeOH was reduced to 5%. It was observed there was 
more separation between cephaclore and cephalexin drugs at 25 QC but less 
resolution between these solutes at 40°C but at 60°C, . their peak appeared together 
as one peak (Figure 3.11 (a-b)). When mobile phase was 100% water, there was a 
better resolution between all drugs at all temperature examined. On increasing 
temperature the separation between cephaclor and cephalexin and also between 
cephalexin and cephradine decreased but were stilI acceptable in quantitative study 
(Figure 3.12(a-b)). When MeCN was used as modifier (Figure 3.13 (a-b)), it was 
found there was no separation between cephaclor and cephalexin at any temperature. 
Therefore it was concluded that with this column the best separation was at 60°C 
using water as eluent. The high temperature RP-HPLC separations (Figures.3.12 
[a,b,]) show that on using 100% of water as eluent there were excelIent separations 
between cephadroxil (peak 1), cephaclor (peak 2), cephalexin (peak 3) and 
cephradine (peak 4) at 60 ·C. 
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Table 3.8: Observed effect of temperatnre on selectivity (a) for cephalosporin 
drugs with different mobile phase: 
Mobile , Drugs 
Phase* Selectivity (a) 
. MeOH· Temperature 
water I Cephadroxil Cephaclor Cephalexin Cephradine 
(vfv) . 
25°C .. 6.46 1.00 1.60 
[15:85] 40°C .. 7.90 1.11 1.48 
60°C 
.. 14.67 1.21 1.40 
. '. 25°C 3.95 1.00 1.69 --
[10:90] 40°C 
-- 4.75 1.00 1.62 
60°C 
--
6.06 1.00 1.51 
25°C 
--
3.40 1.08 1.69 
. 
40°C 
. [5:95] .. , 
--
4.02 1.05 1.70 
..... 
60°C 
-- 5.09 1.00 1.67 
.H20 25°C 
--
3.34 1.20 1.75 
[100%] .... 40°C 
-- 3.59 1.20 1.74 
'. 60°C 
. 
..' --
4.24 1.13 1.68 
MeCN: 25°C 
--
3.69 1.00 1.67 
H2O [3:97] 40°C 
--
4.02 1.00 1.66 
60°C 
-
5.03- 1.00 1.63 
. 
* All mobile phases contamed 0.1 % AcOH 
55 
• 
2+3 
b) 60°C 
40 
30 1 
~ 
~ 20 4 
~ 
.. 
~ 
10 
0 J " \ \ \ 
. , 
·5 
'5 '10 15 Time (Mins) 
Figure 3.11 (a-b): Separation of four cephalosporin drugs on Xterra RP18 
column (150 x4.5 mm I.D.). Chromatographic condition: mobile phase: MeOH: 
H20 (5:95] including 0.1 % AcOH, flow rate: 1 mL/min, temperature: a) 40, and 
b) 60°C, detection: UV absorbance at 254 nm, injection volume: 10 JlL, solute 
concentration: 80 "glmL. Peaks: 1-Cephadroxll, 2 -Cephaclor, 3-Cephalexin, 
4-Cephradine. 
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Figure 3.12 (a-b): Separation of four cephalosporin drugs on Xterra RP18 
column (150 x4.5 mm I.D.). Chromatographic condition: mobile phase: pure 
water including 0.1 % AcOH, flow rate: 1 mL/min, temperature: a) 40, and b) 60 
DC, detection: UV absorbance at 254 nm, injection volume: 10 ~L, solute 
concentration: 80 llg/mL. Peaks: l-Cephadroxil, 2-Cephaclor, 3-Cephalexin, 
4-Cephradine. 
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Figure 3.13 (a-b): Separation of four cephalosporin drugs on Xterra RP18 
column (150 x4.5 mm I.D.). Chromatographic condition: mobile phase: MeCN: 
H20 [3:971 including 0.1 % AcOH, flow rate: 1 mL/min, temperature: a) 40, and 
b) 60°C, 'detection: UV absorbance at 254 nm, injection volume: 10 ~L, solute 
concentration: 80 /Lg/mL. Peaks: l-Cephadroxil, 2-Cephaclor, 3-Cephalexin, 
4-Cephradine. 
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3.2.3.5 Influence of temperature on column efficiency (N) 
. The effect of high temperature on column efficiency using different compositions of 
organic modifier are shown in (Figures 3.14 (a-d)). For each drug examined, the 
general tendency for column efficiency (Nlm) was indirectly proportional to the 
column temperature as efficiency decreased with increased temperature. In addition, 
it was observed that the column efficiency was increased by decreasing organic 
modifier proportion in eluent until 100% of water as mobile phase because the 
. retention time will increase with a more polar solvent. Cephradine gave the highest 
efficiency with Xterra column at 25°C with pure water as eluent. The cephaIexin and 
cephaclor were second regarding the efficiency. The cephadroxil drug has poor 
efficiency with this column in all cases. 
I 
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Figure 3.14 (a): Variation of column efficiency as a function of temperature 
using different proportions of organic modifier on Xterra RP18 column. 
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Figure 3.14 (b-c): Variation of column efficiency as a function oftemperature 
using different proportions of organic modifier on Xterra RP18 column. 
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Figure 3.14 (d): Variation of column efficiency as a function of temperature 
using different proportions of organic modifier on Xterra RP18 column. 
3.2.3.6 Effect of internal diameter of connection tube on separation 
When the best separation conditions were established as using a pure water as eluent 
at temperatures, 25, 40, and 60°C (Figure 3.17), it. was looked at improving 
efficiency by reducing dead volume by changing the connecting tube between 
column and detector to be red line (pEEK,1I16" OD tube LD 0.005 mm) (Figure 
3.15 a-b). It was found there was little effect on the retention time (Table 3.9), but 
. the retention factor was changed in most cases because the retention time of uracil 
was affected. Effect of narrow tube on efficiency can be observed Figure 3.16 
compared to Figure 3.14 a-d. At 60 QC with pure water as eluent the efficiency of 
cephadroxil increased from 8000 to 30797, the efficiency of cephaclor increased 
from 28000 to 69016, cephalexin from 27000 to 62116, and cephradine from 45000 
to 75910. In general, the efficiency of aIJ drugs was significantly improved using 
narrow connection especially between cephaclor and cephalexin. 
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Table 3.9: Retention time, retention factors, and efficiency of four cephalosporin 
drugs using 100% of water as mobile phase using PEEK, 1/16" OD tube I.D 
0.005 mm connection tube 
Drug 25°C 40°C 60°C 
tR k N/m tR k ·.·N/m tR k N/m 
Cephadroxil 7.56 1.78 32044 6.05 1.41 34246 4.35 0.89 30797 
.. 
Cephaclor 17.96 5.60 54452 15.24 5.07 64085 10.95 3.75 69016 
..... 
Cephalexin 21.08 6.74 52653 17.41 5.93 60947 11.97 4.20 62116 
Cephradine. 35.04 11.87 61468 28.33 10.28 70209 18.55 7.06 75910 
From (Figure 3.15) and (Table 3.10). it was noted that the relationship between Ln k 
and lIT for all the drugs was nearly linear. 
Lnk 
2.5 
2 
1.5 
1 
0.5 
o 
-'-x X 
x-
ff: 
::(j 8 
-0.5 +-___ ,---1>" __ --,-___ ,-__ --, __ --,-, 
0.00290 0.00300 0.00310 0.00320 0.00330 0.00340 
Iff (1(') 
--0-- cefadroxiI -0- cefaclor -Is- cefalexin -X- cefradine 
. Figure 3.15: Van't Hoffplots for four cephalosporin drugs using 100% of water 
as mobile phase with PEEK, 1116" OD tube I.D 0.005 mm connection tube. 
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Table 3.10: Analysis of linear Van't Hoff plots on Xterra RP18 column using 
100% of water as mobile phase with PEEK, .1/16" OD tube I.D 0.005 mm 
r- AIl' ut' Drug 
KJmorl . Kcalmor l 
Cephadroxil 0.98 
-16.45 -3.94 
Cephaclor 0.95 
-9.57 -2.29 
. Cephalexin 0.96 
-11.27 -2.70 
Cephradine 0.96 
-12.38 -2.96 
A comparison between (Tables 3.11 and 3.8), showed that the selectivity was similar 
in both cases 
Table 3.11: Selectivity of four cephalosporin drugs using 100% of water 
mobile phase with PEEK,1I16" OD tube I.d 0.005 inch 
as 
Drug 
Selectivity (a) 
CephadroxiL .. 
Cephaclor 3.15 3.60 4.21 
.. Ceph!ilexin ..• 
1.20 1.17 1.12 
Cephradine 1.76 1.73 1.68 
80000 ~ 70000· ~ 
'E' 60000 g, 50000 
i 40000 30000 ~ 0 0 
0'1 20000 
10000 
0 
20 30 40 50 60 ·70 
Temperature ("C) 
~ Cephadroxil -0- Cephaclor -fr-- Cephalexin *- Cephradine 
e 
5 
Figure 3.16: Variation of column efficiency (N/m) as a function of temperatur 
drugs using 100% of water as mobile phase with PEEK,I/16" OD tube I.D 0.00 
mm •. DV absorbance at 254 nrn, injection volume: io J.1L, solu 
concentration:80 /-IglmL. Peaks: l-Cephadroxil, 2-Cephaclor, 3-Cephalexin, 
te 
4-Cephradine. 
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Figure 3.17: Separation of four cephalosporin drugs on Xterra RP18 column 
(150 x4.5 mm I.D.), after using connection tube with PEEK,1/16" OD tube I.D 
0.005 mm Chromatographic condition: mobile phase: pure water including 
0.1 % AcOH, flow rate: 1 mL/min, temperature: a) 40, and b) 60°C,: detection: 
UV absorbance at 254 nm, injection volume: 10 ilL, solute concentration: 80 
p.glmL. Peaks: l-Cephadroxil, 2-Cephaclor, 3-Cephalexin, 4-Cephradine. 
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3.2.3.7 Summary 
The fundamental aspects of the effect of temperature on the separation of 
cephalosporins (Cephadroxil, Cephaclor, Cephalexin, Cephradine) on a Xterra RP18 
column was studied. It was found that the retention factors of all the cephalosporins 
were decreased on increasing temperature from 25 to 60 QC. Also, the van't Hoff 
. relationship was observed to be linear for all drngs with all the mobile phases except 
15% MeCN. The slope of the van't Hoff equation decreased with increasing amount 
of water in mobile phase for all drngs. From the I!J{' values, it was concluded that 
retention of cephalosporins studied is an exothermic process. The effect of the 
temperature on selectivity varied from case to case and between drngs. The 
efficiency decreased for all drngs with increasing temperature. However, it was 
noted that the efficiency and selectivity of all drngs were significantly improved by 
using a narrow connecting tubes. It was found from this study that the best separation 
was at 60 QC with using 100% of water as eluent and this conditions were the best for 
quantitative applications. 
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3.2.4 Selerity Column (Blaze 200 C18 silica column) 
3.2.4.1 Introduction 
Another new stationary phase is Selerity's new Blaze 200 ™ column which is based 
on a new polydentate silica phase and is claimed to be stable at extreme 
temperatures, with a high pH stability [183]. This column is claimed to be used in 
development of a new analysis because polycarbosilane stationary phases are 
hydrolytically stable against collapse in an aqueous environment. In this column, 
there are many points of attachments of the ligand to the silica with a high degree of 
cross-linking to create a good protective barrier over the silica backbone, preventing 
it from hydrolytic attack. The column provides traditional C18 selectivity and it is 
temperature stable up to 200°C [183]. It was therefore also examined for the 
separatiom of cephalosporins. This is a narrow column ( 2.1 1. D. mm) so a low 0.5 
mllmin flow rate was used. 
3.2.4.2 Retention of Drugs with Respect to Temperature 
To examine the effect of temperature on the absolute retention of a mixture of 
cephalosporin drugs on Selerity's Blaze 200 TM column, the separation of 
cephalosporins at different temperatures (40-100 0c) with different mobile phases 
was carried out. As the temperature was increased from 40 to 100°C, the analysis 
time decreased significantly (Table 3.12). The retention factor of cephadroxil was 
reduced from 1.39 to 0.73 when the temperature was ralsed from 40 to 100°C with 
mobile phase MeOH-water (10:90), (including 0.1 % AcOH) when peak overlap was 
occurred with cephaclor. The change with temperature was more obvious when using 
water (100%) as the mobile phase when retention factor changed from 5.36 to 1.61. 
With using MeCN- water (94:6), the retention factor at 40°C and at 100°C was 
equal to that at MeOH-water (10:90) but at this case cephadroxil interfered with 
cephaclor. For cephaclor, with using pure water as mobile phase, the retention factor 
was changed from 8.66 at 40°C to 2.51 at 100°C. In general, cephadroxil and 
cephaclor were separated rapidly under all conditions. The retention factors of 
. cephalexin and cephradine were changed from 6.18 and 9.77 at 40°C to 2.48 and 
3.54 at 100°C respectively with using MeOH-water (10:90). With water as mobile 
phase, it was observed both the retention factors of drugs were high at 40°C 31.47 
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for cephalexin and 54.66 for cephradine but on raising the temperature the retentions 
were reduced approximately four fold for both drugs. 
Table 3.12: Retention factors of four cephalosporin drugs on Selerity's Blaze 
200 ™ column (150 x2.1 mm I.D.) as a function of temperature using different 
proportions of organic modifier 
Mobile .. 
Phase* 
Retention factor, k 
Organic- Drugs Column temperature ("C) 
. 
water 40. 60 80 100 
(v/v) . 
Cephadroxil 1.39 1.00 0.87 0.73 
MeOH-water Cephaclor 2.11 1.44 1.08 0.73 
10:90 Cephalexin 6.18 4.39 3.42 2.48 
Cephradine 9.77 6.71 5.01 3.54 
Cephadroxil 2.60 1.84 1.26 0.97 
MeOH-water Cephaclor 4.23 3.04 2.01 1.34 
. 
5:95 Cephalexin 12.78 9.17 6.06 4.23 
Cephradine 21.11 14.57 9.30 6.29 
Cephadroxil 5.36 3.78 2.68 1.61 
MeOHcwater Cephaclor 8.66 6.36 4.39 2.51 
(0):100 Cephalexin 31.47 21.52 13.57 8.28 
Cephradine 54.66 35.83 21.46 12.73 
Cephadroxil 2.22 1.85 1.31 1.16 
MeCN-water Cephaclor 3.06 2.45 1.66 1.16 
3:97 Cephalexin 10.23 8.04 . 5.63 4.21 
Cephradine 16.72 12.55 8.57 6.21 
Cephadroxil 1.52 1.17 0.89 0.73 
MeCN-water Cephaclor 1.52 1.17 0.89 0.73 
6:94 Cephalexin 5.33 4.13 3.18 2.52 
Cephradine 8.17 ·6.18 4.64 3.59 
* All mobile phases contained 0.1 % AcOH 
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3.2.4.3 Van't Hoff plots 
Altought the range of temperature was not very wide (40-100 0c), the relationships 
ofln k as a function of liT were studied for Selerity column with the different mobile 
phases. (Figure 3.18(a-d)) show the resulting van't Hoff plots. These plots were 
linear for all drugs (r = 0.96-0.99). The values of thethennodynamic properties of 
all drugs at each case of mobile phase were calculated based on van't Hoff equation. 
In all cases, Ml' values were negative indicating that retention of cephalosporins 
studied is an exothennic process (Table 3.13) as it was found with Xterra RP18 
column but also it was noted that in comparison the values of Ml' cefadroxil were 
with Xterra RP18 more negative than with Selerity's Blaze 200 TM except with 100% 
water as eluent. However, it was opposite observation for other drugs as their Mf 
values were with Selerity's Blaze 200 ™ more negative than with Xterra RP18. It 
was concluded that it is energetically more favourable for these drugs to remain in 
the stationary phase than in the mobile phase. It can be seen from the results that with 
increasing polarity of mobile phase the enthalpy and entropy values of solutes 
decreased. This demonstrated that a strong retention interaction between mobile and 
stationary phase occurred when the percentage of organic modifier. in eluent 
decreased. All drugs were transferred from mobile phase to stationary phase 
entropically favourable rather than enthalpically. 
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Table 3.13: Analysis oflinear Van't Hoffplots on Selerity's Blaze 200 TM column 
with differeut mobile phase: 
. 
Mobilephase* 
. ,'- ' .. 
I ~ All· All· Drug 
Kcalmor1 . KJmorl 
. MeOH-water 
.. 
(v/v) . 
10:90 0.97 
-10.12 -2.42 
5:95 0.99 
-16.21 -3.88 
Cefadroxil 0:100 0.98 
-19.05 -4.56 
MeCN- water 3:97 0.97 
-11.13 -2.66 
MeCN- water 6:94 0.99 
-12.02 -2.87 
10:90 0.99 
-16.81 -4.02 
5:95· 0.99 
-18.66 -4.46 
Cephaclor 0:100 0.96 
-19.65 -4.70 
MeCN- water 3:97 0.98 
-15.90 -3.80 
MeCN- water 6:94 0.99 
-12.02 -2.87 
10:90 0.99 
-14.49 -3.47 
5:95 0.99 -18.05 -4.32 
Cephalexin 0:100 0.98 -21.57 -5.16 
MeCN- water 3:97 0.99 -14.60 -3.49 
MeCN- water 6:94 0.99 -12.16 -2.91 
10:90 0.99 
-16.18 -3.87 
5:95 0.99 
-19.75 -4.73 
Cephradine ·0:100 0.99 
-23.60 -5.65 
MeCN- water 3:97 0.99 
-16.22 -3.88 
MeCN- water 6:94 0.99 
-13.35 -3.19 
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a) 
Cefadroxil 
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. Figure 3.18(a-b): Van't HofC plots Cor four drugs on Selerity's Blaze 200 ™ . 
column with different mobile phases. 
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Figure 3.18(c-d): Van't Hoff plots for four drugs on Selerity's Blaze 200 ™ 
column with different mobile phases. 
. 3.2.4.4 Selectivity on Selerity's Blaze 200 ™ column 
The selectivities of the Selerity's Blaze 200 TM column phase, were calculated (Table 
3.14). The separation of four drugs on this column was based oh hydrophobicity 
therefore, the cephadroxil was eluted first because this ring has a phenolic group. 
Cephaclor and cephalexin' are similar structurally with benzene side ring but in 
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cephac10r there is chlorine atom, which is a withdrawing group and could make the 
carboxylic acid group more ionisable, whereas in cephalexin is a methyl group which 
is donor group and could make hydrogen bond with carboxylic group. Lastly, in 
cephradine, the side ring is not aromatic. In general, it can say that with a high 
temperature in this column, the selectivity is reduced. There was good separation 
between all drugs with MeOH-water 5:95 at all temperature (Figure 3.19 a) whereas 
with using water (100%) the separation was better than previous condition between 
all drugs (Figure 3.19 b). However, there were no separation between cephadroxil 
and cephac10r with MeCN-water 3:97 at 100 DC and with MeCN-water 3:97 at all 
temperatures. 
72 
I 
Chapter 3 Cephalosporins 
Table 3.14: Effect oftemperature on selectivity (a) for cephalosporin drugs with 
different mobile phase: 
Mobile 
. Selectivity (a) 
Phase* Temperature Cephadroxil Cephaclor Cephalexin Cephradine 
40°C 
-
1.52 2.93 1.58 MeOH-H2O 
60°C 
-
1.44 3.05 1.53 [10:90] 
80°C 
- 1.24 3.17 1.46 
100°C 
- 1.00 3.40 1.43 
MeOH-H20 40°C - 1.63 3.02 1.65 
[5:95] 60°C - 1.65 3.02 1.59 
80°C 
- 1.60 3.01 1.53 
100°C 
- 1.38 3.16 1.49 
. 
40°C 
- 1.62 3.63 1.74 
. H20 [100] 60°C 1.68 3.38 . 1.66 
-
80°C 
- 1.64 3.09 1.58 
100°C 
-
1.56 3.30 1.54 
40°C 
- 1.38 3.34 1.63 MeCN-H20 
60°C 
- 1.32 3.28 1.56 3:97 
80°C 
- 1.27 3.39 1.52 
100°C 
- 1.00 3.63 1.48 
40°C 
- 1.00 3.51 1.53 
MeCN-H20 60°C 
- 1.00 3.53 1.50 
6:94 80°C 1.00 3.57 1.46 -
100°C 
- 1.00 3.45 1.42 
* All mobile phases contamed 0.1 % AcOH 
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Figure 3.19 (a-b): Separation of four cephalosporin drugs on Selerity's Blaze 
200 ™ column (150 x2.1 mm I.D.) Chromatographic condition: flow rate: 0.5 
mL/min, temperature: 100°C, detection: UV absorbance at 254 nm, injection 
volume: 1 JlL, solute concentration: 80 /lg/mL. Peaks: l-Cephadroxil, 2-. 
Cephaclor, 3-Cephalexin, 4- Cephradine. Using different mobile phases. 
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3.2.4.5 Influence of temperature on column efficiency 
In general, it was noted that the efficiency decreased on increasing the temperature in 
. contrast to theoretical expectation and this. could be related to extra connection 
tubing with some exceptions. The effect of temperature on efficiency of cephadroxil 
is illustrated in (Figure 3.20). It can observed that the best efficiency was with water 
(100%) as eluent at 60°C and the worst efficiency was with MeOH (10%) at 60°C, . 
this could be attributed to peak overlaps that was. occurred with cephac1or. Another 
unexpected observation was with MeOH (5%), efficiency was reduced with 
increased temperature for all drugs. 
Cephadroxil 
10000 
6 ~ 7500 
e- 5000 
= .iIl ~ .. 
= 2500 !>;1 
0 
20 40 60 80 100 120 
Temperature (C) 
--4-water 90% --0-95% -t:r-100% -X-water-MeCN (97:3) 
Figure 3.20: Column efficiency of cepbadroxil as a function of temperature 
using different proportion of organic modifier on Selerity's Blaze 200 ™ 
column. 
The best efficiency of cephac10r was found at 40°C with water (100%) and the 
poorest peak efficiency was at 80 °C MeOH (10%). Also here, the same observation 
was noted, with using MeOH-water (5%:95%), when efficiency was reduced with 
increased temperature. (Figure 3.21). 
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Figure 3.21: Column efficiency of cephaclor as a function of temperature using 
different proportion of organic modifier on Selerity's Blaze 200 ™column. 
The best efficiency for cephalexin was at 60°C with MeOH (5%) and the poorest 
peak efficiency was at 100°C MeOH (10%). The efficiency was increased with 
temperature with water as eluent. But with other mobile phases, the efficiency 
decreased with increased temperature (Figure 3.22). 
15000 
12500 
a g. 10000 
.r 7500. 
~ 5000 i"l 
2500 
Cephalexin 
O+-------~------,-------._------._----_, 
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-<>- water 90% -0- 95% -/r-100% -X- water-MeCN (97:3)· -:1(- water-MeCN (94:6) 
Figure 3.22: Column efficiency of cephalexin as a function of temperatUre using 
different proportion of organic modifier on Selerity's Blaze 200 TM columu. 
For cephradine, the best peak efficiency was observed at 60°C with MeOH (5%) 
similar to cephalexin and the poor efficiency peak was at 60°C with water (100%) 
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Also here, it was observed the efficiency decreased with increasing temperature with 
all mobile phases except water (Figure 3.23) .. 
Cephradine 
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e 12500 g 
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·c 
= .... 5000 1"1 
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0 
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Temperature ( 0c) 
-<>- water 90% -0-95% ---lr-100% 
-x-water-MeCN (97:3) -:I(-water-MeCN (94:6) 
Figure 3.23: Column efficiency of cephradine as a function of temperature using 
different proportion of organic modifier on Selerity's Blaze 200 ™ column. 
3.2.4.6 Summary 
It was found that the separation of four drugs on Selerity's Blaze 200 TM column. 
depends on the hydrophobicity of the benzene ring. The best separation between 
these drugs was using 100% water at 100 QC but the problem was that the efficiency 
of this column was low and shape of peaks especially of last drugs (cephalexin and 
cephradine) were not good (Figure 3.19 b). The van't Hoffplots were linear for all 
drugs and the enthalpy values of all drugs were negative with this therefore, it was 
concb,lded that retention of cephalosporins studied is an exothennic process. In 
general it was noted that there was a decrease in efficiency with increase 
temperature. However, the best efficiencies were observed for cephadroxil and 
cephaclor when using water (100%) as eluent at 60°C and at 40 QC, respectively. 
However, cephalexin and cephradine were provided the best efficiencies at 60°C 
with MeOH (5%). This column was not better than Xterra RP18 column regarding 
resolution, selectivity and efficiency. 
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4.1 Introduction 
Method validation is needed to confIrm that the developed analytical method is capable of 
being applied in a routine analytical laboratory and to ensure that an analytical 
methodology is accurate, specifIc, reproducible and robust over the specifIed range that 
an analyte will be analyzed [184]. Analytical chromatographers must carry out method 
validation in order to be compatible with US Food and Drug Administration (FDA) 
regulations. For pharmaceutical high-performance liquid chromatography (HPLC) 
method validation, the FDA and International Conference on Harmonization (ICH) [184] 
giv.e guidelines (Table 4.1). 
Table 4.1: General guidelines for validation from ICH, USP and FDA 
ICHfUSP valida.tion . FDAAdditional. FDAGMP 
parameter 
.. 
validation requirement (legal) requirement 
SpecifIcity Sensitivity Accuracy 
Accuracy Recovery Sensitivity 
Precision Reproducibility SpecifIcity 
Repeatability Robustness Reproducibility 
Limit of detection 
Sample solution 
stability 
Limit of quantifIcation System stability 
. . 
Linearity 
Range 
Ruggedness 
Robustness 
The Intemational Conference on Harmonization (ICH) of Technical Requirements for the 
Registration of Pharmaceuticals for Human Use has developed an agreement for the 
validation of analytical procedures [185]. The documents comprise defInitions for eight 
validation characteristics. An extension with more detailed methodology is in preparation 
and nearly completed[186]. Both The United States Food and Drug Administration (US 
FDA) and The United States Pharmacopoeia (USP) have proposed guidelines for method 
validation [187-189]. After the earlier study (Chapter 3), the best conditions for the 
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separation of cephalosporins was at 60°C with Xterra RP18 column and 100% of water 
(0.1% AcOH) as eluent. We set out to validate thls method with respects of linearity, limit 
of detection, limit of quantification, and precision (tR' relative peak area%, N/m). 
4.2 Linearity and calibration curve 
The ICH guidelines specify a minimum specified range of concentrations from 80 to 120 
. % of the target concentration [184]. The correlation coefficient and y-intercept of the 
linear regression line for the response versus concentration plot have to be examined. A 
correlation coefficient always used to evaluate the acceptability of analytical method A 
correlation coefficient of >0.999 is generally considered as confirmation of acceptable fit 
of the data to a linear regression line. It is recommended the y-intercept should be less 
than a few percent of the response obtained for the drugs at the target level [184]. We 
applied this strategy in our study. To carry out thls study, five levels of concentrations 
(10, 20, 40, 60 and 80 ppm) were prepared. Each of the levels of concentrations were 
prepared in triplicate, withln three days, In every day, the mobile phase was prepared 
freshly. T11:e experimental results were represented graphically (Table 4.2) and (Figures 
4.1 to 4.4) 
Table 4.2: linearity and calibration study: 
Days Cephadroxi! Cephac10r Cephalexin Cephradine 
. R~ 0.99 0.99 0.99 0.99 
tstDay 
Equation. y- 8430.4x y=6718.6x y-7772.4x y-5458.7x 
+ 3151.4 +10686 + 11188 +3448.8 
R" 0.99 0.99 0.99 0.99 
2nd Day Equation y- 8281.6x y-681lx+ y=8091.1x y= 5543.9x 
+ 8415.4 4795.2 + 1773.3 + 1463.4 
R" 0.99 0.99 0.99 0.99 
3rd Day Equation y=8041.26x y=6392.lx y=7663.7x y= 5712.8x 
. +14250 +13589 +7894.6 + 1559.2 
It can be observed from (Table 4.2) that the linearity of all the calibration curves across 
the concentration range is acceptable for quantification study, as regression coefficients 
were (0.99) for all drugs. Also, there was difference in the slope and intercept from day to 
other and this could be related to instrument effect to change in room condition, such as 
temperature. 
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Figure 4.1: Calibration curve of cephadroxil (10-80 ppm) on day 1 
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Figure 4.2: Calibration curve of cephaclor (10-80 ppm) on day 1 
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Figure 4.4: Calibration curve of cephradine (to-80 ppm) on day t 
4.3 Limit of Detection and Qantification 
The limit of detection is the lowest concentration of analyte that can be detected but not 
necessarily quantified. In chromatography, the detection limit is concentration of the peak 
height at least three times the baseline noise level. The limit of quantification is the 
minimum concentration can be detennined quantitatively with acceptable precision. 
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The limit of detection (LOO), and the limit of quantification (LOQ) were estimated on the 
basis of an equation from Swartz [190]. 
LOO = 3.3(SO/S), LOQ = 10(SO/S), SO is standard deviation and S is a slope of 
response. 
It was found that the current method was very sensitive for all drugs for the limit of 
detection, (LOD) and the limit of quantification (LOQ) with an acceptable relative 
standard deviation (RSTO). (Table 4.3 and 4.4) 
Table 4.3: Determination ofL.O.D 
1.0.D(ppm). . Cephadroxil '. Cephaclor . Cephalexin Cephradine 
1st day. 
. 
4.47 7.59 5.47 . 8.15 
'. 
2 ndd '. 2.94 2.87 3.63 5.55 .' .. ' ay', 
. . ' . 
..... 
. ' 3rd day···· . 5.16 6.75 6.61 5.27 
Mean '. 4.19 5.74 5.24 6.32 
S.D / 1.14 5.74 1.50 1.59 
.. KS.D% 27.12 43.89 28.71 25.12 
Table 4.4: Determination of L.O.Q 
1.0.Q (ppm) CephadroxiI Cephac10r . .. Cephalexin Cephradine 
1st day 13.54 23.00 16.57 24.71 
2nd day 8.90 8.71 11.00 16.82 
I 
3rdday 15.63 20.46 20.02 15.98 
. Mean 12.69 17.39 15.86 19.17 
S.D 3.44 7.62 4.55 4.82 
·R.S.D .' 27.14 43.84 28.69 25.12 
From above (Table 4.3 and 4.4), it was concluded this method is sensitive as 1.0.0 of 
drugs was very low, cephadroxil (4.19 ppm), cephaclor (5.74 ppm), cephalexine (5.24 
ppm), cephradine (6.32 ppm). The 1.0.Q were found to be cephadroxil (12.69 ppm), 
cephaclor (17.39 ppm), cephalexine (15.86 ppm), cephradine (19.17 ppm) but it was less 
sensitive compare to a previous reported method [155] which found limits of detection 
around (30 ppb) using pulsed amperometric detection (pAD). 
4.4 Precision 
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Precision is the measure of the repeatability of an analytical method in optimum 
operation and is normally expressed as the percent relative standard deviation (RSD) for a 
statistically significant number of samples. According to the ICH [184], the precision of a 
method is variation of repeated injections of a standard. The precision Criteria for an assay 
method is that the instrument precision (RSD) should be $1% and the intra-assay 
precision should be :::2% In our case, it was done this test by injecting a standard solution 
(40 ppm) six times within three days and calculated the precision of retention time (tR), 
efficiency (Nlm) and relative peak area. The relative area % was calculated by using the 
equation [peak area of drug]/[ Peak: area of cephac\or] in which cephac\or was 
considered as an internal standard. The results are represented in Tables (4.5 to 4.7). there 
is no specific guidline for RS.D from ICH but the data to be seem acceptaple for 
quantitative analysis. 
Table 4.5: Precision study on cephalosporins 1st day 
a) 
Replication Cephadroxil Relative (n) tR (mins) N/m peak: area tR (min,) 
1 4.35 31965 1.19 10.85 
2 4.38 32909 \;20 10.81 
3 4.39 33444 1.17 10.90 
4 4.38 32949 1.20 10.83 
5 4.47 34888 1.21 10.89 
.6 4.40 33271 1.21 10.88 
Mean 4.39 33237 1.20 10.86 
S.D 0.04 956 0.02 0.04 
RS.D 0.88 2.88 1.33 0.34 
b) 
Replication Cephalexin Relative (n) tR (mins) N/m peak area tR (mina) 
1 11.88 76025 1.16 18.36 
2 11.83 77315 1.17 18.27 
3 11.95 73185 1.19 18.54 
4 11.86 74275 1.19 18.32 
5 11.90 77072 1.19 18.31 
6 11.91 76358 1.18 18.37 
Mean 11.89 75705 1.18 18.36 
S.D 0.04 1636 0.01 0.10 
RS.D 0.36 2.16 1.00 0.52 
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Ce,,-haclor 
Relative N/m peak: area 
73445 1 
74127 1 
73827 1 
74502 1 
76500 1 
73879 1 
74380 1 
1095 1 
1.47 1 
Cephradine 
Relative N/rn 
. peak: area 
91020 0.78 
87931 0.81 
89279 0.79 
89351 0.80 
88239 0.80 
88535 0.81 
89059 0.80 
1113 0.01 
1.25 1.48 
Cbapter4 
Table 4.6: Precision study on cepbalosporins 2nd day 
a) 
Replication 
... Cephadroxil 
(n) .. Nlm Relative tR{rnins) tR (rninS) . 
. peak area 
1 4.33 31891 1.22 ·10.81 
2 4.42 31460 1.29 11.02 
3 4.55 34319 1.27 11.27 
4 4.36 34217 1.21 10.85 
5 4.38 34191 1.22 10.84 
6 4.48 30687 1.31 11.19 
Mean 4.42 32794 1.25 11.00 
S.D 0.08 1633 0.04 0.20 
R.S.D 1.86 4.98 3.36 1.79 
b) 
, .. 
.... CephalexiIl··' Replication . 
I 
.. . Relative (n) tR (mins) . Nlm 
.... peak area tR(mins) 
-"--
1, 11.85 76019 1.19 18.36 
2 12.05 79753 1,19 18.50 
-'-
3. .. , 12.33 78216 1.19 18.84 
·4 11.87 75811 1.18 18.32 
5- 11.87 76216 1.19 18.34 
6 12.25 77263 1.18 18.97 
... Mean 12.03 77213 1.19 18.56 
S.D 0.21 1539 0.01 0.28 
R.S.D 1.76 1.99 1.19 1.53 
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Cephaclor 
Nlm . Relative peak area 
73783 1 
77960 1 
77143 1 
74247 1 
74548 1 
73644 1 
75220 1 
1852 1 
2.46 1 
Cephradine 
Relative Nlm peak area 
86552 0.81 
88556 0.81 
94847 0.77 
85585 0.80 
82620 0.83 
86592 0.80 
87458 0.80 
4105 0.02 
4.695 2.76 
Chapter 4 
Table 4.7: Precision study on cephalosporins 3rd day 
a) 
Relative 
4.4.1 Outlier test: 
Validation study 
Relative 
It was observed on the 3rd day (Table 4.7) that the second injection gave values of relative 
peak area that were not consistent. An outlier Q test test was used to decide if this value 
can be accepted or rejected for all drugs (Table 4.8) .. 
Q test (P value) = I Suspect value- Nearest value I / I Largest value- Smallest value I 
/fP value> 0.621 the value will be rejected [191]. 
It was found that all value from the measurement should be rej ected according to Q test 
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Table 4.8: outIier test: 
. Qtest 
'. Rejected Drugs Suspect Nearest Largest Smallest 
value value value value P value or 
accepted 
Cefadroxil Relative 1.39 1.23 1.39 1.20 0.70 Rejected % 
Cephalexin Relative 1.31 1.21 1.31 1.17 0.78 Rejected % 
Cephradine Relative 0.88 0.83 0.88 0.80 0.86 Rejected % 
4.5 Summary 
The validation of best separation conditions found that the linearity measured in triplicate 
between (10-80 ppm) was good for all drugs with an acceptable regression coefficient for 
all drugs (0.99). Our method was very sensitive as L.O.D in (ppm) was very low: 
(cephadroxil (4.19 ppm); cephaclor (5.74 ppm); cephalexine (5.24 ppm); cephradine' 
(6.32) ppm). And the, L.O.Q was (Cephadroxil (12.69 ppm); Cephac10r (17.39 ppm); 
Cephalexine (15.86 ppm); Cephradine (19.17 ppm). The precision study for a standard 
solution (40 ppm) (n = 6 analyses) showed a RS.D. of retention time (tR), efficiency 
(Nlm) and relative peak area was increased from day to day but was still with acceptable 
. values for a validiation study. 
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Non-steroidal anti-inflammatory drugs 
5.1 General background 
5.1.1 Introduction [192J 
NSAIDs 
Non-steroidal anti-inflammatory drugs (NSAIDs), are drugs that are used for their 
analgesic, antipyretic and anti-inflammatory effects. The first use of NSAIDS as 
medication was in the mid-nineteenth century (in 1829) when scientists succeeded in 
isolating salicylic acid from the folk remedy, willow bark, and this compound is 
considered to be the first drug of the NSAID group. Pharmacists continued to 
develop new generations of this group to relieve pain and help to reduce the intensity 
of inflammation. Nowadays, there are many kinds of these drugs, including 
indomethacin, ketoprofen, sulindac, indoprofen, flurbiprofen, suprofen, naproxen, 
diclofenamic, and niflunamic acid. 
5.1.2 Chemical structure of NSAIDs 
There is no common chemical structural template for the NSAIDs. The only common 
functional group is a carboxylic acid that is presented in almost all of the drugs 
(Table 5.1). 
Table 5.1: Structures, hydrophobicity and acidity of typical NSAID drugs 
Drug Structure XLogP pKa 
Ketoprofen 
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3.556[193] 4.45 
[193] 
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Drug Structure XLogP pKa 
Sulindac 2.693 4.7 [193] 
"rC~ / ~o 
""'" 
J. ~ 
I ;/ 
F "'-
0 
., 
/0 
Indoprofen 2.4 5.8[194] 
o:5-Di-, 
0 
Flurbiprofen 4.078 4.33[193] 
pP' 
I , 
F 
,/ ~ , 
'I 
0 
0, 
H 
Suprofen 2.919 3.91 
'\ [193] 
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Drug Structure XLogP pKa 
Naproxen 3.313 4.15 
[193] 
0 ~ 0" 
I 
<'0 ""- d" 
Indomethacin 3.655 4.5 [193] 
)--0-" 
, 
I j 
"0 "" 
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/ 
'I 
Diclofenac 
'I' 4.218 4.15[193] 
0 
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-
,c, 
~ 
I 
~ 
Niflunamic .~ 4.31[193] acid 
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5.1.3 Classification of NSAIDs 
There are two ways of classifying NSAIDs. One is based on their chemical 
categories: salicylates, p-amirtophenols, indoles, heteroaryl acetic acids, 
arylpropionic acids and enolic acids [192]. Another is based according to their 
relative inhibition of the cyclo-oxygenase isoenzymes (COX-I, COX-2) [195]. ht 
this section, the first strategy of classification will be adapted (chemical categories). 
The NSAIDs can be classified based on chemical structure as follows (Table 5.2): 
Table 5.2: Classification of NSAIDs 
.•..•.•.... Type Of chemical category· .......••. 
.. 
Typical drugs 
Salicylic acid derivatives 
Aspirin, sodium salicylate, choline 
magnesium trisalicylate, salsalate, diflunisal, . 
olsalazine. 
p-Aminophenol derivatives Acetaminophen 
htdole and indene acetic acids htdomethacin, sulindac 
Heteroaryl acetic acid Toimetin, diclofenac, ketorolac 
Arylpropionic acid lbuprofen, naproxen, flurbiprofen, ketoprofen, 
fenoprofen, oxaprozin 
Anthranilic acid Mefenamic acid, meclofenamic acid 
Enolic acids Oxicams (piroxicam, meloxicam) 
Alkenones Nabumetone· 
Diaryl-substituted furanones Rofecoxib 
Diaryl-substituted pyrazoles Celecoxib 
htdole acetic acids Etodolac 
Sulfonamilides Nimesulide 
5.1.4 Medicinal importance of NSAIDs 
These drugs are used as antipyretic, analgesic, and anti-inflammatory agents [192]. 
They are used in the treatment of different diseases, such as cancer and 
cardiovascular disease, and also as relief medication for varieties of diseases, such as 
arthritis (rheumatoid and osteoarthritis ), and inflammatory arthropathies (e.g. 
ankylosing spondylitis, psoriatic arthritis, Reiter's syndrome), acute gout, 
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dysmenorrhea, bone pain, headache and migraine, postoperative pain, renal colic, for 
inflammation and tissue injury, pyrexia, and ductus arteriosus [192]. 
5.1.5 Analysis of NSAIDs by HPLC 
The analysis of NSAIDs has been achived using different analytical procedures, 
included spectrophotometry [196], thin-layer chromatography (TLC) [197], gas 
chromatography-mass spectrometry (GC-MS) [198], and capillary electrophoresis 
[199]. The HPLC methods for the determination of chiral NSAIDs were reviewed in 
1997 [200]. A number of enantiomers of NSAIDs were resolved, such as ketoprofen 
[201] flurbiprofen enantiomers [202] and ketoprofen, indoprofen and suprofen [203]. 
Also the chiral separation of the 2-arylpropionic acids (2-AP As) (ketoprofen, 
pirprofen, fenoprofen, tiaprofenic acid, and flurbiprofen) was carried out and the 
effects of three factors, pH concentration of organic modifier, and buffer 
concentration were studied [204]. The use of temperature to analyse a mixture of 
ketoprofen with ibuprofen as an internal standard was carried out at 40 DC in vitro in 
rat skin permeation samples [205]. At pH (1.5), when ketoprofen is as its fully 
neutral form (PK 5.02), the retention time of keto pro fen increased with temperatures 
[205]. As most of NSAIDs are ionisable compounds, their retention factors were 
effected by the pH of the mobile phase, as the retention factors was observed 
decrease remarkedly in mobile phases with a pH above 4.5, 'whereas there were little 
change up to pH 4.0 [206]. If the pH of the mobile phase decreased in the acidic 
range, the retention times of these drugs increased as they would be in the neutral 
form [207]. Typical separation conditions of HPLC with differ~nt detectors are . 
sununarised for these compounds (Table 5.3). 
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Acetylsalicylic acid, ibuprofen, 
ketoprofen, naproxen, bezafibrate, 
dicJofenac, sodium salt tolfenamic 
acid 
MeOH-water (70:30, 
v/v) acidified with 
(0.2%) formic acid 
and MeCN-{70:30, v/v 
or 50:50, v/v), both 
containing formic acid 
(0.2%) 
Nova-Pak CI8 
column, 
(150 x 3.9 mm I.D., 
4/Lm) 
UV254nm. 
and fluorescence (230 
nm) 208 
~ 
.. 
00 
~ 
~ 
o 
.... 
2: 
~-----------------+------------~----------~----------~------~~ 
Indomethacin, (two its degradation Acetonitrile and 0.2% I) Zorbax SB-Phenyl ~ 
products: 4-chlorobenzoic acid and phosphoric acid (50:50, (75mx4.6 mm,3.5/Lm) E:l 
5-methoxy-2-methylindoleacetic v/v) 2) Zorbax SB-CN UV (237 nm) 209 = 
acid. (ketoprofenor flurbiprofenas (150 x 4.6 mm, 5/Lm) ~ 
internal standard) ~ ~-----------------+------------~--------~~-----------+------~= 
Indomethacin and eight of its MeOH (75%) and ::g Nucleosi1120-5, CI8 , . impurities aqueous solution(25%) (NMR) 210 C":l 
of (0.2%) H3PO. (250 x 4.6 mm I. D) and UV at 320 nm ~ 
~-----------------------+-----------------+---------------+---------------+--------~~ 
Indomethacin residues 
Ketoprofen enantiomers 
Indomethacin( internal standard) 
MeCN-AcOH (0.5% in 
water) (50:50, VN) 
hexane-isopropanol-TI A 
(90:10:0.1). 
OD8-2 column 
(200x 3.9mm 
1.D.,5/Lm). 
Chiralpak AD chiral 
column 
(250 x 4.6 mmI.D) 
UV (254 nm) 211 
UV(254nm) 2i2 
If' •... ,i"'" .. ,CC.:·· . <)"';ii'(:;'«:: "'.: ""'., ;.', :",.,;" ·'}')!'0:;i;!,Fi;;;'"i·.':,·Y' .'. ·•· ••. ;X...... .•. ·"·.I"!"tM!·}'"'c(y·.·· .. '. '?!("'·: .••. ·· .• ·Fte , -~~;, ~,:'.\:, "-:~{{~",,~'>,,\~,,:r-:! I;'.i~~' ..... I " CO!llpounds ..•..•. ", " Mobile phas(ir,.. '. .·Coiunm ",. ,"', ; • !, Detector, J..max.:, "" ,"'.-'" 
, .(., , . 
" .'" 
"\(''':;-';'':'(,.: .. 
.. .', .' ...• ;·.ci.,.· .• " I,,·.>," '.: .•..... :: ' " .;., . . ". ;'" '., ~ 
Ketoprofen: enantiomers, Aqueous lFA(O.1 %) and MeCN '" Micra Nonporous .., 
Tolmetin (internal standard) containing 10 mM Hydroxypropyl octyldecylsilane column LC Spectrophotometer ~-cyclodextrin (33 x 4.6 mm i.d., 1.5 201 
.... 
1Il 
(98:2 v/v) at pH 4.00 (adjusted with /Lm) 
triethylamine (TEA». 
Naproxen, ketoprofen and phenol MeOH (20%), MeCN (28%), and Shimpack VP-ODS UVat 270 nm 213 
water (52%) with OAm1 (4.6 x 250 mm 1.d., 5/Lm) 
triethylamine at pH 3.2 using 
orthophosphoric acid). 
'\ Ketoprofen with ibuprofen as intema1 MeCN -0.01 potassium phosphate KromasiI 100 column UVat260nm 214 
standard. adjusted to pH 1.5 with (250 x 4 mm. l.d.,5 /Lm). 
orthophosphoric acid (60:40, v/v). 
Flurbiprofen MeCN - 20 mMK HPO, Brownlee Fluorescence detection 215 
and its major metaboJite, (pH 3.0) buffer (40:60, v/v). Spheri-~ C18 excitation (260 nm) and 
4' -hydroxyflurbiprofen. (4.6 x 100 mm) emission (320 nm) 
Naproxen and, after hydrolysis, MeCN- MeOH- CH3COONH. SupelcosiI LC-18-DB UV 216 
its glucuronide in human urine (10 mM, pH5) (6:40:54, v/v/v) .. column (250 x 4.6mm (230nm) 
i.d.,5/Lm) 
Naproxen and its main degradation 'TIIF-MeOH 80/20 (v/v) The carbon column UV 217 
products (1 00x/4.6 mm i.d., 7 /LID) (272nm). 
Naproxen MeCN- Water- N Et3 WakosiI ODS 5e18 UV (270 nm) 218 
(50:50:1, v:v) adjusted withH3PO, to column 
pH3. ( 150x4.6 mm, i.d.,5/Lm). '" 
I 
I 
e ..... 
Niflumic acid, the internal standard, CH3COONain water (0.1M) and MeCN Shiseido C 18 UV (288 nm) 219 '" ... 
indomethacin, (37:63, v/v), at pH 6.4. CAPCELLPAK 
(4.6x250 mm, 5p.m,) 
Naproxen and ketoprofen. MeOH -CH3COONH4 (1 00mM) (70:30, Phenomenex packed with UV(240nm.) 220 
v/v, pH 5). BuckySep-RP 
,Ln.) 
Ketoprofen in a topical gel. Phosphate buffer-water- MeCN YMCODS-AQ UV 233nm (8:43:49, v/v), (150x4.6 mm I.D., 5p.m) 221 
at pH 3.5 by H3P04 
Ketoprofen and its degradation products MeCN -water -phosphate buffer Supelco Discovery C 18 
(40:58:2, v/v/v) at pH 3.5 by H,P04 (125x4mm i.d., 5p.m . UV (233nm) 222 
Flurbiprofen, MeCN-MeOH-
T 'AR1 .• 
-phosphate endcapped CI8 UV (248 nm). 223 
buffer (PH 5.6) (40:20:40) (4.6 x 125mm i.d., 5p.m) 
Diclofenac and flurbiprofen MeCN -CH3COO~ (0.1 M) (35:65, C-18 UV (278 nm) 
v:v) at pH 6.3 with AcOH (250 ><4.6 mm, 5p.m 224 
<!1 • 
Diclofenac sOdium, flufenarnic acid, MeCN LC-CN, column MS indomethacin and ketoprofen. CH,COO~(20 mM) (5:1 v:v) at pH 225 
7.4 (150)(4 mm5, p.m) 
Indoprofen,ketoprofen,naproxen,fenbufen A) aqueous formicacid:formate Spherisorb ODS2 UV(254nm) and ibuprofen buffer (0.1 M) of pH 3 (150x4 mm, 5 /Lm) 226 
B) MeOH.In gradiuent mode 
'" 
Naproxen, indomethacin, sulindac, 
ketoprofen, flurbiprofen, diclofenac. 
Naproxen, ketoprofen, 
ibuprofen, diclofenac, piroxicam, 
nimesulide and paracetamol 
Ketoprofen, flurbiprofen, indomethacin, 
diclofenac, flufenamic acid, mefenamic 
acid, and naproxen. 
Diclofenac and 
naproxen(intemal standard). 
Indomethacin 
Diclofenac and its major metabolite, 
4' -hydroxydiclofenac 
Flurbiprofen and 
ibuprofen ( internal standard). 
Phosphate buffer- MeCN at pH 
5.0. 
A)MeCN 
B) water with AcOH (0.1 %) pH 
3.16, In gradiuent mode 
MeCN- HCOONH4 (10 Mm) at 
pH 3.5 by HCOOH (50:50, v/v) 
MeOH -water (68:32, v/v) at pH 
3.2 withH3P04 
MeOH-water - H3P04 
(70:29.5:0.5, v/v) 
MeCN- CHJCOONa 
buffer (75 mM) at pH by 
AcOH (2:1.5 (v/v» 
MeOH -water with H3PO. (I %) 
80:20 (v/v), 
Inertsil ODS-2 colunm 
(l50x4.6 mm, 5 /Lm) 
Agilent Zorbax Eclipse 
XDBC-18 
(150x4.6 mm, 5/Lm). 
COSMOSIL 3C18-MS-I1 
(100 x2.0 mm i.d., 3 f.LID) 
A LiChrospher~100 C18 
125 x 4 mm i.d.,5 pm,) 
Hypersil ODS C18 colunm 
(l25mmx4mm i.d., 5/Lm) 
reversed phase 
C-18 
(25Omx4.6mm i.d., 5/L) 
Shim-Pack CLC-ODS C18 
(50 x4.6 mm 
i.d,,5 /Lm.) 
UV (230 or 320 nm). 
UV (245 nm) and 
(ESI-MS) 
Le-MS 
electrochemical 
detection 
UV(270nm). 
UV(280nm). 
UV ( 254 and 220 nm) 
227 
228 
229 
230 
231 
232 
233 
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Diclofenac A) MeCN -water- AcOH- Phenomenex,Luna C8 
Et)N«200:791.18:8.17:0.65, (100 x2.0 Ld.,3 p.m.) UV(280nm) 234 
v/v/v/v, pH* 3.6) 
B) MeCN -water- AcOH- Et,N 
Diclofenac KH2 PO. aqueous solution (0.05 M Kromasil C column 
adjusted to pH 7 (150x4.6 mm Ld.,3 p.m.) uv (205 nm) 235 
with NaOH) - MeOH- MeCN 
(58:21:21 (v/v/v). 
Ketoprofen, naproxen, tolfenamic A) H3P04 (O.017 M) at pH 2.8 LiChrosphere CI8 photodiode array 
acid, dic1ofenac. with diethylamine (25 x 4.6 mm detection (DAD) 236 B) MeCN -water (80:20 (v/v). i.d.,Sp.m). 240 and 280 nm. 
In gradient mode 
Ketoprofen, sulindac, fenbufen, MeCN "phosphate buffer (0.05 I )Pinkerton ISRP high 
nabumetone and indomethacin. M, pH 7) 20:80 (v/v). (GFF-SS-80, 
(150 x 4.6 mm i.d.) UV(254nm). 207 
2) (SPS-SPM-SS-
100-CI8, 
(150 x 4.6 trim i.d.) 
Ketoprofen,fiurbiprofen, ibuprofen, MeCN - CH3COONa (PH 3.5, ODScolumn UV(255, 
diclofenac sodium, mefenamic, 0.1 M)-MeOH (250x4.6 mmi.d.,5 240 and 220) 206 
naproxen, fenoprofen (35:40:25, v/v/v) p,m) 
Dic10fenac sodium, flufenamic acid, MeCN- CH3COO~ buffer (20 Shimpack GLC-CN, (LC-MS) indomethacin and, ketoprofen. mM)(S:1 v:v) at pH 7.4 . (150x4 mm i.d., 5 p.m) 225 
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5.2 Result and discussion 
5.2.1 Introduction 
The present study set out to use temperature as parameter for the separation of 
NSAIDs. Xterra RP18, a long XBridge™ RP18 shielded (15 cm) and short 
XBridge™ RP18 shielded (5 cm) columns were examined for the simultaneous 
analysis of nine non-steroidal anti-inflammatory drugs (NSAIDs). The analytes were 
studied using different proportions of phosphate or acetate buffers with acetonitrile 
(MeCN) at different pH with temperatures ranging from (40-140 0c) as the mobile 
phase. The effluent from the column was monitored at 230 mn. A 10 J.tl of sample 
(50 ppm) was injected in all cases. 
5.2.2 Xterra RP18 column 
5.2.2.1 Effect of temperature on Retention factor 
The study started by examining the thermal stability of the Xterra RP18 that had 
been used previously for cephalosporins. The initial ·method was based on the 
method [227] by Matsumoto and coworkers that used phosphate buffer at pH 4 55% 
and MeCN 45%. The amount of MeCN was then reduced to 25%. The effect of 
temperature from 40°C to 140°C on the retention factors of the NSAIDs were 
investigated in parallel with changes in pH from 4 to 5 to determine the benefit from 
the increased analyte mass transfer at high column temperatures. The first solute was 
sulindac then in order indoprofen, suprofen, ketoprofen, naproxen, niflunamic acid, 
flurbiprofen and lastly indomethacin. The retention of all the drugs was reduced on 
increasing the temperature and pH. It is clear that with increasing temperature that 
the retention factors decreased similarly for all drugs as in cephalosporin study 
(Chapter 3). This can be ascribed to a decrease of the hydrophobic interactions with 
increasing temperature. There is also possible temperature increase in the pKa of the 
drugs results in increased ionisation of the compounds reducing their hydrophobicity. 
Moreover, it is clear that the effect of both change in the pH of the buffer and the 
mobile composition was greater than the temperature effect. This agreed with the 
literature which suggested that changes in temperature is not as useful as on 
optimization strategy as variations in the mobile phase composition [145]. It was 
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decided not to use a pure water with this column because degradation of silica was 
noted at 140°C. 
Table S.4 Retention factors of NSAID drugs on Xterra RP18 column as a 
function of temperature using different proportions of organic modifier 
Mobile Phase* . Retention factor, k 
...... 
. . 
MeCN-Buffer Drugs Colunmtelllperature (0C) 
(v/v) 40. I. 60 80 100 120 
Sulindac 1.44 1.17 0.96 0.76 -
Indoprofen 1.44 1.17 0.96 0.76 -
Suprofen 1.71 1.34 0.96 0.76 -
Ketoprofen 2.25 1.76 1.42 1.25 -
45:55, pH 4 
Naproxen 2.57 2.01 1.61 1.25 -
Niflunamic acid 3.08 2.01 1.61 1.25 -
Flurbiprofen 4.50 3.45 2.69 2.07 -
Indomethacin 5.45 4.13 3.16 2.40 -
Sulindac - 5.04 3.44 2.36 1.66 
Indoprofen - 5.27 3.44 2.36 1.66 
Suprofen - 7.88 5.06 3.26 2.15 
. 
Ketoprofen - 7.88 5.06 3.42 2.58 
25:75,pH4 
Naproxen - 9.02 5.83 3.82 2.58 
Niflunamic acid - 11.83 7.11 4.28 2.58 
. 
Flurbiprofen - 21.14 12.73 7.80 4.89 
Indomethacin - 32.66 18.82 11.15 6.71 
Sulindac 2.76 1.93 1.75 1.29 0.97 
Indoprofen 4.21 2.72 2.26 1.29 0.97 
Suprofen 4.21 2.88 2.48 1.57 1.11 
Ketoprofen 5.53 3.52 2.85 1.96 1.40 
25:75, pH 5 
Naproxen 5.53 3.52 2.85 1.96 1.40 
Niflunamic acid 10.30 6.57 5.09 3.33 2.34 
Flurbiprofen 12.32 7.45 5.60 3.62 2.43 
Indomethacin 31.79 16.30 10.57 5.65 3.66 
= not exammed. 
* At pH 4 phosphate buffer (50 mM) with phosphoric acid was used. 
* At pH 5 sodium acetate buffer (50 mM) with acetic acid was used. 
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1.14 
1.14 
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3.10 
4.04 
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0.74 
0.74 
0.97 
0.97 
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5.2.2.2 Van't Hoff plots: 
The thermodynamic properties of NSAIDs were evaluated using the van't Hoff 
relationship by plotting the logarithmic of retention factor against the reciprocal 
absolute temperature (Figures 5.1-5.3)). The relationships were linear for all the 
drugs with r between 0.99 and 0.97 (Table 5.5) which indicated that the retention 
mechanism was not changing with increasing temperature. Since the van't Hoff 
_ relationship is based on an equilibrium existing between the entropy and enthalpy 
within a system the enthalpies of the drugs were calculated (Table 5.5). It was found 
the (MI,,) was negative at all cases, that indicates that the retention of the drugs was 
an exothermic process and that the thermodynamic properties were independent of 
temperature. Another observation was that the values of (~H") become more 
negative with increasing water proportion and more negative at pH 4 than pH 5. It is 
energetically therefore more favourable for these drugs to remain in the stationary 
phase than in the mobile phase and agrees with earlier study of cephalosporins. 
Lnk Water 55%, pH 4 
2.0 
1.5 
10 
0.5 
0.0 
-0.5+-----,----r---..,-----c---.----,-~-__, 
0.0026 0.0027 0.0028 0.0029 0.003 0.0031 0.0032 0.0033 
<> Sulinda. -0- Indoprofen --fr- Suprofen -*"" Ketoprofen lIT (Kt) 
-*- Naproxen -0- Niflumi. acid-+- Flurblprofen- Indomethacin 
Figure 5.1: Van't Hoff plots for NSAIDs on Xterra RP18 columu with water 
55% aud MeCN 45%, at pH 4 as mobile phase. 
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c 
..J 
4 
3.5 
3 
2.5 
2 
1.5 
1 
0.5 
0 
0.0024 0.0025 
-<>- Sulindac 
0.0026 
Water 75%, pH 4 
0.0027 0.0028 
1fT (k·') 
-D-Indomethacln -IJr- Suprofen 
0.0029 0.003 
-x- Ketoprofen 
-lK- Naproxen -0- Niflumlc acid -+- Flurbiprofen -Indoprofen 
0.0031 
Figure 5.2: Van't Hoff plots for NSAIDs on Xterra RP18 column with water 
75% and MeCN 45%, at pH 4 as mobile phase. 
~ 
c 
. .J 
4 
3.5 
3 
2.5 
2 
1.5 
1 
0.5 
0 
-0.5 
-1 
0.0024 
water 750/" pH 5 
0.0025 0.0026 0.0021 0.0028 0.0029 0.003 0.0031 0.0032 0.0033 
11T (k·') 
-<>- Sulindac -o-Indomethacin -fr- Suprofen -X- Ketoprofen 
-lK- Naproxen -0- Niflumic acid -+- Fiurbiprofen - Indoprofen 
Figure 5.3: Van't Hore plots for NSAIDs on Xterra RP18 colnmn with water 
75% and MeCN 45%, at pH 5 as mobile phase. 
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Table 5.5: Analysis ofVan't Hoffplots of NSAIDs on Xterra RP18 column with 
different mobile phases: 
* At pH 4 phosphate buffer (50 mM) with phosphoric acid was used. 
* At pH 5 sodium acetate buffer (50 mM) with acetic acid was used. 
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5.2.2.3 Effect of temperature on selectivity 
The effect of temperature on the selectivity of NSAIDs was investigated as a function of 
the column temperature and mobile phase composition with pH on the Xterra RP18 
column (Table 5.6). At 40°C pH 4 with 55% water as eluent, sulindac and indomethacin 
coeluted whereas the other drugs were separated well (Figure 5.4). 
5 
250 
200-
~ 150 
-
'" 100 1+2 ~ 
50 8 
3 4 6 ill 0 , Id lA 
30 10 ~o 30 
Time (Mins) 
Fignre 5.4: Separation of NSAIDs on Xterra™ RP18column (ISO x4.S mm I.D, 3.5 
pm). Chromatographic condition: mobile phase: MeCN (45%): SO mM acetate 
buffer (55% including, at pH 4), flow rate: 1 ml/min,temperature: 40, DC, detection: 
UV absorbance at 230 nrn, injection volume: 10 ILl, solute concentration: SO pg/ml. 
Peaks: Peaks: 1 - sulindac, 2 - indoprofen, 3 suprofen, ~ - ketoprofen - 5- naproxen, 
6 - niflunamic acid, 7 - flurbiprofen, 8 - indomethacin. 
However, when the temperature was increased to 60°C, peak overlap occurred between 
naproxen and niflunamic acid. This behaviour was .also observed at 80°C as wen as 
noting that suprofen coeluted with sulindac and indoprofen. At 100°C, as shown in the 
(Table 5.6) there are peak overlaps as selectivites drop to 1.00 because of the short 
retention times. Therefore, the amount of MeCN was reduced to 25% using the same pH 
at 60°C, In general, if we compared this temperature with the same temperature using 
MeCN 45%, the increased water proportion improved the selectivity, but there was no 
change in order of elution. Here the peak overlap between sulindac and was slightly 
reduced but occurred at higher temperatures (80-140 DC). Suprofen (pKa 3.91) and 
ketoprofen (pKa 4.45) coeluted but this peak overlap was lost at 100, 120 and 140°C that 
this could be attributed to different degrees of ionisation of the drugs with temperature at 
pH 4. A new peak overlap occurred at 120 and 140 °C between ketoprofen, naproxen and 
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niflunamic acid The pH was changed to 5 with the same mobile phase (75:25). Sulindac 
and indoprofen were re"separated well at a low temperature of 40°C whereas they 
co eluted at higher temperatures 100, 120 and 140°C. At 40 and 140 °c, there was peak 
overlap between indoprofen'and suprofen however, this peak overlap was eliminated at 
temperature betweens 60 to 120°C. Ketoprofen and naproxen were coeluted at all the 
temperatures studied. In general we concluded that with this column the best separation 
was observed with 25% acetate buffer at pH. 5 at 80°C with only peak overlap between 
ketoprofen and naproxen (Figure 5.5). 
4+5 
150 
S100 
! 
., 
~ 
1 2 50 
6 7 8 
° 
, 5 10 15 20 
Time (mins) 
Figure 5.5: Separation of NSAIDs on Xterra™ RP18 column (150 x4.5 mm I.D, 3.5 
/Lm.). Chromatographic condition: mobile phase: MeCN (25%): 50 mM acetate 
buffer (75% including, at pH 5), flow rate: 1 mIlmln, temperature: 80, °c, detection: 
UV absorbance at 230 nm, injection volume: 10 J.11, solute concentration: 50 /Lg/mL 
Peaks: Peaks: I-sulindac, 2-indoprofen, 3-suprofen, 4-ketoprofen, 5-naproxen, 6-
niOunamic acid, 7-0urbiprofen, 8-indomethacin. 
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Table 5.6: effect of temperature on selectivity (a) for diuretic drugs with different 
mobile phase on Xterra RP18 column 
Mobile 
, 
Phase* 
Selectivity (a) 
. 
Drugs· 
MeCN- Column 
temperature .. 
Buffer (0C) 
. (Jl :; (Jl ~ .Z Z 
£. c. ... .§ . 
- '" 
:;; 
0 0 .- "'C. 
'" c s· "0 ~ .. "0 .. ~ 51 ffi (v/v) 0. ,~ *,- ~ ~ 0. 3 '" CD 0 CD . 
'" '" 
o· 
'" '" 
. 40 1.00 1.19 1.31 1.14 1.20 -
.... 45:55, 
60 
- 1.00 1.15 1.31 1.14 1.00 pH4 
80 
- 1.00 1.00 1.47 1.14 1.00 
.. 100 
- 1.00 1.00 1.66 1.00 1.00 
40 
- - - - - -
60 
- 1.05 1.49 1.00 1.15 1.31 
25:75, 80 
- 1.00 1.47 1.00 1.15 1.22 
pH4 100 
- 1.00 1.38 1.05 1.12 1.12 
120 
- 1.00 1.30 1.20 1.00 1.00 
I 
..... 
140 
- 1.00 1.23 1.24 1.00 1.00 
40 
- 1.52 1.00 1.31 1.00 1.86 
60 
-I. 1.41 1.06 1.22 1.00 1.87 
.. 25:75, 80 - 1.29 1.10 1.15 1.00 1.78 
pH5 100 
- 1.00 1.22 1.25 1.00 1.70 
120 
- 1.00 1.14 1.25 1.00 1.68 
140 
- 1.00 1.00 1.32 1.00 1.65 
* At pH 4 phosphate buffer (50 mM) With phosphonc aCId was used. 
* At pH 5 sodium acetate buffer (50 mM) with acetic acid was used .. 
5.2.2.4 Influence of temperature on column efficiency (Nlm) 
:!! :; 
C 0. 
a- 0 3 ,~. 
~ 
*" 
~ CD g. 
'" 
1.46 1.21 
1.72 1.20 
1.67 1.18 
1.65 1.16 
- -
1.79 1.54 
1.79 1.48 
1.82 1.43 
1.89 1.37 
1.77 1.31 
1.20 2.58 
1.13 2.19 
1.10 1.89 
1.09 1.56 
1.04 1.50 
1.39 1.03 
One intention of increasing the column temperature in HPLC was to improve peak 
efficiency, therefore, the effect of column temperature on separation efficiency of the 
NSAIDs for all drugs Xterra RP18 column was examined (Figures 5.6-5.13). The 
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efficiency of sulindac (Figures 5.6) and indopprofen (Figures 5.7) were relatively high at 
60 ·C 75% at pH 4, whereas at pH 5 it was observed that the both efficiencies decreased 
with temperature over 40-80 ·C for sulindac and over 60-80 ·C for indoprofen. 
Nevertheless, the same pattern of results was obtained for suprofen (Figures 5.8), as its 
efficiency decreased from 40 to 60 ·C with 55% buffer. Also, it was observed that the 
efficiency decreased with temperature with 75% at both pH 4 and 5 except with 120 ·C at 
pH 5. Meanwhile, the greatest improvement in efficiency was obtained at 60 ·C with 75% 
at pH 5. The efficiency of ketoprofen and naproxen were almost similar as their 
efficiency were decreased by increasing temperature with buffer 55% at pH 4 and with 
buffer 75% at pH 4 respectively. Niflunamic acid's efficiency decreased with 75% buffer 
at pH 4 and 5 except with 100 ·C at pH 4 and over 80-120 pH 5. The last retained drugs 
flurbiprofen and indometacin behaved virtually similarly to each other a decrease with 
temperature in 55% buffer. However, with 75% buffer at pH 4 their efficiency slightly 
. decreased between 60-100 ·C then was roughly stable from 120 to 140 ·C. With 
increasing pH to 5 with the same portion of buffer, it was observed that the efficiency of 
both drugs slightly decreased over temperature 40-100·C then increased at 120 ·C to 
flurbiprofen only and stable after this temperature. With using buffer 55% at pH 4, it was 
noted the peaks shapes of all the drugs were excellent with all temperatures (Figure 5;4) 
and with using 75% buffer, at pH 4 except indoprofen's peak was broadened at 60 ·C. 
Nevertheless, at pH 5 the peak shapes of the last three retained drugs (niflunamic acid, 
flurbiprofen, and indoprofen) were not good especially with increasing temperatures 
(Figure 5.5). 
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Sulindac 
30000 
o 
25000 
'i 20000 
~ 
~ 15000 
= .. 
u 
S 10000 f;o;1 
5000 
0 
20 40 60 80 100 120 140 160 
-0-75%; pH 4 -I:r- 75%, pH 5 Temperature ('C) 
Figure 5.6: Variation of colnmn efficiency of sulindac as a function of temperature 
and pH using different proportions of organic modifier on Xterra RP1S colunm. 
Indoprofen 
25000 
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e- 15000 
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I:: 
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o· 
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Temperature ( DC) 
-0- 75%, pH 4 --ts- 75%, pH 5 
Figure 5.7: Variation of column efficiency of indomethacin as a function of 
temperature and pH using different proportions of organic modifier on Xterra RP1S 
column. 
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Suprofen 
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Figure 5.8: Variation of column efficiency of suprofen as a function of temperature 
and pH using different proportions of organic modifier on Xterra RP18 colunm. 
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Figure 5.9: Variation of column efficiency of ketoprofen as a function of 
temperature aud pH using different proportions of organic modifier on Xterra RP18 
colunm. 
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Figure 5.10: Variation of column efficiency of naproen as a function of temperature 
and pH using different proportion of organic modifier on Xterra RP18 column. 
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Niflunamic acid 
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Figure 5.11: Variation of column efficiency of niflunamic acid as a function of 
temperature and pH using different proportion of organic modifier on Xterra RP18 
column. 
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Flurbiprofen 
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Figure 5.12: Variation of column efficiency of flurbiprofen as a function of 
temperature and pH using different proportion of organic modifier on Xterra RP18 
column. 
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Figure 5.13: Variation of column efficiency of indoprofen as a function of 
temperature and pH using different proportion of organic modifier on Xterra RP18 
column. . 
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5.2.2.5 Summary 
The experimental conditions to analyze a mixture ofNSAIDs on Xterra RP18 column 
were studied. The, main parameters studied were the pH (4 and 5) of eluent and the 
temperature of column. As it was expected the retention factors of all the drugs were 
reduced with increasing temperature and increasing pH (this can explained as all these 
drugs are acidic causes ionisation). The van't Hoff plots were linear (~.0.97-0.99). 
Therefore, it was concluded that over the studied temperature range (40c 140 DC) no 
changes in the retention mechanism for these drugs occurred. In addition, it was observed 
(MI") was negative at all cases indicating the separation of drugs is an exothennic process 
and the thermodynamic properties are independent from the temperature therefore it is 
energetically more favourable for these drugs to remain in the stationary phase than in the 
mobile phase. Regarding the selectivity, it was found the order elution was sulindac, 
indoprofen, suprofen, ketoprofen, naproxen, niflunamic acid, flurbiprofen and lastly 
indomethacin, respectively. This order was not changed with temperature, mobile phase 
composition or pH. There was no resolution between sulindac and indomethacin with 
55% buffer at all temperature and with using buffer 75% at pH' 4 there was a slight 
separation at 60 DC but 'at pH 5 the both drugs were resolved completely at low 
temperature only 40, 60, and 80 DC. An peak overlap was observed between suprofen and 
ketoprofen at 60, and 80 DC with buffer 75% at pH 4. Ketoprofen and naproxen 'also 
coeluted when using 55% buffer at 100 DC and 75% at pH to 5. However, this peak 
overlap disappeared with 75% at pH 4 at low temperature only. In general the resolution 
improved when the hydrophobicity level of the drugs differ from drug to another. The 
best efficiency of sulindac and indoprofen, were obtained with buffer 75% at pH 4 at 60 
DC. Niflunamic acid were separated efficiently with 75% at pH to 5 at 40 DC and. 
Suprofen, ketoprofen, naproxen, flurbiprofen, and indomethacin gave the best efficiency 
at 40 DC with using 55% buffer. Nevertheless, contrast to our expectation it was found (N) 
decreased with increased temperature and this might be related to the degradation of this ' 
column with using high temperature up to 140 DC. 
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5.2.3 XbridgeTM RP18 column: 
5.2.3.1 Effect of temperature and pH on Retention factor, k: 
As it was ,noted that the Xterra RP18 column was starting to degrade at 140°C, which 
might be one cause of the decrease in efficiency (N). Therefore, the column was changed 
, to Xbridge™ RP18 shield column is as this column is polar embedded ethylene bridge 
based material specially desigened for aqueous solution and should be more durable to 
hard conditions because the existence of the ethylene group bridge [Waters catalogue]. 
The NSAIDs were eluted at high temperatures (40, 60, and 80°C) with different mobile 
compositions and a range of pH from 3, 4, 5, and 6. The Xbridge™ RP18 column has a 
smaller surface area compared to Xterra RP18 column resulting in less retentivity, which 
permit the use of a higher proportion of buffer in the eluent. There was change in the 
order of drugs elution compared to Xterra RP18 (Table 5.7). The mobile compositions 
had more effect on elution time than pH or temperature and this agreed with the 
previously work on the Xterra RPI8 column (see Section 5.2.2.1) [145]. The retention 
factors of indoprofen, suprofen, sulindac naproxen, ketoprofen, niflunamic acid, 
flurbiprofen, and dic10fenac were increased by more than 13 ,11,27,14,9,12,14, and 14 , 
times, respectively, when the buffer proportion increased from 75% to 90% at pH 6 and 
80°C. whereas with a change in pH from 3 to 6 at the same temperature with water 75% 
retention factors of indoprofen ( pKa 5.8), suprofen (pKa 3.91), sulindac (pKa 4.7) 
naproxen (pKa 4.15), ketoprofen (pKa 4.45), niflunamic acid (pKa4.31), flurbiprofen 
(pKa 4.33), dic1ofenac(pKa 4.15) and indomethacin (pKa 4.5) were decreased by more 
than 8, 12, 11, 10,9, 5, 10, 9 and 8 times, respectively, based on the degree of ionisation 
of each drug resulted from pH change. This behaviour can be explained, as at pH 6 the 
drugs should be mostly in its charged form based on their pKa. Suprofen was fully 
ionised as it has smallest pKa therefore the decrease in retention was higher than other 
drugs. In general the best mobile phase for the separation was 75% buffer at pH 5 at with 
25% MeCN all temperatures (Figures 5.14 (a-b ). 
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Table 5.7: Retention factors of NSAID drugs on Xbridge RP18 column as a function 
of temperature and pH using different proportions of organic modifier: 
I ' 
I, Mobile 
Phase* 
Retention factor, k 
Drugs 
MeCN-Buffer Columntemperatnre ("C) 
(v/v) 40 60 80 
Indoprofen 13.88 9.03 5.93 
Suprofen 24.88 15.31 9.48 
Sulindac 24.88 16.14 9.48 
Naproxen 27.62 16.82 10.44 
Ketoprofen 27.62 16.82 10.44 25:75, pH3 
Niflunamic 
63.55 39.30 23.36 
acid 
I 
' , 
Flurbiprofen 86.60 48.72 27.87 
Diclofenac 119.41 62.64 33.76 
Indomethacin 134.42 72.88 40.13 
, , 
Indoprofen 8.29 5.88 4.23 
Suprofen 14.05 9.21 6.12 
Sulindac 14.05 9.21 6.12 
Naproxen 17.71 11.70 7.78 
I 
25:75, pH4 Ketoprofen 15.02 10.26 7.01 
Niflunamic 
acid 29.98 17.76 10.78 
Flurbiprofen 50.43 29.76 18.45 
Dic10fenac 65.28 35.79 20.92 
Indomethacin 77.55 43.88 26.20 
112 
ChapterS NSAIDs 
Mobile I 
Phase*. 
Retention factor, k 
.'. 
i 
. Drugs' I .. 
. 
MeCN-Buffer Column temperature ("C) 
'. (v/v) 40 60 .. 80 
Indoprofen 2.84 1.95 1.65 
Suprofen 2.84 2.69 2.06 
Sulindac 4.30 2.69 2.06 
' .. 
Naproxen 6.45 3.97 2.97 
.' . ". Ketoprofen 4.93 .3.27 2.59 
·2S:7S, pH S 
Niflunamic 
acid 13.60 8.37 5.94 
Flurbiprofen 15.77 9.29 6.44 
DicJofenac 20.38 11.46 7.59 
. Indomethacin 26.18 15.08 10.12 
.. . ' 
. ' . Indoprofen 1.21 0.95 0.74 . 
:< . '. 'Suprofen 1.21 0.95 0.74 
.... 
Sulindac 1.14 0.85 .. 1.55 
Naproxen 1.99 1.40 1.01 
": .. Ketoprofen 1.99 1.40 1.15 2S:7S;pH6 . 
. '.i Niflunamic 
.' ........ acid 10.65 7.09 4.52 
Flurbiprofen 5.73 3.92 2.66 
I. DicJofenac 9.13 5.88 3.74 
Indomethacin 11.37 7.60 4.94 
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Mobile 
Phase* 
Retention factor, k 
Drugs 
MeCN-Buffer ' Column temperature ('C) 
(v/v) 40 60 80 
, " Indoprofen N.d 78.46 40.42 
Suprofen N.d 63.90 33.72 
Sulindac N.d N.E 104.09 
Naproxen ' N.d 114.33 57.74 
10:99, pH4 Ketoprofen N.d 114.33 57.74 
0'"' Niflunamic 
acid N.d N.E N.E 
, , Flurbiprofen N.d N.E N.E 
". 
Diclofenac N.d N.E N.E 
, , ", Indomethacin N.d N.E N.E 
Indoprofen N.d 30.68 19.33 
Suprofen N.d 23.55 15.40 
Sulindac N.d 82.86 44.68 
,. ' 
Naproxen N.d 42.43 25.82 
". 
Ketoprofen N.d 42.43 27.24 10:90,pH S 
Niflunamic , 
acid N.d 189.34 101.22 
Flurbiprofen N.d 135.67 76.56 
Dic10fenac N.d 127.80 71.37 
I ' Indomethacin N.d N.E N.E , 
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.... 
.. 
Mobile 
Phase* 
Retention factor, k 
Drngs 
.. 
. 
MeCN-Buffer Column temperature ('C) 
(v/v) 40 60 
Indoprofen N.d 13.83 
Suprofen N.d 11.52 
Sulindac N.d 36.37 
Naproxen N.d 20.25 
. 10:90, pH 6 Ketoprofen N.d 14.59 
Niflunamic 
.. 
N.d N.B 
acid 
I Flurbiprofen N.d 58.52 
I . 
Diclofenac N.d 101.09 
Indomethacin N.d N.B 
* At pH 3 & 4 phosphate buffer (50 mM) with phosphoric acid was used 
* At pH 5 & 6 acetate buffer (50 mM) with acetic acid was used. 
. N. d = not examined, N.E= not eluted. 
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Figure 5.14 :Separation of NSAIDs on Xbridge™ RP18 column (150 x4.5 mm I.D, 
3.S J.!m.) Chromatographic condition: mobile phase: MeCN (25%): 50 mM acetate 
buffer (75% including, at pH 5), flow rate: 1 mIlmin, temperature: a) 40, b) 60°C, 
detection: UV absorbance at 230 nm, injection volume: 10 Ill, solute concentration: 
50 J.!glmI. Peaks: Peaks: l:-indoprofen, 2-suprofen, 3-sulindac, 4-ketoprofen, 5 -
naproxen, 6-niflunamic acid, 7-flurbiprofen, 8-diclofenac, 9-indomethacin. 
5.2.3.2 Van't Hoff plots: 
The thennodynamic properties of the NSAIDs were detennined using the van't Hoff 
equation by plotting logarithmic of retention factor against the reciprocal temperature 
(Figures 5.15-5.18) with MeCN (25%). At pH 3, 4, 5 & 6 the relationships were linear for 
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all drugs with r between (1.00-0.97) (Table 5.8). The linearity indicate the retention 
mechanism is also not changing with this column. The enthalpy of the drugs were 
calculated (Table 5.8). It was found the (6H") was negative at all cases that indicated that 
the separation of the drugs is an exothennic process and the thennodynamic properties are 
independent from temperature. As expected from the increased retention it was found that 
the values of (AHO) were more negative with decreasing pH 6 to 3, with some exceptions 
in case of suprofen from pH 6 to 5 and niflunamic acid from pH 4 to 3 and from pH 6 to 
5. Therefore; it is energetically more favourable for the studied drugs to remain in the 
stationary phase at low pH than in the mobile phase. All the drugs were transferred from 
the mobile phase to the stationary phase entropically favourable rather than enthalpically 
.and this increased with higher temperature and pH and the entropic contribution is the 
dominant separation of these drugs. The (6HO) WM more negative with Xterra RPl8 
phase than Xbridge RPl8 phase (Table 5.5 & 5.2) for indoprofen, suprofen, ketoprofen, 
naproxen, and niflunamic acid whereas vice versa for indomethacin, and flurbiprofen and 
sulindac, ouly at pH 5. 
Water 75%, pH 3 
5.5 
4.: cj;_ 1 
~ 3.: ~ ~~""""=====~~~ 
2.5. ~:=====~= -
2 
1.5 -
1+---~----'---~----~----r----r----~--~----~ 
0.0028 0.00285 0.0029 0.00295 0.003 0.00305 0.0031 0.00315 0.0032 0.00325 
-<>- Sulindac --D-Indomethacin ..or- Suprafen 
-X- Ketoprofen -:1:- Naproxen -<>- Niflumlc acid 
-+- Flurblprofen - Diclofenac ~ Indoprefen 
Figure 5.15: Van't Rof{ plots for NSAlDs on Xbridge RP18 column as a function of 
temperature and pR using water 75% at pR 3. 
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Water 75%, pH 4 
5 
4.5 
4 i= 3.5 !-... ~ .. 3 .... 2.5 
2 ~~ 
---; 
-
1.5 
-
0.0028 0.00285 0.0029 0.00295 0.003 0.00305 0.0031 0.00315 0.0032 0.00325 
-<>- Sulindac -D-Indomethacin -fr-- Suprofen 
-x- Ketoprofen -:1(- Naproxen -0- Niflumic acid 
-+- Flurbiprofen - Diclofenac -Indoprefen 
Figure 5.16: Van't Hoff plots for NSAIDs on Xbridge RP18 column as a function of 
temperature and pH using water 75% at pH 4. 
Water 75%, pH 5 
3.5 
3 
2.5 
2 
... 1.5 
.. 
.... 1 
0.5 
0 
-0.5 
-1 
0.0028 0.00285 0.0029 0.00295 0.003 0.00305 0.0031' 0.00315 0.0032 0.00325 
-<>- Sulindac -D-Indomethacin -fr-- Suprofen 
-x- Ketoprofen -:1(- Naproxen -0- Niflumic acid 
-+-Flurbiprofen - Diclofenac -Indoprefen 
Figure 5.17: Van't Hoffplots for NSAIDs on Xbridge RP18 column as a function of 
, temperature and pH using water 75% at pH 5. 
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Water 75%, pH 6 
3 
2.5 
2 
.!d 1.5 ~ 
" 
1 
...:I 0.5 
0 ~ 
-0.5 
-1 
0.0028 0.00285 0.0029 0.00295 0.003 0.00305 0.0031 0.00315 0.0032 0.00325 
-<>- Sulindac -D-Indomethacin -/Jr- Suprofen 
-X- Ketoprofen -:1(- Naproxen -0- Niflumic acid 
--+- Flurbiprofen ~ Dlclofenac - Indoprefen 
Figure 5.18: Van't Hoff plots for NSAIDs on Xbridge RP18 column as a function of 
temperature and pH using water 75% at pH 6. 
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Table 5.8: Analysis oflinear Van't Hoffplots ofNSAlD drugs ou Xbridge RP18 
columu as a function oftemperature and pH using different proportions of organic 
* At pH 3 & 4 phosphate buffer (50 mM) with phosphoric acid was used. 
* At pH 5 & 6 acetate buffer (SO mM) with acetic acid was used. 
N.D= not determined. 
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5.2.3.3 Effect of temperature and pH on selectivity: 
The effect of temperature on selectivity was also investigated (Table 5.9). The pH of the 
mobile phase can be used to control the ionisation state of acidic drugs, therefore it was 
,used to study the best conditions to separate this group of drugs (NSAIDs) as they have a 
carboxylic acid group. A change in selectivity was found compared to Xterra RP18 column 
(Figure 5.19). This change could be attributed to difference in stationary phases as Xterra 
RP18 column contains methyl group whereas Xbridge RP18 column contains ethylene 
bridge. 
Figure 5.19: Comparison of the order of elution of NSAIDs with Xterra RP18 and 
Xhridge RP18 columns with 75% water at pH 4 at 80°C: 
30 
25 
-~ 
::; 20 
1> 0- --+ 
... 
-;; 15 
:! +-
~ 10 i a; ! <>:: 5 
":" 
0 
Xterra RP18 Xbridge RP 18 
Column 
-+- Sulindac -O-Indomethacin -ts- Suprofen ... Ketoprofen 
-)K-Naproxen '--..Niflunamicacid -t-Flurbiprofen. -Indoprofen 
The order of elution was on Xbridge RP18 column as following indoprofen, suprofen, 
sulindac, ketoprofen, naproxen, niflunamic acid, flurbiprofen, diclofenac and indomethacin 
with using buffer 75% at pH from 3, 4, and 5 at all temperatures. It was noted also at pH 
3, that naproxen (pKa 4.15), and ketoprofen (pKa 4.45) co eluted at all temperatures 
whereas they were separated at pH 4 'and 5. However, they again coeluted together at pH 6 
at 40 and 60°C. At 80 °C the naproxen was eluted before ketoprofen. Another observation 
was that suprofen (pKa 3.91) and sulindac (pKa 4.7) were-eluted at the same time using 
buffer 75% at pH 3, 4, and 5 with a slight separation at 60°C at pH 3. Nevertheless, 
increasing the pH to 6 improved the separation as suprofen eluted early with indoprofen 
(pKa 5.8) at this case. Also at pH 6 at all temperatures, it was noted that there were 
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changes in order elution as flurbiprofen and dic10fenac were eluted before niflunamic acid 
(pKa 4.31). Increasing buffer concentration was carried out to 90% using pH from 4 to 6 at 
temperatures 60 and 80°C. At pH 4 the only few drugs were eluted in order suprofen; 
indoprofen, naproxen, ketoprofen and sulindac at 80°C. Naproxen and ketoprofen coeluted 
at both temperatures. By increasing pH to 5, it was found that diclofenac (pKa 4.15), 
flurbiprofen (pKa 4.33) and niflunamic acid were eluted with good separation unless 
indomethacin (pKa 4.5) and also here, naproxen and ketoprofen were coeluted at 60°C and 
they slightly separated from each other at 80 °c. it was increased pH to 6 with keeping 
mobile phase composition as it was. It was found all drugs were eluted with good 
separation expect indomethacin at 80°C and also niflunamic acid at 60°C. With a reverse 
in order of elution as flurbiprofen was eluted before diclofenac figures (5.20 a-d). The 
order of elution was changed with increasing water proportions to 90% at pH 4 and 5, to 
be suprofen, indoprofen, naproxen, ketoprofen, sulindac, diclofenac, flurbiprofen and 
·niflunamic acid. Indomethacin was not eluted. At pH 6, it was observed that flurbiprofen 
was eluted before dic1ofenac. 
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Mobile MeCN-Buffer 25:75, pH3 25:75, pH 4 25:75,pH5 25:75, pH6 
Phase* (v/v) 
Q~>-l (") 
.... p> =-. 
Q .... =- ., ~ 00;-
.... p>ntll 
'" 1:0 Q • ...
""'. - Ir.C tII n Cl ., 
Column temperature 40 60 80 40 60 80 40 60 80 40 60 80 ("C) 
..... ' 
Indoprof 
= = = = 
=. 
= = = = = = = 
... en 
I Suprofen 1.79 1.70 1.60 1.70 1.57 1.45 1.51 1.38 .1.25 1.00 .1.00 1.00 
Sulindac 1.00 1.05 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.28 1.20 1.14 
Kdoprof 1.11 1.04 1.10 1.07 1.11 1.15 1.15 1.21 1.26 1.28 1.23 1.19+ CIl 
~, .. ·en ... 
~ , t;:j Naproxe . ,.... . a 1.00 1.00 1.14 1.00 1.14+ ·S:- 1.00 1.18 1.11 1.31 1.21 1.14 1.00 
. ~ .. , ~ n . 
.-. 
-, . . ..... 
"s, Nifluna 2.30 2.34 2.24 1.69 1.52 1.39 2.11 2.11 2.00 2.87# 2.79# 2.31# I)lic aci!i 
Flurbipr • 1.36 1.24 ·1.19 1.68 1.68 1.71 1.16 1.11 1.09 1.59# 1.50# 1.41# 
of en 
Diclofen 1.38 1.29 1.21 1.29 1.20 1.13 1.29 1.23 1.18 1.17# 1.21# 1.21# 
ac 
I 
Indomet 1.13 1.16 1.19 1.19 1.23 1.25 1.28 1.32 1.33 1.07 1.07 1.09 hacin 
aml"l 8. ~ 
_.el n 
;t~~ 
... ,." .... 
Cl ;-~ S 
::t.'tI 
.. '" 
= ... s,; 
;- ... 
e '" 
'tI8 
'" '" 
... '" ~;-
... " 
'" ~ ., _. 
=~ 
.120 ,..., 
'tIS 
= .... Cl .. 
<Il ... 
S· Z 
«cOO ~S ;' 
... 120 g d 
"'«c 
'tI'" 
... Q 
.. Cl 
1~ z 00 
""'- ::! S .. . =120 "'~ 
'" 
Mobile MeCN-Buffer 10:90, pH4 10:90, pH 5 10:90, pH6 19 Phase* (v/v) 
'" ., 
Column temperature ("C) 40 60 80 40. 60 80 40 60 80 
Indoprofen . - = = - = - - = = 
. 
1 Suprofen N.d 1.23 1.20 N.d 1.30 1.25 N:d 1.20 1.17 
.. .. . 
.. 
Sulindac N.d 1.46 1.43 N.d 1.38 1.34 N.d 1.06 1.05 
.. 
CIl .. Ketoprofen N.d 1.00 1.00 N.d 1.00 1.06 N.d 1.39 1.40 ~: 
'" 
~ ~ 2< I> Naproxen N.d N.E 1.80 N. d. 1.95 1.64 N.d 1.80 1.55 ~. IJQ ~ ...... 
'" 
. . 
1i' Niflunamic N.E N.E ...., N.d N.d 1.54 1.60 N.d 1.61* 1.64* 
.. acid 
. Flurbiprofen N.d N.E N.E N.d 1.06 1.07 N.d 1.73* 1.40* 
Diclofenac N.d N.E N.E N.d 1.40 1.32 N.d N.E 1.10 
. 
. 
Indomethaci N.d N.E N.E N.d N.E N.E N.d N.E· N.E 
n 
ChapterS 
75 
~o­
! 
o I 
-D 
100 
75 -
10 30 
2+3 
4 
10 20 
NSAIDs 
a)pH3 
7 
6 8 9 
" A' A 
40 '50 60 70 \lo 
Time (Mins) 
b)pH4 
30 '40 50 '60 '70 ' 
Time (Mins) 
Figure (5.20 (a-b): Separation of NSAIDs on Xbridge™ RP18 column (150 x4.5 
mm I.D, 3.5 tnn.) Chromatographic condition: mobile phase: MeCN (25%): 50 
mM acetate buffer (75% including, at pH 3 and 4, flow rate: 1 mlImin, 
temperature: 80, QC, detection: UV absorbance at 230 nm, injection volume: 10 
fil, solute concentration: 50 pg/ml. Peaks: Peaks: l-indoprofen, 2-suprofen, 3-
sulindac, 4-ketoprofen, S-naproxen, 6-niflunamic acid, , 7-flurbiprofen 
8-diclofenac, 9-indomethacin. , 
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Figure (5.20 (c-d): Separation of NSAlDs on Xbridge™ RP18 column (150 x4.5 
mm 1.0, 3.5 /lm.) Chromatographic condition: mobile phase: MeCN (25%): 50 
mM acetate buffer (75% including, at pH 5 and 6, flow rate: 1 mllmin, 
temperature: 80, °c, detection: UV absorbance at 230 nm, Injection volume: 10 
1-11, solute concentration: 50 /Igloo. Peaks: Peaks: 1-indoprofen, 2-suprofen, 3-
sulindac, 4-ketoprofen, 5-napronn, 6-niflunamic acid, 7- flurbiprofen 
8--diclofenac, 9-indomethacin. 
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5.2.3.4 Influence of temperature and pH on column efficiency 
The effect of column temperature on the separation efficiency of the NSAIDs was 
detennined. (Figures 5. 21-5.29). It was found that the efficiency for indoprofen decreased 
on increasing pH with 75% buffer at. all temperatures studied and remained almost 
constant over the temperature range 40-80 °C with using 75% buffer at all pH except at 3 
and 4 there was little drop in efficiency at 80°C. By increasing the aqueous buffer portion 
to 90% at the same pH 4, 5 and 6, it was observed that the efficiency increased with 
temperature from 60 to 80°C. In general, this column gave better efficiency than the 
Xterra column for indoprofen. The efficiency of suprofen decreased at low pH 3 with 
75% buffer it was noted that the efficiency from 60°C to 80 QC. With 90% buffer at pH 
4, and 6, the efficiency was almost decreased at both temperatures whereas it increased at 
pH 5. In comparison the efficiency of suprofen with this column is better than Xterra 
RP18 column. The best efficiency ofnaproxen was observed with 90% buffer at pH 6 at 
60°C. Naproxen with 75% buffer was more efficient at pH 5 and 40°C than at other pH 
. 4, and 6. It was decreased on increasing temperature with using 75% and 90% buffer at 
all pH, except with buffer 90% at pH 5. Also, ketoprofen was similar to naproxen with 
75% buffer at all pH as the efficiency decreased with temperatures, except at pH 4 and 60 
QC. Increasing the polarity of the mobile phase and the pH to 6 lead to improve efficiency, 
especially at 60°C. This column provided better efficiency for naproxen and ketoprofen 
.. than the Xterra RP18 column. Niflunamic acid, flurbiprofen, diclofenac and indomethacin 
gave best efficiency with 75% buffer at pH 6 it was noted their efficiency was 
dramatically increased by increasing pH and but decreased on increasing temperature 
with 75% buffer. In contrast to indoprofen, suprofen, ketoprofen and naproxen, it was 
noted with these drugs efficiency decreased on increasing the polarity of the mobile phase 
to 90%. Sulindac efficiency was decreased by increasing pH and temperature with using 
75% buffer. Regarding the peak shapes of drugs, it was found that the shapes of first five 
drugs are better than the four less polar drugs but these were much better on Xterra RP18. 
Another observation was that peak shapes were improved by increasing temperature and 
increasing pH with using 75% buffer and all peak shapes were excellent with this mobile 
phase at all pH and temperature. When the buffer proportion was increased to 90%, it was 
noted the peak shapes worsened especially for last three retained drugs (diclofenac, 
flurbiprofen, and niflunamic acid) at pH 5 and 6. 
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This column provided better efficiency for all drugs compared to the Xterra RP18 
column. In general it was found the effect of increasing temperature in parallel with 
changes in pH on efficiency with the Xbridge RP18 column slightly decreased the 
efficiency for most drugs. 
80000 -
70000 
i 60000 -
~ 50000 
;.. 40000 5 30000 
.c:l 20000 
~ 10000 
Indoprofen 
+ 
o+--------.--------,--------,,-------~ 
20 40 60 
-<>- water 75%, pH 3 -0- 75%, pH 4 
-)1(- 90%, pH 4 --0- 90%, pH 5 
80 100 
Temperature (C) 
---tr 75%, pH 5 
--+- 90%, pH 6 
Figure 5.21: Variation of column efficieucy of indoprofen as a function of 
temperature and pH using different proportions of organic modifier on Xbridge 
RP18 column. . 
Suprofen 
,-., 70000 
.@ 60000 t - ~ 1; 50000 
~ 40000 
.~ 30000 
IS 20000 
~ 10000 
0 
20 40 60 80 100 
Temperature (C) 
-<>- water 75%, pH 3 -::1(- 90%, pH 4 --0- 90%, pH 5 -+-90%, pH 6 
Figure 6.22: Variation of column efficiency of suprofen as a function of temperature 
and pH using different proportions of organic modifier on Xbridge RP18 column. 
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Naproxen 
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~~~~-~~ 
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-)1(- 90%, pH 4 --0- 90%, pH 5 -+- 90%, pH 6 
Figure 5.23: Variation of column efficiency ofnaproxen as a function liftemperature 
and pH using different proportions of organic modifier on Xbridge RP18 column. 
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Ketoprofen 
0+---------,--------,---------.--------. 
20 40 60 80 100 
Temperature ("C) 
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--0- 90%, pH 5 -+- 90%, pH 6 
Figure 5.24: Variation of column efficiency of ketoprofen as a function of 
temperature and pH using different proportions of organic modifier on Xbridge 
RP18 column. 
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Niflunamic acid 
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Figure 5.25: Variation of column efficiency of niflunamic acid as a function of 
temperature and pH using different proportions of organic modifier on Xbridge 
RP18 column. 
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Figure 5.26: Variation of column efficiency of flurbiprofen as a function of 
temperature and pH using different proportions of organic modifier on Xbridge 
RP18 column. . . 
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Figure 5.27: Variation of column efficiency of diclofenac as a function of 
temperature and pH using different proportion of organic modifier on Xbridge 
RP18 column. 
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Figure 5.28: Variation of colunm efficiency of indomethacin as a function of 
temperature and pH using different proportions of organic modifier on Xbridge 
RP18 column. 
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Figure 5.29: Variation of column efficiency of suIindac as a fnnction of temperature 
and pH using different proportions of organic modifier on Xbridge RP18 column. 
5.2.3.5 Summary 
The experimental conditions to analyze a mixture of NSAIDs on a Xbridge™ RP18 
column were studied. The main parameters studied were the pH 3, 4, 5 and 6 of the eluent 
and the temperature of column 40, 60, and 80°C with 75% & 90% buffer. The effect of 
temperature, pH, and mobile compositions on the retention factors was investigated and it 
was concluded the mobile composition had a larger effect on the time of elution than pH 
and temperature, respectively.· Increasing the temperature and pH reduced !he retention 
factors of all the drugs. The linearity of van't Hoff plots indicate the retention mechanism 
is not changing with increasing temperature with this column, similarly to the Xterra 
RP18 column. Also, it was found the (M!") was negative at all cases and was more 
negative at low pH that indicate the separation of drugs is exothermic process and 
therefore, it is energetically more favourable for these drugs to remain in the stationary 
phase than in the mobile phase especially at low pH. With Xbridge™ RP18 column, there 
was a change change in selectivity compared to Xterra RP18 column. With 75% buffer at 
pH from 3, 4, and 5 at all temperatures, but. at pH 6, the naproxert was eluted before 
ketoprofen and at all temperatures, flurbiprofen and diclofenac were eluted before 
niflunamic acid. On increasing the buffer proportion to 90% at pH 4, there was change in 
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. order as suprofen eluted before indoprofen, diclofenac before flurbiprofen. Increasing the 
polarity of mobile phase by using 90% buffer and increasing pH to 6 completely gave 
resolution of all the drugs. Whereas the best condition for the separation of these drugs 
with this column was with buffer concentration 75% at pH 5 at 80 DC with only peak 
overlap between sulindac and suprofen. The best efficiencies were obtained for all drugs 
was as following, indoprofen with 90% at pH 6 at 80 DC, suprofen and ketoprofen at same 
buffer and pH at 60 DC, naproxen with 75% at pH 5 at 40 DC, niflunamic acid, 
flurbiprofen, indomethacin and diclfenac, with 75% at pH 6 at 40 DC, and lastly sulindac : 
with using buffer 90% at pH 5 at 80 DC. The best condition for separation NSAIDs in 
terms of all parameters (k, a, NIM) as mixture was observed with using 75% pH 5 at 80 
DC (Figure 5-20 c). 
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5.2.4 Effect of temperature and flow rate on separation with short column 
5.2.4.1/ntroduction 
Although the separation of the NSAIDs could be carried out with 90% water as the 
eluent at pH 6 some drugs had a long retention time. It was therefore decided to try using 
the same stationary phase but in a shorter column to reduce the retention time and use an 
increasing flow rate. It was intended to see if it was feasible to use 100% water as the 
eluent. The separation of the NSAIDs was therefore examined on a short Xbridge RPI8 
column [4.5 x 50 mm, 3.5 /Lm] at 80 QC using 90% and 95% buffer and at 120 QC using 
100% buffer .. 
5.2.4.2 Effect on retention factor (k) and selectivity (a) 
Separations were carried out at three different eluent compositions of buffer (90%, 95% 
(at 80 QC) and 100% (at 120 QC) at a constant pH 6 with different flow rates 1-3 mUmin 
(Table 5.10). It was observed that the retention factors increased when the flow rate was 
increased and this could be attributed to inefficient heating with precolumn so that the 
incoming solvent was not up to column temperature and was cooling the column. Ideally 
the incoming solvent needs to be exactly the same as the column temperature [54]. The 
change in the retention factors was relatively small when the flow rate was increased from 
lto 2 mUmin and much greater from 2 to 3 mUmin for most of the polar NSAIDs 
generally with using 90% buffer. Also, it was found that the peak shapes deterioated 
(Figure 5.30) and 95% at 80 QC (Figure 5.31). Nevertheless, this change in retention 
factors was greater for the more retentive less polar drugs (sulindac, flurbiprofen, 
dic1ofenac, niflunamic acid and indomethacin) especially with using 95% buffer at 80 QC. 
With using 100% buffer at 120 QC, it was noted the changes of the retention factors was 
relatively high when flow rate was increased from 1 to 2 mllmin especially for the less 
polar drugs. The order of elution of these drugs was as follows using buffer 90% 
suprofen,. naproxen, indoprofen, ketoprofen sulindac, flurbiprofen, dic1ofenac, niflunamic 
acid and indomethacin with two peak overlaps as naproxen and indoprofen coeluted and 
other peak overlap between diclofenac and niflunarnic acid as with 90% buffer. However, 
on increasing the eluent polarity to 95%, there was a change in this order as sulindac was 
eluted before ketoprofen. It was found with this eluent that the only peak overlaps were 
between naproxen and indoprofen and between diclofenac and niflunamic acid. They 
were resolved from each other at 1 and 2 mUmin then co eluted at 3 mUmin. It was also 
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observed that indomethacin was not detected with this eluent. On increasing the 
temperature to 120°C 
using a pure buffer 100% (Figure 5.32) at pH 6, the resolution became much poorer and 
many related peaks coeluted, there was also a change to flurbiprofen, niflunamic, 
dic10fenac and sulindac. There was virtually no change in the selectivity when flow rate 
was increased from 1 to 3mUmin with this eluent. There were two peak overlaps one 
between suprofen and naproxen and other between flurbiprofen and niflunamic acid. 
Table 5.10: Effect of flow rate using different proportions of organic modifier 
On retention factor (k) and selectivity (a) for NSAIDs on short (5 cm) Xbridge RP18 
column 
. 
1··· . . 2 3 
k ····a k a .. k a 
.. .. 
8.35 
10.03 1.20 
10.03 1.00 
14.29 
23.17 
6 
36.89 . Fh.irbiprofen: 1.59 80°C . ... .. . .. 
60.07 
60.07 
.• Ind6iriethacm 134.81 
22.82 
25.90 
25.90 
32.23* 
40.81 * 
6 
so°C 
101.89 
149.24 
149.24 
N.E 
1.63 
1.00 
2.24 
1.13 
1.00 
1.24* 
1.27* 
2.50 
1.46 
. 
1.00 
N.E 
ChapterS 
Phase* 
Buffer 
(v/v) 
6 
120°C 
a. 
* Sulindac was eluted before ketoprofen. 
rate 
k 
18.40 = 
1.11 
1.70# 
1.00 
NSAIDs 
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k a 
= = 
= = 
-
= 
= = 
= = 
= = 
# The order changed to flurbiprofen, niflunamic, diclofenac and sulindac. 
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Figure 5.30: Separation of NSAIDs on Xbridge™ RP18 column (50 x4.5 mm I.D, 3.5 
/Lm.). Chromatographic conditions: mobile phase: MeCN 10%: 50 mM acetate 
buffer (90%, pH 6), flow rate: 3 InIfmin, temperature: 80, cC, detection: UV 
absorbance at 230 nm, injection volume: 10 Ill, solute concentration: 50 lIg1ml. 
Peaks: Peaks: 1 - suprofen, 2 - indoprofen, 3 -naproxen, 4 - sulindac, 5- ketoprofen, 
6 - flurbiprofen, 7- diclofenac, 8-niflumic acid, 9-indomethacin. 
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Figure 5.31: Separation of NSAIDs on Xbridge™ RP18 column (50 x4.5 mm I.D, 3.5 
/Lm.). Chromatographic conditions: mobile phase: MeCN 10%: 50 mM acetate 
buffer (95% pH 6), flow rate: 3 m1Imin, temperature: 80, °c, detection: UV 
absorbance at 230 nm, injection volume: 10 Ill, solute concentration: 50 /Lg!ml. 
Peaks: Peaks: 1 - suprofen, 2 - indoprofen, 3 -naproxen, 4 -:- sulindac, 5- ketoprofen, 
6 - flurbiprofen, 7- diclofenac, 8-niflumic acid, 9-indomethacin. 
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Figure 5.32: Separation of NSAIDs on Xbridge™ RP18 column (50 x4.5 mm I.D, 3.5 
pm.). Cbromatographic condition: mobile phase: 50 mM acetate buffer (100% pH 
6), flow rate: 2 mllmin, temperature: 120, GC, detection: UV absorbance at 230 nm, 
injection volume: 10 Ill, solute concentration: 50 pg/ml. Peaks: Peaks: 1 - suprofen, 
2 -naproxen, 3-indoprofen, 4- ketoprofen, 5 - flurbiprofen, 6- niflunamic acid, 7 -
diclofenac, 8 - sulindac. 
5.2.4.3 Effect on efficiency (Nlm) 
The investigation studied the effect of temperature and flow rate with eluent composition 
on efficiency (N/m) on the short Xhridge RPI8 colunm. (Table 5.11). In general, it was 
observed with using 90% buffer, that the change of efficiency is moderately small when 
flow rate is increased from 1 to 2 mIlmin for most of the polar NSAlDs and dramatically 
dropped from 2 to 3 mUmin generally for the NSAlDs. This could be related to thermal 
. mismatching between the incoming solvent and colunm temperature. In order to minimise 
this effect it is recommended to use a reasonable length of the smallest tube I.D. (e.g. 
0.005--0.0070 mm) and smaller I.D colunm (<4.5 mm) [54]. The peaks shapes were better 
with low flow rates especially for the more polar drugs. With increasing eluent polarity to 
95% at 80°C, this observation was disappeared from 1 to 2 mUmin and similar to with 
using 90% buffer flow rate from 2 to 3 mUmin. Generally, better efficiency was observed 
with using 95% than 90% buffer with I and 2 mIlmin for suprofen, naproxen, 
indoprofen, and diclofenac. With using pure water as eluent at 120°C, decreasing 
efficiency was found with increasing flow rate for all the drugs. With compared this 
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eluent to previous eluent 90% and 95% buffer, it was found that the efficiency for all 
drugs were decreased and this could be related to extra column connection and would be 
necessary to optimise the length of this connection 
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Table 5.11: Effect of flow rate usiug different proportions of organic modifier 
efficiency (N/m) for NSAIDs on short (5 cm) Xbridge RP18 column 
Mobile Phase* flow rate(mllmin) 
Drugs MeCN-Buffer 1 2 3 
'(v/v) N/m N/m N/m 
10-90, pH 6 5}740 51760 19620 
Suprofen 5-95, pH 6 72380 57200 21420 
0-100, pH 6 30940 17000 -
10-90, pH 6 42740 38520 16820 
Naproxen 5-95, pH 6 67500 54880 13780 
0-100, pH 6 30940 17000 -
10-90, pH 6 42740 38520 16820 
5-95, pH 6 67500 54880 13780 
Indoprofen 
0-100, pH 6 42980 9860 = 
10-90, pH 6 65760 57400 11128 
Ketoprofen 5-95, pH 6 . 62860 53100 13600 
0-100, pH 6 41860 9480 = 
10-90, pH 6 75600 52540 12220 
Sulindac 5-95, pH 6 66800 51900 12260 
0-100, pH 6 25560 11080 N.d 
10-90, pH 6 63020 50620 12940 
Flurbiprofen 5-95, pH 6 42760 15920 4600 
0-100, pH 6 15960 12320 N.d 
10-90, pH 6 36640 29960 10660 
Diclofenac 5-95, pH 6 56900 27500 7220 
0-100, pH 6 34340 14380 N.d 
10-90, pH 6 36640 29960 10660 
Niflunamic acid 5-95, pH 6 25640 28240 7220 
0-100, pH 6 15960 12320 N.d 
10-90, pH 6 45040 39660 9920 
Indomethacin 5-95, pH 6 N.E N.E N.E 
0-100, pH 6 N.E N.E -
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5.2.4.4 Summary 
These experiments have highlighted the problem of temperature and flow rate for the 
NSAIDs analyses on a short Xbridge RPl8 column. The flow rate was found to effect the 
retention factors which was attributed to thermal mismatching between column and 
incoming solvent. There was no effect of flow rate on the order of elution. The 
resolutions between all the drugs decreased on increasing flow rate from 1 to 2 mUmin 
. with using 90% and 95% buffer at 80°C then decreased approximately by half times from 
2 to 3 mUmin. The efficiency dramatically dropped on increasing flow rate and this was 
also thought to be caused thermal mismatching because the column was much colder than 
the incoming solvents. The best efficiency was observed for suprofen, naproxen, 
indoprofen and dicIofenac with 95% at 80°C at 1 mVmin. For ketoprofen, suIindac, 
niflunamic acid flurbiprofen and indomethacin best efficiencies were obtained with 90% 
buffer at 80°C at 1 rnl/min. 
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5.2.5 Programming temperature 
Temperature-programmed analyses was used to with relatively short separation to achieve 
high-speed separations of mixtures of NSAIDs with both using xBridge™ RP18 (IS cm) 
and XBridge™ RP18 (S cm) short columns starting at about SO °C to 140°C using 100% 
buffer as eluent at pH 6 (Table S.12). 
Table 5.12: conditions oftemperature programmed separation 
XBridge™ XBridge™ 
80-120 80-120 50-120 80-120 80-140 
30 10 S S S 
60 60 60 60 60 
'. :: :::::~ll'~I'-' S 3 3 3 3 
The retention factors and selectivity obtained using conditions are summarised in Table 
(S.13), The short XBridge™ RPl8 column was studied under three conditions and the 
differences were the initial time (30,10, and S mins), the temperature range was varied 
(SO-120 0c) and the rate of temperature increase was reduced from S-3 °C /min in both 
condition 2 and 3. The order of elution was not changed from the isothermal condition 
with XBridge™ RP18 short columns in conditions 1 (Figure5.33), 2 and 3. There were 
peak overlaps between suprofen and naproxen, between niflunamic acid and flurbiprofen 
and between diclofenac and suIindac except with condition 3. With long XBridge™ RP18 
column, the selectivity between naproxen and indoprofen wa,s better. with condition 4. 
The peak overlap between suprofen and naproxen was observed and indoprofen was 
interfered with them with condition (S) but between niflunamic acid and flurbiprofen was 
only observed with condition (4). Complete separation was achieved between diclofenac 
and sulindac with both conditions· 4, and S. It was observed that with short column the 
base line was distorted after 30 minutes (Figure S.33) whereas it was not observed that 
with the longer column (Figure S.34). 
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Table 5.13: Effect of temperature programming on retention factors and selectivity 
of NSAlDs 
Effect oftemperatureprol!ramminl! on separation 
Drugs Condition 1 -Condition 2 Condition.3 Condition 4 ConditionS 
I·.·· .... 
.k a. k a k .a k a k a 
Suprofen 34.74 23.64 30.83 22.23 15.95 
Naproxen 34.74 1.00 23.64 1.00 30.83 1.00 22.23 . 1.00 15.95 1.00 
Indoprofen 46.86 1.35 28.92 1.22 35.87 1.16 30.63 1.38 15.95 1.00 
Ketoprofen 57.35 1.22 38.50 1.33 45.09 1.26 33.64 1.10 18.87 1.18 
Niflunamic acid 62.96 1.10 43.31 1.12 49.72 1.10 50.45 1.50 20.42 1.08 
Flurbiprofen 62.96 1.00 43.31 1.00 49.72 1.00 50.45 1.00 27.03 1.32 
.... 
Diclofenac 70.88 1.13 49.79 1.15 55.89 1.12 53.54 1.06 28.64 1.06 
Sulindac 70.88 1.00 49.79 1.00 57.58 1.03 63.81 1.19 32.29 1.13 
The effect of temperature programming on and efficiency (N/m) was investigated (Table 
5.14). The best efficiency of all the drugs were obtained with long XBridge™ RP18 
colunm in conditions 5 and were better with XBridge™ RP18 short columns in condition 
3 compared conditions I and 2. The peak shape with the short colunm under all 
conditions were acceptable except for last two retained drugs (dic1ofenac and sulindac) 
and with long colunm were better than short colunm. 
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Figure 5.33: Separation of NSAlDs on Xbridge™ RPI8 column (50 x4.5 mm I.D, 3.5 
/lm.). Chromatographic Condition I: mobile phase:'50 mM acetate buffer (100% 
including, at pH 6), UV absorbance at 230 nm, flow rate 1 mlfmin, injection volume: 
10 ftl, temperature range 80-120 cC, initial time 30 mins, final time 60 mins, rate 5 
°C/min, solute concentration: 50 /lg/m1. Peaks: Peaks: l-suprofen, 2-naproxen, 3-
indoprofen, 4-ketoprofen, 5-flurbiprofen, 6-niflunamic acid, 7-diclofenac, 8-
sulindac. 
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Figure 5.34: Separation of NSAlDs on Xbridge™ RP18 column (150 x4.5 mm I.D, 
3.5 /lm.). Chromatographic Condition 4: mobile phase: 50 mM acetate buffer (100% 
inclnding, at pH 6), UV absorbance at 230 nrn, flow rate 1 mlfmin, injection volume: 
10 ftl, temperature range 50-120°C, initial time 5 mins, final time 60 mins, rate 3 
°C/min,solute concentration: 50 /lg/ml. Peaks: Peaks: l-suprofen, 2-naproxen, 3-
indoprofen, 4-ketoprofen, 5-flurbiprofen, 6-niflunamic acid,7-diclofenac, 8-
sulindac. 
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Table 5.14: Effect oftemperature programming on efficiency (N/m) ofNSAIDs 
Drugs Effect of temperature programming on separation Condition 1 Condition 2 Condition 3 Condition 4 ConditionS 
N/m Nfm Nlm Nlm Nlm 
Suprofen 15040 53100 126840 57185 102794 
I 
Naproxen 15040 53100 126840 57185 102794 
lindoprofen 71700 40980 110740 58125 102794 
Ketoprofen 18580 36760 85520 52098 86274 
Niflunamic acid 35728 24020 60740 33037 69316 
FIurbiprofen 35728 24020· 60740 33037 59686 
. Diclofenac 50866 39960 57555 30682 50017 
Sulindac 50866 39960 21620 30475 49502 
5.2.5.1 Summary 
Temperature programming was found to be suitable for the elution of a mixture of 
NSAIDs with pure water as eluent except indomethacin, using both XBridge™ RP18 15 
cm and XBridge™ RP18 5 cm colunms. The elution of the most retained compound 
could be decreased significantly by applying a temperature gradient starting from SO to 
120°C in particularly with the short XBridge~ RP18 and better than isothermal 
condition at 120°C. However, with long XBridge™ RP18 colunm provided best 
separation of these drugs 
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Chapter 6 Diuretic drugs 
6.1 General background 
6.1.1 Introduction [2371 
Diuretic drugs are known as effective medications to reduce the accumulation of excess 
fluid in the body by increasing the volume of urine excretion. Six different classes of 
diuretic drugs have been recognised but there is no common chemical structural 
relationship between them. All of them have the same diuretic effect regarding the 
balance of fluid in the body (Na+,K+, cr, w,pol-, HC03- , M,i+, and Ca2l. These 
classes include inhibitors of carbonic anhydrase, osmotic diuretics, inhibitors ofNa+, K+, 
er (loop diuretics, high ceiling diuretics), inhibitors of Na+- cr symport (thiazide and 
thiazide-like diuretics), inhibitors of renal epithelial Na + channels (K+-sparing diuretics), 
antagonists of mineralocorticoid receptors (aldosterone). The current study, will focus on 
thiazide· and thiazide-like diuretics (chlorothiazide, hydrochlorothiazide, 
hydroflumethiazide, chlorothalidone, . clopamide, methyclothiazide, clorexolone, 
mefruside, benzothiazide, polythiazide and cyclopenthiazide). 
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6.1.2 Classification of diuretics [237J 
The drugs can be classified based on site of mechanism of action (Table 6. I). 
Table 6.1: Classification of diuretics [237] 
Type of diureti~s Site of action Drugs 
Inhibitors of carbonic The proximal tubule. Acetazolamide, 
anhydrase dichlorphenamide, 
methazolamide 
Osmotic diuretics Mainly, the loop of Henle. Glycerin, isosorbide, mannitol, 
urea 
Loop diuretics, high The thick ascending limb. Fursornide, bumetanide, 
ceiling diuretics etIilicrynicacid, torsemide, 
aiosernide, muzolimine, 
Ipiretanide,. triparnide 
Thiazide and thiazide- The distaI tubule. Chlorothiazide, 
like diuretics hydrochlorothiazide, hydroflumethiazide, 
chlorothalidone, indapamide, 
metalzone, polythiazide, 
chlorothalidone, cIoparnide, 
methyclothiazide, clorexolone, 
mefiuside, benzothiazide, 
polythiazide and lastly 
cyclopenthiazide 
K +-sparing diuretics The late distal Amiloride, triamterene 
tubule and the collecting 
duct. 
Aldosterone diuretics Epithelial cells in the late Spironolactone, canrenone, 
distal tubule and potassium caurenone 
collecting duct 
6.1.3 Chemical structure of thiazide and thiazide-like diuretics 
The chemical structures of thiazide and thiazide-like diuretics are recognised by the 
presence of the moderate acidic sulfonamide functional group (R-S(~O)2-NH2)' where R 
, , 
is an organic group. (Table 6.2) 
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Table 6.2: Stl"Uctures and properties of typical thiazide and thiazide-like diuretic 
dl"Ugs 
Drug Structure XLogP 
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Drug Structure XLogP 
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Drug Structure XLogP 
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Drug Structure XLogP 
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6.1.4 Medicinal importance of thiazide and thiazide-like diuretics [237J 
The diuretics are used in treatment in many diseases that are associated with oedema 
(increase of interstitial fluid in body), such as congestive heart fai lure, hepatic cirrhosis, 
nephrotic syndrome, chronic renal failure, and acute glomerulonephritis [237]. Also they 
are given to patients with hypertension (high blood pressure). Other medicinal uses of 
these drugs are to cure calcium nephrolithiasis and osteoporosis by reducing urinary 
calcium excretion. Nephrogenic diabetes insipidus can be treated by thiazide and thiazide-
like diuretics. 
6.1.5 Diuretic drugs analysis by HPLC 
Many analytical procedures have been reported for the determination of diuretic drugs 
(thiazide and thiazide-like diuretics) in samples, such as clinical and pharmaceutical 
samples. These methods included chemiluminescence [240], capillary 
electrochromatography (CEC) [241] and gas chromatography- mass spectrometry (GC-
MS) [242]. However, HPLC is considered as the most suitable technique for their 
determination (Table 6.3). Review articles have summarised the HPLC methods for the 
determination of these drugs [243]. RP- HPLC was used to relate structure-retention 
relationship parameters to the retention times of some diuretics (amiloride, 
hydrochlorothiazide and methyldopa) [244]. A number of diastereoisomeric thiazides 
(bendroflumethiazide, penfluthiazide, cyclopenthiazide, buthiazide, methylchlothiazide, 
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bemetizide, have been resolved by using chiral stationary phases with HPLC [245]. The 
use of temperature for the separation of a mixture of diuretics (a1thiazide, amiloride, 
bendroflumethiazide, benzthiazide, bumetanide, canrenone, chlortalidone, clopamide, 
dichlorphenamide, ethacrynicacid, furosemide, hydroflumethiazide, indapamide,. 
piretanide, polythiazide, andspironolactone, triamterene, trichlonnethiazide, and 
xipamide) was studied over the range 40-70 °c [246]. With increasing temperature, an 
improvement in resolution and a decrease of retention were observed but the retention 
remained practically constant for spironolactone, amiloride and triamterene. Linear van't 
Hoff plots were found for all the drugs over the temperature range studied. In another 
study [247], temperature was used as variable for the separation of a mixture of 
enantiomers diuretics (butizide, cicletanine and bemetizide, bendroflumethiazide, 
polythiazide, chlorthalidon and mefruside). When the temperature was increased from 25 
to 50°C the retention times decreased, while was found the resolution was only slightly 
changed [247]. 
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trichloromethiazide, indapamide. 
~. [ 
Q, 
'P 
~ 
'" Q, 
~. 
Bendrofluazide, chlorothiazide, (A): 530 mL water, 145 = ~ 
chlorthalidone, clopamide, epitizide, mL triethylamine, 650 mL .... (j' 
furosemide, hydrochlorothiazide, phosphoric acid Lichrospher column 100 
indapamide, mefruside. (PH = 3.3) and 470 mL RP-I 8. Octadecylsilyl 
MeCN. encapped UV273nm 251 
(B) 800 mL water, 14~ (5 mm) 
mL triethylamine and 380 
'" =0 
1:1 
~ 
~. 
.. 
C' 
~ 
mL phosphoric 
acid (PH = 6.0) and 200 
mT.Mp('N 
Hydrochlorothiazide. Acetate buffer (0.2M) and Waters Symmetry CI8 Photodiode array 
MeCN (v/v, 60:40) Column (4.6 x 250 detector. 252 
mm,S iJll1 
~ 
t:;j n S· 
~ 
::t. 
" '" 
n 
.?' ~'t: . .; '·"'~~:¥(~l:~~'~~~;i).8i~~.;·~.2~C<w.? .", r~.;;'~·I·.·. ~/ ! 
Butizide, cicletanine, bemetizide, ~ 
bendroflumethiazid, polythiazide, 
chlorthalidone, mefruside. 
Hydrochlorothiazide. 
Hydrochlorothiazide, chlortalidone, 
bendroflumethiazide, butizide 
Althiazide, bendroflumethiazide, 
benzthiazide, bumetanide, chlorothiazide, 
chlorthalidone, hydrochlorothiazide, 
trichloromethiazide, xipamide. 
Benzthiazid, althiazide, benzthiazide, 
bendroflumethiazide, clopamide, 
dichlorphenamide, hydrofiumethiazide, 
xipamide, trichlonnethiazide. 
Different mobile phases of aqueous 
solutions combined with different 
amounts of Me OH and MeCN. 
• Aqueous AcOH (0.1 %) and MeCN 
(93:7, v:v) pH 3 
MeOH and water (80:20) with adding 
LiCI04 (2 gIl) 
MeCN-water 
Mobile phases with several organic 
modifiers PrOH, BuOH, PentylOH 
and 
MeCN or 1HF with water containing 
sodium dodecyl sulphate SDS ( 40 
mM) 
I) Chiralcel OD-RHR 
column 15 x0.46 cm I.D. 
2) Chiralcel OJ-RR column 
15xO.46 cmlD. 
3) Chirobiotic TkR column 
25x0.46 cm 
I.D . 
Hypersil C18, 
(150 x2.0 nunI.D., 3 p.m) 
Brownlee Lab RP-18 (100 x 
4.6 mm I.D., 5 
p.m) 
Kromasil C18 column 
(125mm x 4.6mm i.d. 5p.m) 
Hypersil C 18 column (150 
x3.0 mm I.D., 5 p.m) 
UV 254 and 230 nm 
UV272run 
Electrochemical 
detection 
and UV detector 240 
run 
UV 274 run 
Photodiode-array 
detector 
range 190-360 run· 
247 
253 
254 
144 
246 
Benzthiazide, butizide, chlorothiazide, 
chlorthalidone, c\opamide, cyclothiazide, 
hydrochlorothiazide, xipamide, 
hydroflumethiazide, indapamide, 
mefiuside, polythiazide, 
trichlonnethiazide. 
Hydrochlorothiazide, xipamide, 
f1umethiazide, polythiazide 
methyclothiazide, clopamide, 
hydroflumethiazide, chlortalidone , 
indapamide, mefiuside, cyclothiazide, 
benzthiazide, 
bendroflumethiazide, 
trichlonnethiazide. 
Hydrochlorothiazide 
A) 
(0.2 mM NI!, Ac in water 
+ acetonitrile (95+5» and 
B) (0.2 mM NIl4 Ac in 
water+MeCN), (5+95). 
(A) formic ammonium-
fonnic acid buffer (PH 
3.5) 
(B)MeCN 
Gradient elution 
A) [0.2% CF3CO,H (TFA) 
(PH 1.8)] 
B) (MeCN): 87: 13 gradient 
elution 
AnXDBC8 
(Zorbax, 4.6 x 75 mm, 
3.5 p.m) 
Agilent Zorbax SB·C18 
column (ISO x 2.1 mm, 5 
p.m). 
DIAMONDSC18 
column (l50mmx4mm 
i.d.,5p.m) 
Tandem mass 
spectrometry. 
LC·MS 
Atmosphere pressure 
chemical ionization 
(APCn and electrospray 
ionization (ESn 
LC-APeI·MS 
DV 263nm 
255 
256 
257 
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6.2 Result and discussion 
6.2.1 Introduction: 
A XBridge™ RP18 shielded column and a XBridge™ C18 short column were examined 
by isothennal and gradient temperature elution to detennine a practical method for the 
simultaneous analysis of eleven thiazide and non-thiazide diuretics drugs. Different 
proportions of acetonitrile (MeCN) with 1 % aqueous acetic acid (AcOH), were examined 
under different temperature ranging from (40-140 0c) as the mobile phase. A 10 ILl of 
mixture of solution of the thiazides (50 ppm) Wlls injected in all cases. The eluent was 
monitored at 271 nm. 
6.2.2 XBridge RP18 column: 
6.2.2.1 Effect of temperature on Retention factor, k: 
The initial conditions were based on a method by Smith and co-workers [258] who used 
MeCN-water containg 1 % AcOH (30% - 70%) as mobile phase for a RP18 column. This 
was applied to a XBridge™ RP18 shielded reversed-phase column at temperatures 
ranging from 40°C to 140°C with different mobile phase compositions. The elution 
order of the drugs changed with the mobile phase and column temperature and will be 
discussed in detail in the selectivity study. The effect of temperature using different 
compositions of mobile phases was studied with 1% AcOH in aqueous proportions 
starting from 70% of 1% AcOH up to 100% of 1% AcOH water as the eluent. From 
(Table 6.4 and Figures 6.1- 6.4) it is clear that with increasing temperature the retention. 
factors decreased for all the drugs as it was noticed in the cephalosporin and NSAlDs 
studies. With using pure water of 1% AcOH as the mobile phase and raising the 
temperature from 100°C to 140 QC, it was found that the retention factors o~ 
hydrochlorothiazide, c!oparnide and hydroflumethiazide were decreased to one third. 
However, other drugs retention factors were reduced approximately to a quarter except 
polythiazide and chlorothiazide were reduced to fifth and twelfth times respectively. 
Cyclopenthiazide was not eluted with pure water at 140°C. The comparison between 
retention factors at first start temperature at 40°C using 30% MeCN and using pure water 
at 140°C showed that the time of elution of chlorothiazide, hydrochlorothiazide, 
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hydroflumethiazide and benzothiazide was less with pure water at 140°C whereas for 
other drugs their retention factors were higher in this case. 
: 
I 
Table 6.4: Retention factors of diuretics drugs on Xbridge RP18 columu as a 
function of temperature using different proportions of organic modifier 
Mobi1ePhase* Drugs' .' Retention factor. k 
MeCN-H20. . Column tern, erature ("C) 
(v/v) ·40' 60 80 
0.32 Un Un resolved peak 
resolved from 
Chlorothiazide peak from hydrochlorothiazide hydrochlo 
rothiazide 
, 
0.41 0.26 0.20 Hydrochlorothiazide 
: 0.79 0.51 0.37 
'. 
Hydroflumethiazide 
Chlorothalidone 0.79 0.51 0.47 
> 
[3.0:701 ... : Clopamide 1.32 1.23 1.10 
Methyclothiazide 2.29 1.45 0.96 
... : 
' .. 
3.64 2.79 1.87 
..... Clorexolone 
Mefruside 4.33 2.99 2.14 
" .. ' 
Benzothiazide 4.99 2.99 2.14 
, ...... 
Polythiazide 7.12 4.15 2.53 
". 8.31 4.91 3.02 
, ··:·i Cyc10penthiazide 
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Mobile Phase* .. Retention factor, k 
MeCN-H20 Drugs . Column temperature ('C) 
(v/v) 60 80 100 
Chlorothiazide 0.53 0.37 Unresolved from Hvdrochloro-thiazide 
Hydrochlorothiazide 0.66 0.45 0.57 
Hydroflumethiazide 1.40 0.91 0.55 
ChIorothalidone 2.84 1.92 1.22 
Clopamide 5.11 4.29 3.23 
[15:85) MethycIothiazide 5.67 3.33 1.91 
Mefruside 16.02 10.24 6.39 
Benzothiazide 16.84 9.55 5.16 
Clorexolone 17.87 11.12 6.99 
Po\ythiazide 26.07 13.38 6.99 
CycIopenthiazide 33.73 17.34 9.08 
.. DriI2s 100 120 140 
Chlorothiazide 0.38 0.36 
Unresolved 
from 
hvdrochloro-thiazide 
Hydrochlorothiazide 0.48 0.36 0.03 
Hydroflumethiazide 0.99 0.73 0.14 
Methyclothiazide 4.49 2.97 0.35 
Chlorothalidone 6.21 2.97 1.49 
{5:95) Benzothiazide 9.11 4.01 1.99 
Clopamide 19.76 7.83 4.52 
Polythiazide 21.23 10.24 5.68 
Mefruside 21.23 12.47 5.68 
Clorexolone 26.15 13.98 7.08 
CycIopenthiazide 32.31 18.24 9.16 
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Mobile Phase* . . . Retention factor,k Drugs 
:-". 
MeCN-H20 Column tem erature ("C) 
(v/v) 100 120 140 
Chlorothiazide 0.62 0.40 . 0.05 
Hydrochlorothiazide 0.77 0.40 0.22 
Hydroflumethiazide 1.52 0.78 0.47 
Chlorothalidone 7.86 3.51 2.12 
Methyclothiazide 10.52 4.31 2.61 
(lOO] Benzothiazide 13.66 5.56 3.29 
.. 
...... 
19.04 9.61 7.15 
.: Clopamide 
Polythiazide 42.97 15.58 8.65 
Clorexolone 65.10 26.00 16.15 
'. 
, ". Mefi'uside 41.13 17.58 11.32 
Cyclopenthiazide Not Not Not eluted 
eluted eluted 
* All aqueous portions contained 1% AcOH. 
40 
__ Chlorothiazide 
-x- Chl0rothaJidone 
-+- Clopamide 
-0- Mefruside 
Water 70% 
60 80 
Temperature ("C) 
-0- Hydrochlorothiazide -l:r- Hydroflumethiazide 
-)1(- Methyc lothiazide -0- Benzothiazide 
- Po\ythiazide - Clorexolone 
--Cyclopenthiazide 
Figure 6.1: Effect of temperature on retention factors of diuretics on XBridge™ 
RP18 shielded column with water 70% as mobile phase. 
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33 
30 
'227 
';:;' 24 
~ 21 
~ 18 
~ 15 J 1~ 
Diuretics 
Water 85% 
~1-~----~~~~~~~~~~~~~~~~~------, 
60 80 100 
Temperature ("C) 
-+- ChIorothiazide -0-Hydrochlorothiazide ~ Hydroflumethiazide 
-X-ChIorothalidone -:1(- Methyclothiazide -0-Benzothiazide 
-+-Clopamide - Polythiazide - Clorexolone 
~Mefruside -tI-Cyclopenthiazide 
Figure 6.2: Effect of temperature on retention factors of diuretics on XBridge™ 
RP18 shielded column with water 85% as mobile phase. 
33 g 30 
27 
a 24 ~ i~ 
g 15 
'g 12 
.s 9 ~-~ 6 
3 
0 
100 
-+-ChIorothiazlde 
-X-ChIorothalidone 
-+-Clopamide 
~Mefruside 
Water 95% 
120 140 
Temperature ("C) 
-0-Hydrochlorothiazide ~ Hydroflumethiazide 
-:1(-Methyclothiazide -0-Benzothiazide 
- Polythiazide 
___ Cyclopenthiazide 
- Clorexolone 
Figure 6.3: Effect of temperature on retention factors of diuretics on XBridge™ 
RP18 shielded column with water 95% as mobile phase. 
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lOO 
__ Chlorothiazide 
-X-Chlorothalidone 
-+-Clopamide 
-<>- Meflus ide 
Diuretics 
Water 100% 
120 140 
Temperature (q 
-0-Hydrochlorothiazide -l:r-Hydroflulrethia2ide 
-:1:-Methyclothiazide -0-Benzothiazide 
--Poly thiazide ---,- Clorexolone 
Figure 6.4: Effect of temperature on retention factors of diuretics on XBridge™ 
RP18 shielded column with water 100% as mobile phase 
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6.2.2.2 Van't Hoff plots: 
To study the effect of temperature on the mechanism of separation on the XBridge™ 
RP18 shielded column, In (k) vs. lIT (van't Hoffplots) were plotted for the diuretic drugs 
(Figures 6.5 to 6.8). The linearity of thevan't Hoff plots indicated that the retention 
mechanism did not change with increasing temperature. These plots were used to 
determine the thermodynamic properties (Table 6.5). The values of thermodynamic 
properties of all drugs at each case of mobile phase were calculated based on the van't 
Hoff equation. It was found that in all cases, the Mio values were negative indicating that 
retention of diuretic drugs studied is an exothermic process (Table 6.5). It is energetically 
more favourable for these drugs to remain in the stationary phase than in the mobile 
phase. The van't Hoff relationship was linear with most drugs indicated there was no 
change in mechanism of separation of these drugs (clopamide, benzothiazide, 
clorexolone, mefruside, polythiazide, and cyclopenthiazide). The linearity of other drugs 
changed from case to case. Chlorothiazide was linear with 70% of 1 % AcOH, but with 
85% and 95% of 1 % AcOH, it was uuresolved under peak of hydrochlorothiazide, 
whereas with 100% of 1 % AcOH the linearity was 0.86 respectively. All drugs were 
transferred from mobile phase> to stationary phase entropically favourable rather than 
enthalpially and this increased with high temperature. 
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Table 6.5: Analysis of linear van't Hoff plots of diuretics on XBridge™ RP18 
column with different mobile phases: 
. Mobile 
.. 
phase* ~ All· 
All· 
Drug 
! . [MeCN~ ... KJmol-l Kcalmol-l 
water] 
[30:70] 0.99 -10.76 -2.57 
[15:85] - N.D N.D 
Chlorothiazide 
[5:95] = 
1 
N.D N.D 
[100] 0;86 N.D N.D 
[30:70] 0.98 -16.55 -3.96 
N.D N.D [15:85] 
.' 
0.17.. . 
Hydrochlorothiazide 
[5:95] '0.80 . • N.D N.D 
....., ........ 
,. 
. [100] 1 -40.11 -9.60 
[30:70] 0.99 -17.45 -4.18 
[15:85] 0.99 
-24.06 -5.76 Hydroflumethiazide 
[5:95] 0;84 •.•...•.•.••... ...•...... N.D. N.D 
[100] 0.99 -37.64 -9.00 
[30:70] 0.89 
'1 . N.D N.D 
[15:85] 0.99 -21.76 -5.21 
Chlorothalidone 
[5:95] 0.99 
-45.69 -10.93 
[100] 0.99 -42.08 -10.07 
[30:70] 0.97 -4.16 -1.00 
[15:85] 0.97 -11.78 -2.82 
Clopamide 
[5:95] 0.99 -47.40 -11.34 
[100] 0.96 -31.54 -7.55 
[30:70] 1 -19.96 -4.78 
[15:85] 0.99 -28.05 -6.71 
Methyclothiazide 
[5:95] 0.85 N.D N.D 
[100] 0.98 -44.81 -10.72 
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Drug Mobile 
phase* 
[MeCN-
water] 
[30:70] 
Clorexolone 
[15:85] 
[5:95] 
[100] 
[30:70] 
Mefruside 
[15:85] 
[5:95] 
[100] 
[30:70] 
[15:85] 
Benzothiazide . 
[5:95] 
[100] 
[30:70] 
[15:85] 
Poly thiazide 
[5:95] 
[100] 
[30:70] 
[15:85] 
Cyclopenthiazide 
[5:95] 
[100] 
* All aqueous portions contained 1 % AcOH. 
N.D - not detennined. 
r" .... 
0.98 
0.99 
0.99 
0.97 
1 
0.99 
0.98 
0.98 
0.99 
·0.99 
0.99 
0.98 
0.99 
0.99 
0.99 
0.98 
0.99 
0.99 
0.99 
none 
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All" mO 
KJmol-l Kcal mol-l 
-15.22 -3.64 
-24.21 -5.79 
-41.77 -9.99 
-44.84 -10.73 
I 
-16.18 -3.87 
-23.69 -5.67 
-42.04 -10.06 
-41.50 -9.93 
-19.50 . -4.67 
-30.48 -7.29 
-48.73 -11.66 
-45.75 -10.94 
-23.75 -5.68 
-33.96 -8.12 
-42.26 -10.11 . 
-51.51 -12.32 
-23.24 -5.56 
-33.85 -8.10 
-40.54 -9.70 
- -
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2.5 
2 
1.5 
1 
.>( 0.5 
;l 0 
-0.5 
-1 
-1.5 
-2 
0.0028 
Water 70% 
: : I -)K 
r I i X 
~ X -g 
0 0 
0.00285 0.0029 0.00295 0.003 0.00305 0.0031 0.00315 0.0032 
~ Chlorothlazide 
-X-Chlorothalldone 
-+-Clopamide 
-+- Mefruside 
-0- Hydrochlorothiazide A Hydroflumethazide 
-:1(- Methyclothiazide -0- Benzothiazide 
~ Polythlazlde ~ Clorexolone 
-11-- Cyclopenthiazlde 
Diuretics· 
0.00325 
Ifl'(K') 
Figure 6.5: Van't Hoff plots for dinretics on XBridge™ RP18 shielded column with 
water 70% as mobile phase 
4 
3.5 
3 
2.5 
2 
~ 1.5 
= 1 ... 
0.5 
0 
-0.5 
-1 
-1.5 
0.0028 
Water 85% 
i : a-e:: + r + "'- X )1(- X t::,. X 
~ t::,. 9 
=g 
0.00285 0.0029 0.00295 0.003 0.00305 0.0031 0.00315 0.0032 0.00325 
Iff(Kl) 
~ Chlorothlazide -0- Hydrochlorothiazide A Hydroflumethazide 
-x- Chlorothalidone -:1(- Methyclothiazide -0- Benzothiazide 
-+- Clopamide· - Polythlazide - Clorexolone 
-+- Mefruside __ Cyclopenthlazide 
Figure 6.6: Van't Hoff plots for diuretics on XBridge™ RP18 shielded colnmn with 
water 85% as mobile phase 
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.:.= 
= 
.... 
Water 95% 
4 
3 ~ : 2 1 0 g 
-1 
-2 
-3 .~ 
-4 
0.0028 0.00285 0.0029 0.00295 0.003 0.00305 0.0031 0.00315 0.0032 0.00325 
lIT (Kt) 
---<>- Chlorothiazide -0- Hydrochlorothiazide -A- Hydroflumethazlde . 
-X-Chlorothalldone -%-Methyclothlazlde -0- Benzothlazlde 
--+-Clopamlde - Polythlazlde ~ Clorexolone 
-.-Mefruside __ Cyclopenthlazld<3 
Figure 6.7: Van't Hore plots for diuretics on XBridge™ RP18 shielded column with 
water 95% as mobile phase. 
Water 100% 
5 
4 ~ 3 $ k ..: 2 ~ ~ .. ..:I ~ 0 ~ -1 g 
~+----.-----r----~---' __ ---r----'-----.---~----~ 
0.0028 0.00285 0.0029 0.00295 0.003 0.00305 0.0031 0.00315 0.0032 0.00325 
liT (Kt) 
-0- Chlorothiazide -0- Hydrochlorothiazide -A- Hydrotlumethazide -X- Chlorothalidone 
-%- Metbyclothiazide -0-Benzothiazide --+- Clopamide - Polythiazide 
~ Clorexolone -+-Mefiuside 
Figure 6.8: Van't Hore plots for diuretics on XBridge™ RP18 shielded colunm with 
water 95% as mobile phase. 
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6.2.2.3 Effect of temperature on selectivity 
The effect of temperature on the selectivity and resolution of diuretic drugs was 
investigated as a function of colunm temperature and mobile phase compositions (Table 
6.6). With MeCN (30%) with 1% AcOH of (70%) as eluent it was foUnd that the drugs 
were separated well at 40°C in the order chlorothiazide, hydrochlorothiazide, 
hydroflumethiazide, chlorothalidone, c1oparnide, methyclothiazide, c1orexolone, 
mefruside, benzothiazide, polythiazide and lastly cyclopenthiazide. On increasing 
temperature to 60°C, it was noted that the fust two drugs coeluted. However, on reaching 
temperature 60°C, mefruside and benzothiazide also co eluted. However, this change in 
selectivity might be related to effect temperatures on structural confirmation of both drugs 
as it was reported that there was no effect on degree of ionisation of diuretics as their pKa 
(8-1O) by change pH of mobile phase [258]. Also it was noted in general the most 
selectivity values between all drugs decreased between some drugs and increased between 
others with increase temperature. 
Table 6.6: Effect 1>f temperature on selectivity (a) for diuretic dI:ugs with 70% 
water' 30% MeCN . 
.. 
• 
.. .. Selectivity (aF . Drugs . ·c Column temperature ("C) . 
. 
Order 40 ... 60 ...... Dtugs order 80 . 
Chlorothiazide Chlorothiazide 
Hydrochlorothiazide 1.27 1.00 Hydrochlorothiazide 1.00 
Hydroflumethiazide 1.92 1.93 Hydroflumethiazide 1.82 
Chlorothalidone . . 1.00 1.00 Chlorothalidone 1.26 
Cloparnide . 1.68 2.43 Methyclothiazide 2.07 
MethycliJthiazide .......• 1.73 1.18 ... ·Clopamide 1.14 
Clorexolone .. 1.59 1.93 Clorexolone 1.71 
Mefruside ..... 1.19 1.07 Mefruside 1.14 
... Benzothiazide .. 1.15 1.00 Benzothiazide 1.00 
Po!ytlIiazide . 1.43 1.39 Polyt\1iazide 1.18 
Cyclopenthiazide . 1.17 1.18 Cyclopenthiazide 1.20 
The amount of MeCN was reduced to 15% with 85% water to increase retention. The 
order of eluent was changed compared to previous cases and the separation was improved 
(Table 6.7). The elution of drugs at 60°C in order was chlorothiazide, 
hydrochlorothiazide, hydroflumethiazide, chlorothalidone, clopamide, methyclothiazide, 
mefruside, benzothiazide, c1orexolone, polythiazide and finally cyc!openthiazide. The 
first two drugs here were separated well and there was no peak overlap at all. By raising 
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temperature to 80°C, there was a change in elution' order of drugs as methyclothiazide 
eluted before clopamide and benzothiazide before mefruside and at this temperature there 
was no peak overlap although the selectivity values were decreased. At 100°C, it was 
found that the order of elution was similar at 80°C but with improvement in selectivity in 
between clopamide and methyclothiazide and also it was found some values of selectivity 
remained constant between mefruside and clorexolone and between polythiazide and 
cyclopenthiazide. 
Table 6.7: Effect of temperature on selectivity (a) for diuretic drugs with 85% 
water: 15% MeCN 
Drugs Selectivity (a) 
. Column temperature ("C) Order 60 Drugs order . 80 100 
. Chlorothiazide ,. Chlorothiazide ' 
Hydrochlorothiazide, 1.26 Hydrochlorothiazide, 1.24 1.00 
Hydroflumethiazide, 2.11 Hydroflumethiazide, 2.01 0.96 
Chlorothalidone .•. 2.03 Chlorothalidone 2.10 2.22 
Clopamide 1.80 ...... . MethYclotliiazide 1.74 1.57 
, Methyclothiazide. 1.11 . , '. . Clppaiiiide . . '. 1.29 1.69 
Mefruside 2.83 ., .... Benzothiaiide . .' 2.23 1.60 
. BenZothiazide " 1.05 Mefruside .. 1.09 1.00 
Cl<itexolone •• 1.06 Clorexolone };09 1.09 
P()lythiazide 1.46 Polythiazide 1.20 1.00 
Cyclopenthiazide . 1.29 Cyclopenthiazide 1.30 1.30 
With increasing the polarity ofthe mobile phase by using 95% of 1 % AcOH (Table 6.8)., 
the drugs separated at 100°C and the elution order in this case was chlorothiazide, 
hydrochlorothiazide, hydroflumethiazide, methyclothiazide, chlorothalidone, 
benzothiazide, clop amide, polythiazide, mefruside, clorexolone and cyclopenthiazide. 
Under in these conditions there was no change in elution order by increasing temperature. 
There was only peak overlap at 100°C between polythiazide and mefruside. At 120 and 
140°C they were separated well but. peak overlap was found between chlorothiazide and 
hydrochlorothiazide at 120°C, another peak overlap was between methyclothiazide and 
chlorothalidone at 120°C but they were completely separated at 140 QC. In this case, it 
was found that there is no big change in the selectivity values except between 
hydrochlorothiazide and hydroflumethiazide and also between hydroflumethiazide and, 
methyclothiazide, and between methyclothiazide and chlorothalidone when temperature 
increased from 120 to 140°C. 
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Table 6.8: Effect of temperature on selectivity (a) for diuretic drugs with 95% 
water: 5% MeCN 
Drugs Selectivity (a) Column temperature ("C) 
100 120 140 
.. Chlorothiazide 
Hydrochlorothiazide 1.24 1.00 1.00 
H..xdroflumethiazide 2.07 2.04 5.26 
MethyclothillZide. . 4.53 4.05 2.42 
Chlorothalidone 1.38 1.00 4.29 
Benzothiazide . 1.47 1.35 1.34 
Clop amide 2.17 1.95 2.28 
Polyiliiazide 1.07 1.31 1.25 
Mefniside 1.00 1.22 1.00 
Clorexolone 1.23 1.12 1.25 
Cyclopenthiazide 1.24 1.31 1.29 
on using 1 % AcOH in water as the eluent, it was found all the. drugs were separated well 
at 100°C in the order chlorothiazide, hydrochlorothiazide, hydrofiumethiaziile, 
chlorothalidone, methycJothiazide, benzothiazide, cJopamide, mefruside, polythiazide and 
lastly clorexolone (Table 6.9) .. CycJopenthiazide was not eluted at all using pure water as 
eluent. The peak overlap existed between the first two drugs at. 120°C and another 
observation was the change in elution order between mefruside and polythiazide. 
However, using 140°C, it was found the selectivity was improved between all drugs and 
there was no peak overlap. In this case, it was found that there is no big change in the 
selectivity values except between chlorothiazide and hydrochlorothiazide when 
temperatnre was increased from 120 to 140°C. 
Table 6.9: Effect oftemperature on selectivity (a) for diuretic drugs with 100% 
water 
Drugs 
.. Selectivity (a) 
Column temperatnre (OC) 
. Order 
100 Drugs order .. 120 .. 140 
. Ch1orothiazide Chlorothiazide 
Hydrochlorothiazide, 1.23 Hydrochlorothiazide, . 1.00 4.52 
Hydrofiumethiazide, 1.99 Hydrofiumethiazide, 1.93 2.17 
Ch10rothaJidone 5.16 ChlorothaJidone 4.53 4.54 
11ethyclothiazide 1.34 11ethyclothiazide 1.23 1.23 
Benzothiazide 1.30 Benzothiazide 1.29 1.26 
Cloparnide 1.39 Clopamide 1.73 . 2.18 
11efruside 2.16 . Po1ytl1iazide 1.62 1.21 . 
PolytiJiazide -'- 1.04 11efruside 1.13· 1.31 
... . Clorexolone 1.52 Clorexolone 1.48 1.43 
Cyclopenthiazide - Cyclopenthiazide - -
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6.2.2.4 Influence of temperature on column efficiency 
The effect of high temperature on columl::t efficiency was studied using different 
compositions of organic modifier (Figures 6.15 to 6.25). For each drug examined, the 
general tendency for column efficiency (N/m) was indirectly proportional to the column 
temperature. In addition, it was observed that the column efficiency decreased on 
increasing column temperature in using 70% of water as mobile phase. With using 85% 
of water, it was observed that efficiency of most drugs decreased with temperature 
increasing except benzothiazide,polythiazide, mefruside and cyclopenthiazide. However, 
decreasing efficiency at high temperature could be attributed to using a non-optimum 
flow rate 1 mllmin and it might be better to use higher flow rate as it was explained, in 
(Figure 1.3) as C-term of Van Deemter equation. On using 95% and 100% of using water 
as eluent, the efficiencies varied from drug to another. The efficiency of chlorothiazide 
was improved by raising the temperature from 100 to 140°C in case 100% indicated 
(Figure 6.15). With hydrochlorothiazide, the efficiency was decreased by raising the 
temperature using 100% of water was reduced as illustrated (Figure 6.16). However, the 
efficiency of separation of hydroflumethiazide was decreased by raising the temperature 
in- cases 85%, 95% and 100% as indicated in (Figure 6.17). The efficiencies of 
chlorothalidone and methyclothiazide were decreased by increasing the temperature all 
cases as can be shown in (Figure 6.18 and 6.19). The efficiency ofbenzothiazide did not 
improve with temperature 120 and 140°C in the case of 95% water as eluent but showed 
a small improvement in case 100% but still not efficient at all temperatures (Figure 
6.20). The efficiency of clopamide improved with temperature at 120°C and then slightly 
decreased at 140°C with 95% water as eluent but with 100% draffiatically improved 
especially at 120°C (Figure 6.21). Efficiency of clorexolone was little improved by 
increased temperature from 100 to 120°C then decreased at 140 °C with 95% water as 
eluent. However, this behaviour was also observed in case 100% water (Figure 6.23). 
Efficiency of clorexolone was little improved by increased temperature from 100 to 120 
°C then decreased at 140°C with 95% water as eluent. However, this behaviour was also 
observed in case 100% water. Efficiency of mefruside was little improved by rising 
temperature to 120 then atl40 °C was similar to 120°C with 95% water. However, using 
100% water, the efficiency was dramatically improved at 120°C then dramatically 
reduced at 140 °C (Figure 6.24). Efficiency of cyclopenthiazide was improved little by a 
rising temperature to 120 then atl40 °C was similar to 120°C with 95% water (Figure 
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6.25). In addition, it was observed that the peak shapes of drugs were excellent at all 
temperatures with 70% of water (see Figure 6.9). However, the peak shapes of the first 
six drugs were still excellent which were eluted within 12 minutes. But the most retained 
drugs; mefruside benzothiazide, clorexolone, polythiazide and cyclopenthiazide, fronted 
at 60°C (see Figure 6.10) with using 85% of water but they improved at 80 and 100°C 
, 
(see Figure 6.11). This observation was also more noticeable with increasing water 
portions in mobile phase 95% and 100% when the drugs were eluted within 10 minutes 
the peak shape was excellent but after that the peak shape start to deteriorate and the 
peaks shapes improved on increasing temperatures, (see Figure 6.12, 613, and 6.14.). 
This . observation can be attributed to solubility problem as less polar drugs could be 
precipitated in higher water portion of mobile phase or to in compatible temperature on 
the ail system and also other possible reason to this decrease efficiency is a degradation of 
the column with using high temperature. 
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Figure 6.9: Separation of 11 thiazide drugs on XBridge™ RP18 column (ISO x4.S 
mm LD, 3.Sllm.). Chromatographic conditions: mobile phase: MeCN (30%): water 
(70% including 1% AcOH), flow rate: 1 mlfmin, temperature: 80, DC, detection UV 
absorbance at 271 nm, injection volume 10 J.11, solute concentration SO Ilg/ml. Peaks: 
Peaks: l-chlorothiazide, 2-hydrochlorothiazide, 3-hydroflumethiazide, 4-
chlorothalidone, S-clopamide, 6-methyclothiazide, 7-clorexolone, 8-mefruside, 
9-benzothiazide, lO-cyclothiazide, II-Polythiazide, 12-cyclopenthiazide. 
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Figure 6.10 Separation of 11 thiazide drugs on XBridge™ RP18 column (150 x4.5 
mm I.D, 3.5 pm.). Chromatographic conditions: mobile phase: MeCN (15%): water 
(85% including 1 % AcOH), flow rate: 1 mIImin, temperature: 60, DC, detection: UV 
absorbance at 271 nm, injection volume: 10 ~I, solute concentration: 50 pg/ml. 
Peaks: l-chlorothiazide, 2-hydrochlorothiazide, 3-hydroflumethiazide, 4-
chlorothaIidone, 5-Clopamide, 6-methyclothiazide, 7- cIorexolone, 8- mefruside, 
9-benzothiazide, 10 - poly thiazide, U-cycIopenthiazide. 
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Figure 6.11: Separation of 11 thiazide drugs on XBridge™ RPIS column (150 x4.5 
mm I.D, 3.5 pm.). Chromatographic conditions: mobile phase: MeCN (15%): water 
(85% including 1 % AcOH), flow rate: 1 mIlmin, temperature: 100, DC, detection: 
5 10 
UV absorbance at 271 nm, injection volume: 10 ~I, solute concentration: 50 pg/ml. 
Peaks: l-chlorothiazide, 2-hydrochlorothiazide, 3-hydroOumethiazide, 4-
chlorothaIidone, 5-clopamide, 6-methycIothiazide, 7-clorexolone, 8-mefruside, 
9-benzothiazide, 100polythiazide, ll-cyclopenthiazide. 
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Figure 6.12: Separation of 11 thiazide drugs on XBridge™ RP18 column (150 x4.5 
mm I.D, 3.5flm.). Chromatographic conditions: mobile phase: MeCN (5%): water 
(95% including 1% AcOIl), flow rate: 1 mI/min, temperature: 100, QC, detection: 
UV absorbance at 271 nm, injection volume: 10111, solute concentration: 50 flg/mI. 
Peaks: l-chlorothiazide, 2-hydrochlorothiazide, 3-hydroflumethiazide, 4-
chlorothalidone, 5-clopamide, 6-methyclothiazide, 7-clorexolone, 8-mefruside, 
9-benzothiazide, 100polythiazide, ll-cyclopenthiazide. 
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Figure 6.13: Separation of 11 thiazide drugs on XBridge™ RP18 column (150 x4.5 
mm I.D, 3.5 /lm.). Chromatographic conditions: mobile phase: MeCN (5%): water 
. (95% including 1% AcOIl), flow rate: 1 niIlmln, temperature: 140, QC, detection: 
UV absorbance at 271 nm, injection volume: 10 111, solute concentration: 50 /lg/ml. 
Peaks: l-chlorothiazide, 2-hydrochlorothiazide, 3-hydroflumethiazide, 4-
chlorothalidone, 5-c1opamide, 6-methyclothiazide, 7-clorexolone, 8-mefruside, 
. 9-benzothiazide, 100polythiazide, ll-cyclopenthiazide. 
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Figure 6.14: Separation of 11 thiazide drugs on XBridge™ RP18 column (ISO x4.S 
mm I.D, 3.S I'm.). Chromatographic conditions: mobile phase: water (100% 
including 1% AcOH), flow rate: 1 mlImin, temperature: 140, DC, detection: UV 
absorbance at 271 nm, injection volume: 10 )11, solute concentration: SO Itglml• 
Peaks: l-Chlorothiazide, 2-hydrochlorothiazide, 3-hydroflumethiazide, 4-
chlorothalidone, S-Clopamide, 6-methyclothiazide, 7-clorexolone, 8-mefruside, 
9-benzothiazide, 100polythiazide, ll-Cyclopenthiazide. 
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Figure 6.15: Variation of column efficiency of chlorothiazide as a function of 
temperature using different proportion of organic modifier XBridge™ RP18 
shielded column. 
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Figure 6.16: Variation of column efficiency of hydrochlorothiazide as a function of 
temperature using different proportion of organic modifier on XBridge™ RP18 
shielded column. 
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Figure 6.17: Variation of column efficiency of hydroflumethiazide as a function of 
temperature using different proportion of organic modifier on XBridge™ RP18 
shielded column. 
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Figure 6.18: Variation of column efficiency of chlorothalidone as a function of 
temperature using different proportion of organic modifier on XBridge™ RP18 
shielded column. 
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Figure 6.19 Variation of column efficiency of methyclothiazide as a function of 
temperature using different proportion of organic modifier on XBridge™ RP18 
shielded column. 
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Figure 6.20: Variation of column efficiency of benzothiazide as a function of 
temperature using different proportion of organic modifier on XBridge™ RP18 
shielded column. 
177 
Chapter 6 
70000 
60000 
'i 50000 
-to!; 40000 
~ 
l! 30000 
" .~ e 20000 
r-1 10000 
Clopamide 
x 
<>-----
--<>---~ 
Diuretics 
~x 
O+-----~------,_----_,------,_------r_----_r---
20 40 60 80 100 120 140 
Temperature ("C) 
-<>-70% water -0- 85% --tr- 95% -X-100% 
Figure 6.21: Variation of column efficiency of clopamide as a function of 
temperature using different proportion of organic modifier on XBridge™ RP18 
shielded column. 
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Figure 6.22: Variation. of column efficiency of poly thiazide as a function of 
temperature using different proportion of organic modifier on XBridge™ RP18 
shielded column. 
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Figure 6.23: Variation of colunin efficiency of c1orexolone as a function of 
temperature using different proportion of organic modifier on XBridge™ RP18 
shielded column. 
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Figure 6.24: Variation of colunm efficiency of mefruside as a function of 
temperature using different proportion of organic modifier on XBridge™ RP18 
shielded column. I 
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Cyclopenthiazide 
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Figure 6.25: Variation of column efficiency of cyclopenthiazide as a function of 
temperature using different proportion of organic modifier on XBridge™ RP18 
shielded column. 
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6.2.2.5 Van Deemter 
The increase in pressure in HPLC nonnally strictly limits the use of high flow rates to 
shorten analysis times. One way to resolve this problem is to increase column temperature 
because the the viscosity of mobile phase will be reduced, diffusion of solute will increase 
while decreasing the resistance to flow in the column. The relationship between the plate 
height, H, in a column and the linear velocity of the mobile phase through the column, u: 
can be defined based on van Deemter equation: 
H=A+B/u+Cu Equation (7-1) 
Where H is the theoretical plate height and A, B, and, C are in order the coefficients for 
"eddy "diffusion (which allows for the different paths a solute may follow when passing 
over particles of different sizes), longitudinal diffusion (describe the contribution caused 
by molecular diffusion of the solute while passing through the column, and finally 
resistance. to mass transfer (which allow for the limited rate of transfer. of the solute 
between the stationary phase and mobile l'hase) [133]. The effect of flow rate was studied 
to compare differences in the efficiency and mass transfer characteristics at 140°C 
temperatures using 100% water as eluent with an XBridge™ RPI8 shielded column 
(Figure 6.26) as a plot of reduced plate height (H) vs. reduced linear velocity (v) with 
flow rates (I, 1.5, and 2 ml) concluded At flow rate 1.5 mllmin, the mass transfer term in 
the van Deemter equation controls the plate height, and at higher temperature and low 
flow rate, the longitudinal diffusion term governs the plate height Consequently, under 
constant high temperature conditions, the plate height decreases with increasing flow rate 
and increases with increasing temperature at elevated temp'erature. The use of high flow 
rates is preferred when using high temperature as the backpressure decreasing by 
temperature allows the use of high flow rate withouth decreasing (Figure 1.3, section 1.8) 
[82,97]. This was confinned in (Figure 6.26) as H decreased as flow rate increased.! 
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Plots with chlorothalidone as solutes 
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Figure 6.26 Plot of plate height (11) vs. linear velocity (u) for chlorothalidone (at 140 
0c) on a XBridge™ RP18 shielded column n (150 mm, 4.6 mm id, 3.5 /L, ). Mobile 
phase: water (1 % AcOIl), detection: 271 nm. 
6.2.3 Programming temperature 
Temperature-programmed analyses from 80°C to 140°C were examined for all diuretic 
drugs with both using shielded XBridge™ RP18 and non-Shielded XBridge™ C18 short 
colunms to improve separation. The effect of temperature-programmed high-temperature 
on.separation was evaluated with 1 % AcOH of water as Table 6.10. 
Table 6.10: Conditions oftemperature programmed separation 
Condition Condition 1 Condition 2 Condition 3. . Condition 4 
Shielded Shielded Non-Shielded Non-Shielded 
C\oluum XBridge™ XBridge™ XBridge™ XBridge™ C18 short C18 short RP18 RP18 
coluum column 
Temperature 100-140 100-140 100-140 80-140 
ran2e ("C) 
Initial time 10 5 10 10 (min) 
Final 60 60 60 60 time(min) 
IDtte ("C lmin) 3. 3 3 3 
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The shielded column was studied under two conditions. The retention factors and 
selectivity are summarized (Table 6.11 and 6.12) The order of elution was not changed 
from isothennal conditions with shielded column. It was chlorothiazide, 
hydrochlorothiazide, hydroflumethiazide, chlorothalidone, methyclothiazide, 
benzothiazide, cIopamide, polythiazide, mefruside, clorexolone. The peak shapes of the. 
first six drugs in were efficient but, the shapes of the last four .drugs were not good and 
they were distorted (Figure 6.27). This behaviour was observed also with isothennal 
conditions using pure water as the eluent at all temperatures at 100 and 120°C. The time 
of elution was done in conditions one within 34.57 minutes (Figure 6.27) and in 
conditions two within 30.87 minutes (Figure 6.28) most of it was similar to isothennal 
condition at 140°C. On comparing the retention factors in both conditions (1&2) to 
. isothennal conditions at 140°C, it can be seen that there were big differences especially 
for first two drugs and this difference decreased to last retained drugs. The selectivity 
values were almost the same with isothermal conditions at 140 QC. The only significant 
difference being between the first two drugs, as temperature was only 100°C when they 
were eluted. When we used non-Shielded XBridge™ C18 short column in conditions 
(3&4) (Figure 6.29 & 6.30), the order of elution was changed after elution of the first 
three drugs (chlorothiazide, hydrochlorothiazide, and hydroflumethiazide) and it was then 
methycIothiazide, chlorothalidone, clopamide benzothiazide, polythiazide, mefruside, 
cyclopenthiazide and clorexolone. This column eluted cyclopenthiazide which did not 
elute at any conditions with XBridge™ RP18 column. In condition 3, there were two peak 
overlaps; the first one was between chlorothiazide, hydrochlorothiazide, and the second 
between mefruside and cyclopenthiazide. Both previous peak overlaps were disappeared 
in condition 4 and this can be attributed the cooler initial temperature in condition 4 
The selectivity with XBridge™ Cl8 column was better than with shielded XBridge™ 
RP18 column. In addition, it was noted that peak shapes were better with XBridge™ Cl8 
column (Figure 6.29 & 6.30), than XBridge™ RP18, this observation can be explained as 
there is no amide group in XBridge™ C18 column and less degradation of the XBridge™ 
RP18 column at high temperature. 
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Table 6.11: Effect of temperature programming on retention factors and selectivity 
of diuretic drugs with XBridge™ RP18 column 
Drugs Effect oftemperature proerammine on separation 
Condition 1 Condition 2 
k a k a 
Chlor()thiazide 0.42 - 0.38 -
Hydrochlorotbiazide 0.54 1.28 0.49 1.29 
Hydroflumethiazide 1.06 1.96 0.99 2.00 
Chlorothalidone 5.31 5.00 4.72 4.79 
Methyclothiazide 6.28 1.18 5.43 1.15 
Benzothiazide 7.85 1.25 6.66 .1.23 
Clopamide 9.75 1.24 8.52 1.28 
Polythiazide 13.56 1.39 11.61 . 1.36 
Mefruside 14.20 1.05 12.35 1.06 
. Clorexolone 17.60 1.24 15.59 1.26 
Cyclopenthiazide - =. = -
Table 6.12: Effect of temperature programming on retention factors and selectivity 
of diuretic drugs with XBridge™ C18 column 
Drugs . Effect oftemperatnre pr()erammine on separation . 
Condition 3 Condition 4 
.. k a· . ·k· a 
Chl()rothiazide 0.20 - 0.32 -
Hydrochlorothiazide. 0.20 1.00 0.32 1.00 
Hydroflumethiazide . 0.39 1.99 0.76 2.40 
Methyclothiazide 3.34 8.49 5.64 7.41 
Chlotothalidone 6.64 1.99 11.98 2.12 
... CI()pamide 14.43 2.17 19.87 1.66 
Benzothiazide 18.30 1.27 35.93 1.81 
Polythiazide 21.26 1.16 41.75 1.16 
. Mefruside 35.50 1.67 51.80 1.24 
Cyclopenthiazide· .. 35.50 1.00 56.82 1.10 
Clorexolone 45.09 1.27 64.41 1.13 
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Figure 6.27: Separation of 11 thiazide drugs on XBridge™ RP18 column (150 x4.5 
mm I.D, 3.5 pm.) under Condition 1. Chromatographic cOliditions: mobile phase: 
water (100% including 1 % AcOH), flow rate: 1 mlImin, detection: UV absorbance 
at.271 nm, injection volumel0 J.lI, temperature range lOO-140°C, initial time 10 
mins, final time 60 mins, rate 3 °C/min, solute concentration: 50 pglmL Peaks: 1-
chlorothiazide, 2-hydrochlorothiazide, 3-hydroflumethiazide, 4-chlorothalidone, 5-
clopamide, 6- methyclothiazide, 7-clorexolone, 8-mefruside, 9-benzothiazide, 10-
poly thiazide, 11- cyclopenthiazide. 
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Figure 6.28: Separation of 11 thiazide drugs on XBridge™ RP18 column (150 x4.S 
mm I.D, 3.5 /Lm.) under Condition 2, Chromatographic conditions: mobile phase: 
water (100% including 1% AcOH), flow rate: 1 mlfmin, detection: UV absorbance 
at 271 nm, injection volume: 10 JlI, temperature range lOO-140°C, initial time 5 
mins, final time 60 mins, rate 3 °C/min,solute concentration: SO /Lg/ml. Peaks: 1-
chlorothiazide, 2-hydrochlorothiazide, 3-hydroflumethiazide, 4- chlorothalidone, S~ 
clopamide, 6-methyclothiazide, 7-clorexolone, 8-mefruside, 9-benzothiazide, 10-
poly thiazide, ll-cyclopenthiazide. 
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Figure 6.29: Separation of 11 thiazide drugs on XBridge™ C18 column (50 x4.5 mm 
I.D, 3.5 pm.) under Condition 3, Chromatographic conditions: mobile phase: water 
(100% including 1% AcOH), flow rate~ 1 mIlmin, detection~ UV absorbance at 271 
nm, injection volume: 10 JlL, temperature range lOO-140°C, initial time 10 mins, 
final time 60 mins, rate 3 °C/min, solute concentration: 50 pg/m!. Peaks: 1-
chlorothiazide, 2-hydrochlorothiazide, 3-hydroflumethiazide, 4-chlorothaIldone, 5-
Clop amide, 6-methyclothiazide, 7-clorexolone, 8-mefruside, 9-benzothiazide, 10-
polythiazide, 11- cyclopenthiazide. 
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Figure 6.30: Separation of 11 thiazide drugs on XBridge™ C18 column (50 x4.5 mm 
I.D, 3.5 pm.) under Condition 4, Chromatographic conditions: mobile phase: water 
(100% including 1% AcOIl), flow rate: 1 m1/min, detection: UV absorbance at 271 
nm, injection volume: 10 Ill, temperature range 80-140 QC, initial time 10 mins, final 
time 60 mins, rate 3 °C/min,solute concentration: 50 pg/ml. Peaks: l-chlorothiazide, 
2-hydrochlorothiazide, 3-hydroflumethiazide, 4-chlorothalidone, 5-c1opamide, 6-
methyclothiazide, 7-clorexolone, 8-mefruside, 9-benzothiazide, 100polythiazide, 11-
. cyclopenthiazide. 
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6.2.4 Summary: 
Performing the separation of eleven thiazide and non-thiazide (chlorothiazide, 
hydrochlorothiazide, hydroflumethiazide, chlorothaIidone, cIopamide, methycIothiazide, 
clorexolone, mefruside, benzothiazide, polythiazide and lastly cyclopenthiazide) diuretics 
at a high temperature considerably reduces their analysis times. The degree of decrease 
varied from one drug to another and from one condition to another. Linear van't Hoff 
plots were obtained for the drugs and the enthalpy of transfer (M!O:> values computed 
from these plots indicated that the retention of diuretic drugs studied is an exothermic 
process therefore all drugs were transferred from mobile phase to stationary phase 
entropically favourable rather than enthalpically and this iricreased with high temperature. 
There were changes in order of elution with increases in the temperature with (70%, 85%, 
and 100% water of 1% AcOH). There was a decrease in efficiency on increasing column . 
temperature in using 70%. of 1% AcOH water and also with 85% of water with except 
benzothiazide, mefruside and cyclopenthiazide. Also it was observed that the peak shapes 
of drugs were excellent under all temperature used in using 70% of water and also for 
fIrst six drugs at 60°C with using 85% of water fronting in peak shape were observed 
with last retained drugs which improved at 80 and 100°C. With 95% and 100% of 1 % 
AcOH water, it was found efficiency of chlorothiazide and hydrochlorothiazide were 
improved whereas the efficiency of other drugs decreased. 
The XBridge™ C18 short column provide better separation with high temperature-
progranuned for time analysis and peak shape than XBridge™ RP18 shielded column 
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Chapter 7 
Conclusion and Future work 
7.1 Cephalosporins study 
The pharmaceutical field is growing rapidly and has generated continuing demand for 
analytical methods that need a low proportion llf organic to eluent be environmentally and 
economically useful. This study investigated methods for the determination of six 
cephalosporins (cephadroxil, cephaclor, cephalexine, cephradine, cephamandol, and 
cephoxazole) using high temperature HPLC on different columns. The Pathfinder column 
was not sufficiently reliable to establish a quantification method for cephalosporins at 
high temperature with different conditions. 
The linearity relationship of the drugs according to Van't Hoff equation was studied. The 
efficiency and resolution of all drugs was significantly improved with using narrow 
connections. 
In using Selerity's Blaze 200 TM column, it was found the best separation between these 
drugs was using 100% water at 100°C but efficiency was not good and shape of peaks 
were not sharp especially of later eluting drugs (cephalexin and cephradine). The van't 
Hoffplots were linear showed marked change with temperature. 
With Xterra C18 column, it was concluded the best separation was at 60°C with using 
100% of water as eluent and this condition were the best for quantitative applications.). It 
was found this method had good linearity for all the drugs with an acceptable regression 
coefficient, and was sensitive as the L.O.D and L.O.Q but were high compared to 
previous studied using other detectors [155]. The precision study for a standard solution 
(40 ppm) (n = 6 analyses) showed that the R.S.D. of retention time (tR), efficiency (N/m) 
and relative peak area, increased from day to day see (Tables 4.5 to 4.7), but still in 
acceptable for validity study. 
7.2 NSAIDs study 
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This investigation developed an analytical method for the separation of mixture of 
NSAIDs by using isothermal and programmed temperature. The effect of temperature, 
pH, and flow rate were evaluated in respect of different chromatographic parameters 
including retention factors, thermodynamivc properties, selectivity and efficiency. In this 
study, three column were used, Xterra RP18, long XBridge™ RP18 shielded (15 cm) and 
short XBridge™ RP18 shielded (5 cm). 
The retention factors of all drugs were found to decrease with increased temperature and 
pH. However, with increased flow rate there was thermal mismatching between 
incoming solvent on the short XBridge™ RP18 shielded (5 cm) column which caused 
increased in retention factors (Table 5-11). The linearity of van't Hoff and (Mf,,) with 
both Xterra RP18, 10ngXBridge™ RPl8 shielded (15 cm) colunms indicated the 
separation of theses. drugs was an exothermic process and there was no change in 
mechanism of separation. The selectivity of drugs was different from column to another 
under the same conditions. With XBridge™ RP18 shielded (15 cm) column, it was found 
there were changes in selectivity with changes in pH as the degree of ionisation of drugs 
were different. Whereas, there was no change on order of elution of these drugs with. of 
flow rate. It was found that the efficiency decrease with increasing temperature on the 
. Xterra RP18 column and, however, on the Xhridge RP18 column, increasing temperature 
in parallel with change in pH caused with less the efficiency. General Xbridge RP18 
colunm was better than Xterra RP18 in term of efficiency. With increasing flow rate, the 
efficiencies were dropped dramatically as resulted thermal mismatching between column 
and incoming solvents. The best condition for separation of NSAIDs was observed with 
using 75% pH 5 at 80°C with Xbridge RP18 column (15 cm). Temperature progrannning 
was examined for the elution of a mixture of NSAIDs with pure water as eluent at pH 6 
under different five conditions. It was found that all drugs· were eluted except 
indomethacin with XBridge™ RPl8 and XBridge™ RP18 short columns. However, the 
long XBridge™ RP18 column provided best separation of these drugs. 
7.3 Diuretics drug study 
The experimental conditions to analyze a mixture of eleven thiazide and non-thiazide 
diuretics at a high temperature on XBridge™ RP18 shielded colunm were determined 
The main parameters studied were the eluent compositions and the temperature of column 
which reduces considerably the analysis times of all drugs. The thermodynamic study 
indicated that retention was an exothermic process and transfer of the drugs from mobile 
phase to stationary phase· was entropically favourable rather than entIialpically and this 
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increased with high temperature. There were some change in selectivity with increasing 
temperature with buffer (70%, 85%, and 100% of 1% AcOH of water). However, a 
decrease was noted in efficiency by increasing column temperature in using 70% and also 
with 85% of water with except for benzothiazide, mefruside, and cyclopenthiazide. Also 
it was observed that the peak shapes of drugs were excellent under all temperature using 
70% water and also for first six drugs but at 60 DC. On using 85% water, fronting were 
observed with last retained drugs which improved at 80 and 100 DC. The efficiency of 
most polar drugs (chlorothiazide and hydrochlorothiazide) were improved whereas 
efficiency of other drugs was decreased with eluent buffer (95% and 100%). In general it 
was found that the temperature improved peak shapes. However, the separation of these 
drugs was achieved except cyc10penthiazide with using pure water as eluent at 140 DC 
without any peak overlaps between all drugs. Temperature-programming was used for 
separation of these drugs using pure water as eluent and it was found that the XBridge™ 
. C18 short column provided better separation regarding selectivity, time analysis and peak 
shape than XBridge™ RP18 shielded column. 
7.4 Generasl conclusions 
In this thesis, it was investigated some of the key issues of High temperature LC (HTLC) 
to broaden the horizons in terms of practice and theory ofHTLC. 
HTLC considered to be utilised as a routine analytical tool in the development of 
separation methods of some pharmaceutical coumpounds. The benefits of this methods 
can be summariesd in the following points: 
1) Increasing of analysis speed (separations on of a few minutes) to save cost oftime 
2) Improve of resolution via altering chromatographic selectivity, so 
3) Increase capability of analysis of complex samples (up to 10 11 soluted) 
4) Improve efficiency if connection tube is optimised and optimum flow rate used 
5) The possibility of using pure water as a mobile phase for "green" liquid 
chromatographic analyses where no hazardous waste is produced. 
High temperature HPLC is becoming an important part of RP-HPLC, but its future 
deponds on development of new stationary phases that are stable the hard conditions of 
high temperature anad using a pure water as a mobile phase. 
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7.4 Future work 
The future work should be directed to the application of this method to real samples from 
patients who have taken individual cephalosporin drug. As well as to industrial sample of 
group of cephalosporins as mixture to ensure purity of products. A systematic comparison 
should be done with existing standard methods to evaluate this new method. 
Finaly, the examination of this method with different detectors, such as FID, 
electrochemical detector, MS to improve sensitivity. 
Future work should also be directed into two points one to validate the best conditions the 
for separation NSAIDs using buffer 75% pH 5 at 80°C and temperature programmed 
condition 5 with Xbridge RPl8 column (15 cm). Another should look at the applicability 
o~ these conditions to real samples from industry or from patients those take NSAIDs 
drugs and applied this method to another NSAIDs with different'detectors such as flame 
ionisation detector (FID), electrochemical detector, and fluorescence detector to improve 
sensitivity, 
Meanwhile, in diuretics study, future work shold be focused on using long XBridge't'M 
Cl8 column to improve sepration using both isothennal and gradient temperatre for 
separation these drugs. 
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Appendix 
Postgraduate Research Student Skills (PRS) Training Record for 2005/2006/2007 
academic years 
Activity Time Date Claimed 
1. Bimemic copper heme copper 02 chemistry 
I (seminar) 
10/01/2005 2 hrs . 
2. Safety induction 13/0112005 1 day 
3. PhD induction 1110112005 1 day 
4. Word: getting stylish 03/02/2005 2hrs 
5. Word: large documents 10/02/2005 2 hrs 
6. Excel (part A) 17/03/2005 2hrs 
7. Excel (part B) 31103/2005 2hrs 
8. Securing the Apache Web Server 13/4/2005 Ihr 
9. Sigma-Aldrich seminar Sheffield 27/04/2005 1 day 
10. Transferable Skills in the Curriculum 10/5/2005 3hrs 
11. Teaching Skills - Preparing to Teach and 20/5/2005 3 hrs 
Promoting Learning 
two parts 27/5/2005 
3 hrs 
12. Analytical research forum (ARF05) 18-201712005 3 days 
13. Essential Introductory Skills for your PhD i)23/5/2005 1 day 14. (2 day programme) 
ii) 30/5/2005 1 day 
15. Delivering Workshops for Effective 
Learning 27/9/2005 3 hrs 
16. Distance Learning Forum 08/12/2005 Ihr 
17. Getting Articles Published 13/12/2005 3 hrs 
18. Teaching Small Groups 19/112006 2:30 hrs 
19. Marking for Postgraduates and Research 20/112006 3 hrs Assistants 
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20. Research Assistants and Postgraduates -
Applications including CVs 23/112006 2:30 hrs 
21. Designing Workshops for Effective 
Learning 25/112006 3 hrs 
22. Statistics - Cluster Analysis 2112/2006 2hrs 
23. Learning Technologies -Using Them 
Effectively to Support Student Learning 27/2/2006 2:30 
24. Data Protection Issues 8/3/2006 3 hrs 
25. InteIlectual Property 10/3/2006 3hrs 
26. Using the Optical Mark Recognition I Service to Process Multiple Choice Tests 13/3/2006 Ihr 
and Exams 
27. FrontPage - Part A 
26/4/2006 2hr 
28. FrontPage - Part B 
3/5/2006 2hr 
29. FrontPage - Part C 
10/5/2006 2hr . 
30. Database of the Month -Refworks 
7/612006 1:30 hr 
31. Plagiarism, Citation and Managing Your 
References 14/6/2006 2hr 
·32. Demonstration in department 13,20,27/2-
5/3/2006& 
16&23/02/2 6 days 
007 
33. Leamdirect Taster Ihr 15/1/2007 
34. VIVA - What Happens? 
19/1/2007 2hr 
35. Keeping your Research Up-ta-Date for 
Postgraduates 11212007 2:30hr 
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36. Writing up your PhD Thesis 
2/3/2007 3hrs 
37. Fundamentals of Teaching, Learning and 
Assessment 25/09/2007 2:30hr 
38. Teaching Skills - Working with Small 
Groups 10/10/2007 3hrs 
39. Online Courses - enrolment and drop in 
centre 8/1112007 2 hrs 
40. Seminar in analytical chemistry by Dr 
Brendan Keely (in department) 15/02/2007 1hr 
41. Analytical seminars by Professor Stephen 
Haswell (in department) 22/0112007 1hr 
42. Analytical seminars by Professor Colin 
Creaser (in department) 23/01/2007 1hr 
43. Analytical seminars by Dr Paul Thomas 
(in department) 26/0112007 1hr 
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